<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">81067</article-id><article-id pub-id-type="doi">10.7554/eLife.81067</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="heading"><subject>Neuroscience</subject></subj-group></article-categories><title-group><article-title>Biological brain age prediction using machine learning on structural neuroimaging data: Multi-cohort validation against biomarkers of Alzheimer’s disease and neurodegeneration stratified by sex</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-286740"><name><surname>Cumplido-Mayoral</surname><given-names>Irene</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1967-7025</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286741"><name><surname>García-Prat</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286783"><name><surname>Operto</surname><given-names>Grégory</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286742"><name><surname>Falcon</surname><given-names>Carles</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286758"><name><surname>Shekari</surname><given-names>Mahnaz</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286759"><name><surname>Cacciaglia</surname><given-names>Raffaele</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="fund13"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286760"><name><surname>Milà-Alomà</surname><given-names>Marta</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286761"><name><surname>Lorenzini</surname><given-names>Luigi</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286762"><name><surname>Ingala</surname><given-names>Silvia</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-204582"><name><surname>Meije Wink</surname><given-names>Alle</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286763"><name><surname>Mutsaerts</surname><given-names>Henk JMM</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-0894-0307</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286764"><name><surname>Minguillón</surname><given-names>Carolina</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286765"><name><surname>Fauria</surname><given-names>Karine</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286766"><name><surname>Molinuevo</surname><given-names>José Luis</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="pa1">†</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-286767"><name><surname>Haller</surname><given-names>Sven</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7433-0203</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-137309"><name><surname>Chetelat</surname><given-names>Gael</given-names></name><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con16"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286768"><name><surname>Waldman</surname><given-names>Adam</given-names></name><xref ref-type="aff" rid="aff9">9</xref><xref ref-type="fn" rid="con17"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-145453"><name><surname>Schwarz</surname><given-names>Adam J</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9743-6171</contrib-id><xref ref-type="aff" rid="aff10">10</xref><xref ref-type="fn" rid="con18"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-277473"><name><surname>Barkhof</surname><given-names>Frederik</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="aff" rid="aff11">11</xref><xref ref-type="fn" rid="con19"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286769"><name><surname>Suridjan</surname><given-names>Ivonne</given-names></name><xref ref-type="aff" rid="aff12">12</xref><xref ref-type="fn" rid="con20"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-286770"><name><surname>Kollmorgen</surname><given-names>Gwendlyn</given-names></name><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="con21"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-286771"><name><surname>Bayfield</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff13">13</xref><xref ref-type="fn" rid="con22"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-245698"><name><surname>Zetterberg</surname><given-names>Henrik</given-names></name><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="aff" rid="aff16">16</xref><xref ref-type="aff" rid="aff17">17</xref><xref ref-type="aff" rid="aff18">18</xref><xref ref-type="fn" rid="con23"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-41437"><name><surname>Blennow</surname><given-names>Kaj</given-names></name><xref ref-type="aff" rid="aff14">14</xref><xref ref-type="aff" rid="aff15">15</xref><xref ref-type="fn" rid="con24"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-286772"><name><surname>Suárez-Calvet</surname><given-names>Marc</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff19">19</xref><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund12"/><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con25"/><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" corresp="yes" id="author-286773"><name><surname>Vilaplana</surname><given-names>Verónica</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6924-9961</contrib-id><email>veronica.vilaplana@upc.edu</email><xref ref-type="aff" rid="aff20">20</xref><xref ref-type="other" rid="fund14"/><xref ref-type="fn" rid="con26"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-204579"><name><surname>Gispert</surname><given-names>Juan Domingo</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-6155-0642</contrib-id><email>jdgispert@barcelonabeta.org</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con27"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><collab>ALFA study</collab><xref ref-type="fn" rid="con28"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><collab>EPAD study</collab><xref ref-type="fn" rid="con29"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><collab>ADNI study</collab><xref ref-type="fn" rid="con30"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><collab>OASIS study</collab><xref ref-type="fn" rid="con31"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01nry9c15</institution-id><institution>Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04n0g0b29</institution-id><institution>Universitat Pompeu Fabra</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03a8gac78</institution-id><institution>IMIM (Hospital del Mar Medical Research Institute)</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff4"><label>4</label><institution>CIBER Fragilidad y Envejecimiento Saludable (CIBERFES)</institution><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>France</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02g87qh62</institution-id><institution>Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)</institution></institution-wrap><addr-line><named-content content-type="city">Madrid</named-content></addr-line><country>Spain</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/008xxew50</institution-id><institution>Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam</institution></institution-wrap><addr-line><named-content content-type="city">Amsterdam</named-content></addr-line><country>Netherlands</country></aff><aff id="aff7"><label>7</label><institution>CIRD Centre d'Imagerie Rive Droite</institution><addr-line><named-content content-type="city">Geneva</named-content></addr-line><country>Switzerland</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02vjkv261</institution-id><institution>Normandie Univ, UNICAEN, INSERM, U1237, PhIND &quot;Physiopathology and Imaging of Neurological Disorders&quot;, Institut Blood and Brain</institution></institution-wrap><addr-line><named-content content-type="city">Cyceron</named-content></addr-line><country>France</country></aff><aff id="aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01nrxwf90</institution-id><institution>Centre for Dementia Prevention, Edinburgh Imaging, and UK Dementia Research Institute at The University of Edinburgh</institution></institution-wrap><addr-line><named-content content-type="city">Edinburgh</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff10"><label>10</label><institution>Takeda Pharmaceutical Company Ltd</institution><addr-line><named-content content-type="city">Cambridge</named-content></addr-line><country>United States</country></aff><aff id="aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jx3x895</institution-id><institution>Institutes of Neurology and Healthcare Engineering, University College London</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff12"><label>12</label><institution>Roche Diagnostics International Ltd</institution><addr-line><named-content content-type="city">Rotkreuz</named-content></addr-line><country>Switzerland</country></aff><aff id="aff13"><label>13</label><institution>Roche Diagnostics GmbH</institution><addr-line><named-content content-type="city">Penzberg</named-content></addr-line><country>Germany</country></aff><aff id="aff14"><label>14</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01tm6cn81</institution-id><institution>Institute of Neuroscience and Physiology, University of Gothenburg</institution></institution-wrap><addr-line><named-content content-type="city">Mölndal</named-content></addr-line><country>Sweden</country></aff><aff id="aff15"><label>15</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/04vgqjj36</institution-id><institution>Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital</institution></institution-wrap><addr-line><named-content content-type="city">Mölndal</named-content></addr-line><country>Sweden</country></aff><aff id="aff16"><label>16</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jx3x895</institution-id><institution>Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff17"><label>17</label><institution>Hong Kong Center for Neurodegenerative Diseases</institution><addr-line><named-content content-type="city">Hong Kong</named-content></addr-line><country>China</country></aff><aff id="aff18"><label>18</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jx3x895</institution-id><institution>UK Dementia Research Institute at UCL</institution></institution-wrap><addr-line><named-content content-type="city">London</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff19"><label>19</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03a8gac78</institution-id><institution>Servei de Neurologia, Hospital del Mar</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff><aff id="aff20"><label>20</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03mb6wj31</institution-id><institution>Department of Signal Theory and Communications, Universitat Politècnica de Catalunya</institution></institution-wrap><addr-line><named-content content-type="city">Barcelona</named-content></addr-line><country>Spain</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Miller</surname><given-names>Karla L</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Wong</surname><given-names>Ma-Li</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01q1z8k08</institution-id><institution>State University of New York Upstate Medical University</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group><author-notes><fn fn-type="present-address" id="pa1"><label>†</label><p>H.Lundbeck A/S, Copenhagen, Denmark</p></fn></author-notes><pub-date publication-format="electronic" date-type="publication"><day>17</day><month>04</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e81067</elocation-id><history><date date-type="received" iso-8601-date="2022-06-14"><day>14</day><month>06</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-04-10"><day>10</day><month>04</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2022-06-28"><day>28</day><month>06</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.06.23.22276492"/></event></pub-history><permissions><copyright-statement>© 2023, Cumplido-Mayoral et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Cumplido-Mayoral et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-81067-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-81067-figures-v2.pdf"/><abstract><p>Brain-age can be inferred from structural neuroimaging and compared to chronological age (brain-age delta) as a marker of biological brain aging. Accelerated aging has been found in neurodegenerative disorders like Alzheimer’s disease (AD), but its validation against markers of neurodegeneration and AD is lacking. Here, imaging-derived measures from the UK Biobank dataset (N=22,661) were used to predict brain-age in 2,314 cognitively unimpaired (CU) individuals at higher risk of AD and mild cognitive impaired (MCI) patients from four independent cohorts with available biomarker data: ALFA+, ADNI, EPAD, and OASIS. Brain-age delta was associated with abnormal amyloid-β, more advanced stages (AT) of AD pathology and <italic>APOE</italic>-ε4 status. Brain-age delta was positively associated with plasma neurofilament light, a marker of neurodegeneration, and sex differences in the brain effects of this marker were found. These results validate brain-age delta as a non-invasive marker of biological brain aging in non-demented individuals with abnormal levels of biomarkers of AD and axonal injury.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>brain age prediction</kwd><kwd>neuroimaging</kwd><kwd>alzheimer's disease</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007601</institution-id><institution>Horizon 2020 - Research and Innovation Framework Programme</institution></institution-wrap></funding-source><award-id>948677</award-id><principal-award-recipient><name><surname>Suárez-Calvet</surname><given-names>Marc</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004587</institution-id><institution>Instituto de Salud Carlos III</institution></institution-wrap></funding-source><award-id>PI19/00155</award-id><principal-award-recipient><name><surname>Suárez-Calvet</surname><given-names>Marc</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>La Caixa Foundation</institution></institution-wrap></funding-source><award-id>100010434</award-id><principal-award-recipient><name><surname>Suárez-Calvet</surname><given-names>Marc</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100007601</institution-id><institution>Horizon 2020 - Research and Innovation Framework Programme</institution></institution-wrap></funding-source><award-id>847648</award-id><principal-award-recipient><name><surname>Suárez-Calvet</surname><given-names>Marc</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution>EU/EFPIA Innovative Medicines Initiative Joint Undertaking AMYPAD</institution></institution-wrap></funding-source><award-id>115952</award-id><principal-award-recipient><name><surname>Gispert</surname><given-names>Juan Domingo</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution>La Caixa Foundation</institution></institution-wrap></funding-source><award-id>100010434; LCF/PR/GN17/50300004</award-id><principal-award-recipient><name><surname>Suárez-Calvet</surname><given-names>Marc</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution>TriBEKa Imaging Platform project</institution></institution-wrap></funding-source><award-id>TriBEKa-17-519007</award-id><principal-award-recipient><name><surname>Cumplido-Mayoral</surname><given-names>Irene</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government</institution></institution-wrap></funding-source><award-id>2017-SGR-892</award-id><principal-award-recipient><name><surname>Cumplido-Mayoral</surname><given-names>Irene</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100013296</institution-id><institution>EIT Digital</institution></institution-wrap></funding-source><award-id>Grant 2021</award-id><principal-award-recipient><name><surname>Gispert</surname><given-names>Juan Domingo</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution>Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI) MCIN/AEI /10.13039/501100011033</institution></institution-wrap></funding-source><award-id>RTI2018‑102261, co-funded by the European Regional Development Fund (FEDER)</award-id><principal-award-recipient><name><surname>Gispert</surname><given-names>Juan Domingo</given-names></name></principal-award-recipient></award-group><award-group id="fund11"><funding-source><institution-wrap><institution>NIHR biomedical research center at UCLH</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Barkhof</surname><given-names>Frederik</given-names></name></principal-award-recipient></award-group><award-group id="fund12"><funding-source><institution-wrap><institution>Instituto de Salud Carlos III</institution></institution-wrap></funding-source><award-id>PI22/00456</award-id><principal-award-recipient><name><surname>Suárez-Calvet</surname><given-names>Marc</given-names></name></principal-award-recipient></award-group><award-group id="fund13"><funding-source><institution-wrap><institution>Spanish Ministry of Science and Innovation (MCIN)/Spanish Research Agency (AEI) MCIN/AEI/10.13039/501100011033</institution></institution-wrap></funding-source><award-id>PID2021-125433OA-100</award-id><principal-award-recipient><name><surname>Cacciaglia</surname><given-names>Raffaele</given-names></name></principal-award-recipient></award-group><award-group id="fund14"><funding-source><institution-wrap><institution>Spanish Research Agency (AEI)</institution></institution-wrap></funding-source><award-id>PID2020-116907RB-I00 of the call MCIN/ AEI /10.13039/501100011033</award-id><principal-award-recipient><name><surname>Vilaplana</surname><given-names>Verónica</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Brain-Age delta is a non-invasive marker of biological brain aging that is sensitive to the presence of risk factors and altered biomarkers of Alzheimer's disease in non-demented individuals.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Age is the main risk factor for Alzheimer’s Disease (AD) and most neurodegenerative diseases. However, the mechanisms underlying this association are still poorly understood (<xref ref-type="bibr" rid="bib34">Fjell et al., 2014</xref>). Both normal aging and AD are associated with region-specific cerebral morphological changes characterized by the occurrence of atrophy (<xref ref-type="bibr" rid="bib3">Bakkour et al., 2013</xref>; <xref ref-type="bibr" rid="bib34">Fjell et al., 2014</xref>). Both aging and AD have differential and partially overlapping effects on specific regions of the cerebral cortex like, for instance, the dorsolateral prefrontal cortex (<xref ref-type="bibr" rid="bib3">Bakkour et al., 2013</xref>; <xref ref-type="bibr" rid="bib34">Fjell et al., 2014</xref>; <xref ref-type="bibr" rid="bib66">Pichet Binette et al., 2020</xref>). Conversely, some regions are predominantly affected by age (e.g. calcarine cortex) and some others are predominantly affected by AD (e.g. medial temporal cortex; <xref ref-type="bibr" rid="bib3">Bakkour et al., 2013</xref>). A better understanding of the mechanistic links between the brain aging process and neurodegenerative diseases is an urgent priority to develop effective strategies to deal with their rising burden amid an ageing population (<xref ref-type="bibr" rid="bib36">Franke and Gaser, 2019</xref>). Therefore, a growing amount of research is focusing on using neuroimaging techniques to develop a biomarker of biological brain aging. In this framework, the concept of brain-age has emerged as an appealing comprehensive marker that enables determining on an individual basis, the risk for age-associated brain diseases (<xref ref-type="bibr" rid="bib18">Cole and Franke, 2017a</xref>; <xref ref-type="bibr" rid="bib20">Cole et al., 2017c</xref>; <xref ref-type="bibr" rid="bib35">Franke et al., 2010</xref>; <xref ref-type="bibr" rid="bib36">Franke and Gaser, 2019</xref>). However, this is a challenging task because, even though the cerebral structural changes related to aging are well established, the older population is characterized by substantial variation in neurobiological aging trajectories (<xref ref-type="bibr" rid="bib21">Cole et al., 2018</xref>; <xref ref-type="bibr" rid="bib34">Fjell et al., 2014</xref>).</p><p>Recently, machine learning techniques have gained popularity as brain-age prediction models (<xref ref-type="bibr" rid="bib19">Cole et al., 2017b</xref>; <xref ref-type="bibr" rid="bib23">Dafflon et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">de Lange et al., 2019</xref>; <xref ref-type="bibr" rid="bib36">Franke and Gaser, 2019</xref>), due to their ability in identifying relevant data-driven patterns within complex data (<xref ref-type="bibr" rid="bib86">Zhavoronkov et al., 2019</xref>). These models learn the association between chronological age and cerebral morphological features derived from structural magnetic resonance imaging (MRI) in healthy individuals, yielding a predicted brain-age for each individual. Individuals with a predicted brain-age higher than their chronological age may have an ‘older’ brain than expected, whereas an individual with an estimated brain-age lower than their chronological age has a ‘younger’ brain. Subtracting chronological age from estimated brain-age hence provides an estimate of accelerated brain aging, namely the brain-age delta. Recent literature has shown the adequacy of using a brain-age predicted measurement in the assessment of the clinical severity of AD, by finding higher brain-age deltas in AD and individuals with mild cognitive impairment (MCI) with respect to cognitively unimpaired (CU) individuals (<xref ref-type="bibr" rid="bib6">Beheshti et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Kaufmann et al., 2019</xref>). A higher brain-age delta has also been reported in other diseases, such as multiple sclerosis, epilepsy and psychiatric disorders, with respect to healthy controls (<xref ref-type="bibr" rid="bib6">Beheshti et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Kaufmann et al., 2019</xref>). In addition, brain-age delta has also been associated with other biological measures such as: lifestyle factors (<xref ref-type="bibr" rid="bib22">Cole, 2020</xref>)<bold>,</bold> cognition (<xref ref-type="bibr" rid="bib6">Beheshti et al., 2018</xref>; <xref ref-type="bibr" rid="bib22">Cole, 2020</xref>) hypertension (<xref ref-type="bibr" rid="bib26">de Lange et al., 2020a</xref>) and prediction of mortality (<xref ref-type="bibr" rid="bib21">Cole et al., 2018</xref>).</p><p>Even though these studies support the association of brain-age delta as a biomarker of biological aging with relevance to various brain diseases, it is of interest to further validate this measurement in association with specific biological markers of AD pathology (i.e. Amyloid-β[Aβ] and tau pathology), neurodegeneration and cerebrovascular disease in the earliest stages of AD. This is a very relevant aspect since the recent AD research framework criteria defines AD as a biological construct, namely the presence of both abnormal Aβ (A+) and tau (T+) biomarkers, regardless of clinical manifestations (<xref ref-type="bibr" rid="bib44">Jack et al., 2018</xref>). The term ‘Alzheimer’s pathological change’ is proposed whenever there is evidence of Aβ but not tau pathology (A+T-). The umbrella term ‘Alzheimer’s <italic>continuum</italic>’ includes both ‘Alzheimer’s pathological change’ (A+T-) and ‘Alzheimer’s Disease’ (A+T + ). Under this definition, A-T +individuals would not fall into the AD <italic>continuum</italic>. Then, under this framework, neurodegeneration biomarkers (N) and cognitive status (i.e. CU, MCI and dementia syndromes) are used to stage disease progression.</p><p>Recent literature has studied the associations between brain-age delta and the above-mentioned biomarkers with different aims. Brain-age delta was recently associated with plasma biomarkers of neurodegeneration and with imaging biomarkers of cerebrovascular disease in the 1946 British Birth Cohort <xref ref-type="bibr" rid="bib83">Wagen et al., 2022</xref>; however, it was not associated with CSF biomarkers of neurodegeneration (<xref ref-type="bibr" rid="bib61">Millar et al., 2022</xref>). Moreover, although brain-age delta was significantly associated with AD biomarkers of amyloid and tau in MCI individuals, these associations were not found in CU individuals (<xref ref-type="bibr" rid="bib61">Millar et al., 2022</xref>; <xref ref-type="bibr" rid="bib83">Wagen et al., 2022</xref>). Conversely, Another study focusing on the impact of training the brain-age prediction model in individuals with Aβ pathology (Aβ+) showed that CU Aβ+individuals had a higher brain-age delta than CU Aβ- individuals (<xref ref-type="bibr" rid="bib55">Ly et al., 2020</xref>). Other lines of research have employed brain-age delta to predict conversion to different disease stages. For instance, it was previously studied the impact of using brain-age, alone and in combination with several biomarkers, to predict progression from MCI to AD (<xref ref-type="bibr" rid="bib68">Popescu et al., 2020</xref>). In addition, a recent study used brain-age measurements to identify amnestic MCI (aMCI), the typical clinical presentation of prodromal AD, from other individuals with MCI, by studying the association with AD risk factors such as apolipoprotein Ε (<italic>APOE</italic>) and Aβ (<xref ref-type="bibr" rid="bib42">Huang et al., 2021</xref>). The association of brain-age with these biomarkers have also been shown in other diseases, by which brain-age was associated with Aβ deposition in Down syndrome (<xref ref-type="bibr" rid="bib19">Cole et al., 2017b</xref>). Nonetheless, there remains a need to replicate some of these results and to study the associations between brain-age prediction and abnormal biomarkers of AD and neurodegeneration in preclinical and prodromal AD stages in different and independent cohorts and in a larger sample size. These results would be particularly informative to potentially inform therapeutic interventions.</p><p>Moreover, given that female individuals have a higher AD prevalence compared to males (<xref ref-type="bibr" rid="bib62">Nebel et al., 2018</xref>) and display different lifetime trajectories in the brain morphological features (<xref ref-type="bibr" rid="bib37">Gennatas et al., 2017</xref>), it is of interest to determine the effect of sex on brain age delta and its interaction with AD biomarkers. Literature describes sex differences in AD biomarkers, such as that females with abnormal Aβ who are <italic>APOE</italic>-ε4 carriers show greater subsequent increase in cerebrospinal fluid (CSF) tau than their male counterparts (<xref ref-type="bibr" rid="bib13">Buckley et al., 2019</xref>), or that females with higher Aβ burden show higher entorhinal cortical tau than their male counterparts (<xref ref-type="bibr" rid="bib13">Buckley et al., 2019</xref>). Conversely, levels of the neurodegeneration biomarker CSF neurofilament light (NfL) have been widely reported to be higher in males than in females (<xref ref-type="bibr" rid="bib59">Mielke, 2020</xref>; <xref ref-type="bibr" rid="bib60">Milà-Alomà et al., 2020</xref>). In line with this, sex differences in the brain-age delta have been also reported. For instance, AD risk factors have been associated with greater brain aging in women than men (<xref ref-type="bibr" rid="bib72">Sanford et al., 2022</xref>; <xref ref-type="bibr" rid="bib79">Subramaniapillai et al., 2021</xref>) and a lower brain aging has been found in the lower in the prefrontal cortex and insula in females (<xref ref-type="bibr" rid="bib72">Sanford et al., 2022</xref>). These results need to be replicated and further studied in different cohorts.</p><p>Therefore, in the present study, we aim to validate brain-age delta as a clinically relevant marker of brain aging, which can be impacted by AD pathology and neurodegeneration even in non-demented individuals. For this purpose, we determine the association between the predicted structural brain-age delta with biomarkers and risk factors for AD and neurodegeneration in non-demented individuals, as well as to study the effect of sex on these associations. We trained a model to predict the brain-age separately for females and males, using machine learning on imaging-derived measures of cortical thickness, cortical volume, and subcortical volume from the UK Biobank cohort (N=22,661). Using this model, we then estimated brain-age in four independent cohorts: ALFA+ (N=380), ADNI (N=719), EPAD (N=808), and OASIS (N=407). In each cohort, we studied the associations of brain-age delta with biomarkers of AD pathology (CSF Aβ and p-tau as continuous values, as well as categorized in AT stages), the <italic>APOE</italic>-ε4 genotype which is the main genetic risk factor for AD, neurodegeneration (CSF and plasma NfL), and small vessel disease (White Matter Hyperintensities [WMH]). Finally, we studied the sex differences in brain age prediction and the sex effects with these biomarkers on brain-age delta.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Participants’ characteristics</title><p><xref ref-type="table" rid="table1">Table 1</xref> summarizes the demographic characteristics of the cohorts included in the study. ADNI and EPAD cohorts included both CU and MCI individuals, while the UK Biobank, ALFA + and OASIS cohorts only included CU individuals. <xref ref-type="table" rid="table2">Table 2</xref> summarizes the variables used to study the associations with brain-age delta, which included biomarkers for AD (Aβ positron emission tomography [PET] and CSF Aβ and p-tau), neurodegeneration (CSF and plasma NfL), and cerebrovascular pathology (WMH on MRI), as well as the aging signature composite (<xref ref-type="bibr" rid="bib3">Bakkour et al., 2013</xref>), both cross-sectional and longitudinally. The aging signature composite is a map of specific brain regions that undergo cortical thinning in normal aging, which has been used as a proxy measurement for brain aging. These validation variables were correlated with chronological age for all cohorts (see <xref ref-type="table" rid="app1table1">Appendix 1—table 1</xref>). Some of the participants for ALFA+ (N=25), ADNI (N=116), and EPAD (N=71) fell into the A-T +group, corresponding to non-AD pathologic change. Since our aim was to specifically validate the brain-age delta measurements in the AD <italic>continuum</italic>, we excluded these participants from subsequent analyses; and they are reported within <xref ref-type="table" rid="table1">Table 1</xref> and <xref ref-type="table" rid="table2">Table 2</xref> solely for descriptive purposes. In addition, the number of MCI individuals with available data of CSF NfL and of aging signature change was relatively low and, therefore, these variables were excluded from the analysis in MCI individuals.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Sample demographics and characteristics separated by cohort and by diagnosis.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="bottom" colspan="6">CU</th><th align="center" valign="bottom" colspan="2">MCI</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="2"><bold>Characteristics</bold></td><td align="left" valign="bottom"><bold>UK Biobank</bold></td><td align="left" valign="bottom"><bold>ALFA+</bold></td><td align="left" valign="bottom"><bold>ADNI</bold></td><td align="left" valign="bottom"><bold>EPAD</bold></td><td align="left" valign="bottom"><bold>OASIS</bold></td><td align="left" valign="bottom"><bold>ADNI</bold></td><td align="left" valign="bottom"><bold>EPAD</bold></td></tr><tr><td align="left" valign="bottom">(N=22,661)</td><td align="left" valign="bottom">(N=380)</td><td align="left" valign="bottom">(N=284)</td><td align="left" valign="bottom">(N=653)</td><td align="left" valign="bottom">(N=407)</td><td align="left" valign="bottom">(N=435)</td><td align="left" valign="bottom">(N=155)</td></tr><tr><td align="left" valign="bottom"><bold>Age, years</bold></td><td align="left" valign="bottom">64.54 (7.55)</td><td align="left" valign="bottom">60.61 (4.72)</td><td align="left" valign="bottom">71.42 (6.36)</td><td align="left" valign="bottom">64.96 (7.01)</td><td align="left" valign="bottom">69.07 (9.42)</td><td align="left" valign="bottom">71.09 (7.31)</td><td align="left" valign="bottom">69.08 (6.97)</td></tr><tr><td align="left" valign="bottom"><bold>Age range, years</bold></td><td align="left" valign="bottom">[44, 81]</td><td align="left" valign="bottom">[48, 73]</td><td align="left" valign="bottom">[55, 89]</td><td align="left" valign="bottom">[50, 88]</td><td align="left" valign="bottom">[42, 89]</td><td align="left" valign="bottom">[55, 91]</td><td align="left" valign="bottom">[52, 88]</td></tr><tr><td align="left" valign="bottom"><bold>Female, n (%</bold>)</td><td align="left" valign="bottom">11,767 (51.92)</td><td align="left" valign="bottom">254 (60.76)</td><td align="left" valign="bottom">126 (50.00)</td><td align="left" valign="bottom">386 (59.11)</td><td align="left" valign="bottom">244 (59.95)</td><td align="left" valign="bottom">249 (50.00)</td><td align="left" valign="bottom">81 (47.74)</td></tr><tr><td align="left" valign="bottom"><bold>Education, years</bold></td><td align="left" valign="bottom">17.75 (5.42)</td><td align="left" valign="bottom">13.43 (3.71)</td><td align="left" valign="bottom">16.54 (2.49)</td><td align="left" valign="bottom">14.83 (3.56)</td><td align="left" valign="bottom">15.93 (2.59)</td><td align="left" valign="bottom">16.23 (2.71)</td><td align="left" valign="bottom">14.17 (3.77)</td></tr><tr><td align="left" valign="bottom"><bold><italic>APOE</italic>-ε4 carriers, n (%</bold>)</td><td align="left" valign="bottom">6,334 (27.95)</td><td align="left" valign="bottom">221 (52.87)</td><td align="left" valign="bottom">72 (28.57)</td><td align="left" valign="bottom">217 (33.23)</td><td align="left" valign="bottom">118 (28.99)</td><td align="left" valign="bottom">218 (43.78)</td><td align="left" valign="bottom">60 (38.71)</td></tr><tr><td align="left" valign="bottom"><bold>MMSE</bold></td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">29.15 (0.95)</td><td align="left" valign="bottom">28.985 (1.24)</td><td align="left" valign="bottom">28.82 (1.40)</td><td align="left" valign="bottom">29.03 (1.31)</td><td align="left" valign="bottom">27.57 (2.19)</td><td align="left" valign="bottom">27.86 (1.97)</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: Data are expressed as mean (M) and standard deviation (SD) or percentage (%), as appropriate. Abbreviations: APOE, apolipoprotein E; MMSE, Mini-Mental State Examination.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Biomarkers separated by cohort and by diagnosis.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" rowspan="2"/><th align="left" valign="bottom" colspan="8">CU</th><th align="left" valign="bottom" colspan="4">MCI</th></tr><tr><th align="left" valign="bottom" colspan="2">ALFA+</th><th align="left" valign="bottom" colspan="2">ADNI</th><th align="left" valign="bottom" colspan="2">EPAD</th><th align="left" valign="bottom" colspan="2">OASIS</th><th align="left" valign="bottom" colspan="2">ADNI</th><th align="left" valign="bottom" colspan="2">EPAD</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>BIOMARKERS</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Mean (SD</bold>)</td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Mean (SD</bold>)</td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Mean (SD</bold>)</td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Mean (SD</bold>)</td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Mean (SD</bold>)</td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Mean (SD</bold>)</td></tr><tr><td align="left" valign="bottom"><bold>Centiloids</bold></td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">407</td><td align="left" valign="bottom">13.468 (28.138)</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom"><bold>CSF Aβ42 (pg/mL)</bold><xref ref-type="table-fn" rid="table2fn3">*</xref></td><td align="left" valign="bottom">380</td><td align="left" valign="bottom">1318.059 (599.223)</td><td align="left" valign="bottom">284</td><td align="left" valign="bottom">1223.890 (556.648)</td><td align="left" valign="bottom">653</td><td align="left" valign="bottom">1403.617 (681.736)</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">435</td><td align="left" valign="bottom">986.248 (446.402)</td><td align="left" valign="bottom">155</td><td align="left" valign="bottom">1245.181 (741.756)</td></tr><tr><td align="left" valign="bottom"><bold>CSF p-tau (pg/mL</bold>)</td><td align="left" valign="bottom">380</td><td align="left" valign="bottom">16.289 (7.813)</td><td align="left" valign="bottom">283</td><td align="left" valign="bottom">22.234 (9.692)</td><td align="left" valign="bottom">627</td><td align="left" valign="bottom">18.326 (8.380)</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">434</td><td align="left" valign="bottom">26.490 (14.402)</td><td align="left" valign="bottom">151</td><td align="left" valign="bottom">24.715 (14.897)</td></tr><tr><td align="left" valign="bottom"><bold>CSF NfL (pg/mL)</bold><xref ref-type="table-fn" rid="table2fn4">†</xref></td><td align="left" valign="bottom">380</td><td align="left" valign="bottom">82.717 (29.124)</td><td align="left" valign="bottom">26</td><td align="left" valign="bottom">1052.444 (376.095)</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">48</td><td align="left" valign="bottom">1383.638 (918.231)</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom"><bold>Plasma NfL (pg/mL</bold>)</td><td align="left" valign="bottom">368</td><td align="left" valign="bottom">10.519 (3.739)</td><td align="left" valign="bottom">184</td><td align="left" valign="bottom">35.843 (17.988)</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">404</td><td align="left" valign="bottom">38.157 (18.908)</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom"><bold>WMH volume</bold></td><td align="left" valign="bottom">360</td><td align="left" valign="bottom">0.045 (0.845)</td><td align="left" valign="bottom">240</td><td align="left" valign="bottom">–0.0085 (1.267)</td><td align="left" valign="bottom">456</td><td align="left" valign="bottom">0.038 (1.072)</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">458</td><td align="left" valign="bottom">–0.005 (1.229)</td><td align="left" valign="bottom">108</td><td align="left" valign="bottom">0.048 (1.076)</td></tr><tr><td align="left" valign="bottom"><bold>Aging signature</bold><xref ref-type="table-fn" rid="table2fn4">†</xref></td><td align="left" valign="bottom">360</td><td align="left" valign="bottom">2.387 (0.071)</td><td align="left" valign="bottom">240</td><td align="left" valign="bottom">2.284 (0.105)</td><td align="left" valign="bottom">456</td><td align="left" valign="bottom"/><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">458</td><td align="left" valign="bottom">2.251 (0.109)</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom"><bold>Aging signature V2</bold><xref ref-type="table-fn" rid="table2fn4">†</xref></td><td align="left" valign="bottom">187</td><td align="left" valign="bottom">2.376 (0.072)</td><td align="left" valign="bottom">45</td><td align="left" valign="bottom">2.299 (0.118)</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">46</td><td align="left" valign="bottom">2.257 (0.119)</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom"><bold>Aging signature change</bold> ( <inline-formula><mml:math id="inf1"><mml:mfrac bevelled="true"><mml:mrow><mml:mi mathvariant="bold-italic">V</mml:mi><mml:mn>2</mml:mn><mml:mo>-</mml:mo><mml:mi mathvariant="bold-italic">V</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="bold"> </mml:mi><mml:mi mathvariant="bold-italic">t</mml:mi></mml:mrow></mml:mfrac></mml:math></inline-formula>)<xref ref-type="table-fn" rid="table2fn4">†</xref></td><td align="left" valign="bottom">187</td><td align="left" valign="bottom">–0.003 (0.011)</td><td align="left" valign="bottom">45</td><td align="left" valign="bottom">–0.0007 (0.037)</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">46</td><td align="left" valign="bottom">–0.003 (0.050)</td><td align="left" valign="bottom">0</td><td align="left" valign="bottom">-</td></tr></tbody></table><table-wrap-foot><fn><p>Data are expressed as mean (M) and standard deviation (SD) or percentage (%), as appropriate. Amyloid-β status was defined by CSF (ALFA+, ADNI and EPAD) or amyloid PET (OASIS). For ALFA+ and ADNI, we calculated the aging signature from MRI scans acquired 3 years later than the original MRI scan, called aging signature V2. Aging signature change was calculated as the difference in aging signature over these two MRI scans.</p></fn><fn><p>Abbreviations: CSF, cerebrospinal fluid; NfL, neurofilament light; WMH, White Matter Hyperintensities.</p></fn><fn id="table2fn3"><label>*</label><p>Individuals that fell into the A-T+group: 25 from ALFA+, 116 from ADNI and 71 from EPAD.</p></fn><fn id="table2fn4"><label>†</label><p>As the number of MCI individuals with CSF NfL and aging signature change was relatively low, we excluded them from the following results.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-2"><title>Brain-age prediction and chronological age</title><p>We trained the prediction model using the UK Biobank cohort and tested the model using four independent cohorts (ALFA+, ADNI, EPAD, and OASIS), as shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>. <xref ref-type="table" rid="table3">Table 3</xref> shows the prediction accuracy for the combined female and male predictions. The average prediction accuracy of the model run on UK Biobank using 10-fold cross-validation as measured by the mean absolute error (MAE) and by Pearson’s correlation were MAE = 4.19 and <italic>R</italic>=0.71 (<xref ref-type="table" rid="table3">Table 3</xref> and <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Overview of project steps.</title><p>Illustration of the methods used to generate predicted brain-age and to study the associations between the brain-age delta and the biomarkers and risk factors used. 3D T1-weighted MRI scans across all cohorts were segmented into volumes and thickness using the Desikan-Killiany and the aseg atlas. <bold>1. Training phase</bold>: We trained XGBoost regressor models for females and males from the UK Biobank. For this we performed a cross-validation scheme with 10-folds and 10 repeats per fold. <bold>2. Testing phase</bold>: We tested the age prediction models on unseen data from independent cohorts: ALFA+ (in blue), ADNI (in green), EPAD (in gray), and OASIS (in orange). <bold>3 Analyses phase</bold>: We computed the brain-age delta for each cohort. We then studied the associations with the biomarkers and risk factors of AD, neurodegeneration, and cardiovascular risk. We performed these analyses within the whole sample and stratified by sex. The table on the bottom left shows the available biomarkers and risk factor available for which cohorts.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81067-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Predicted brain-age in validation subsamples of UK Biobank for females (blue) and males (orange).</title><p>On the left, original prediction. On the right, prediction after bias correction.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81067-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Predicted brain-age versus chronological age for (<bold>a</bold>) ALFA+, (<bold>b</bold>) ADNI, (<bold>c</bold>) EPAD, and (<bold>d</bold>) OASIS cohorts.</title><p>In blue, female subjects and in green, male subjects.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81067-fig1-figsupp2-v2.tif"/></fig></fig-group><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Prediction metrics for all independent cohorts.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Cohorts</th><th align="left" valign="bottom" colspan="2">Correlation with age</th><th align="left" valign="bottom">MAE (y)</th><th align="left" valign="bottom" colspan="2">R<sup>2</sup></th><th align="left" valign="bottom" colspan="2">RMSE</th></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>R</bold></td><td align="left" valign="bottom"><bold>P-value</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom" colspan="2"/><td align="left" valign="bottom" colspan="2"/></tr><tr><td align="left" valign="bottom" colspan="8">Before bias correction</td></tr><tr><td align="left" valign="bottom"><bold>UK Biobank</bold></td><td align="char" char="." valign="bottom">0.712 (0.007)</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">4.19 (0.07)</td><td align="char" char="." valign="bottom" colspan="2">0.51 (0.03)</td><td align="char" char="." valign="bottom" colspan="2">5.25 (0.08)</td></tr><tr><td align="left" valign="bottom"><bold>ALFA+</bold></td><td align="char" char="." valign="bottom">0.448</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">4.31</td><td align="char" char="." valign="bottom" colspan="2">0.20</td><td align="char" char="." valign="bottom" colspan="2">4.18</td></tr><tr><td align="left" valign="bottom"><bold>ADNI</bold></td><td align="char" char="." valign="bottom">0.587</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">7.21</td><td align="char" char="." valign="bottom" colspan="2">0.34</td><td align="char" char="." valign="bottom" colspan="2">5.47</td></tr><tr><td align="left" valign="bottom"><bold>EPAD</bold></td><td align="char" char="." valign="bottom">0.629</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">4.63</td><td align="char" char="." valign="bottom" colspan="2">0.40</td><td align="char" char="." valign="bottom" colspan="2">5.62</td></tr><tr><td align="left" valign="bottom"><bold>OASIS</bold></td><td align="char" char="." valign="bottom">0.733</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">6.99</td><td align="char" char="." valign="bottom" colspan="2">0.54</td><td align="char" char="." valign="bottom" colspan="2">6.42</td></tr></tbody></table><table-wrap-foot><fn><p>The Pearson’s correlation coefficient (R) between predicted brain-age and chronological age, R<sup>2</sup>, root mean square error (RMSE), and mean absolute error (MAE) for UK Biobank and for each of the independent cohorts before bias correction. For UK Biobank, the metrics, given as mean (standard deviation) are computed from 10-fold cross validation repeated 10 times.</p></fn></table-wrap-foot></table-wrap><p>We then investigated the association of predicted brain-age with chronological age on each of the independent cohorts. All the cohorts showed a similar positive correlation and fitting performance metrics as measured by the MAE, R and root mean squared error (RMSE) between chronological age and predicted brain-age. Correlation coefficients were not different between cohorts (<italic>P</italic>&gt;0.05, for all comparisons, see <xref ref-type="table" rid="app1table2">Appendix 1—table 2</xref>). We also studied the performance metrics for the two different diagnostic groups (CU and MCI) for each cohort, see <xref ref-type="table" rid="app1table3">Appendix 1—table 3</xref>.</p><p>In order to study the effect of sex on brain age prediction, we also computed the performance metrics stratified by females and males (<xref ref-type="table" rid="app1table4">Appendix 1—table 4</xref> and <xref ref-type="table" rid="app1table5">Appendix 1—table 5</xref>). Correlations and fitting performance metrics were not significantly different between females and males (Pearson’s r (William’s test), <italic>P</italic>&gt;0.05; RMSE (F-test) <italic>P</italic>&gt;0.05), see <xref ref-type="table" rid="app1table6">Appendix 1—table 6</xref>. Plots of the correlations between predicted brain-age and chronological age for females and males in each of the cohorts can be seen in the <xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>. Additionally, results for a secondary analysis in which we compared the fitting performance of XGBoost brain-age and of the neuroanatomical aging signature (<xref ref-type="bibr" rid="bib3">Bakkour et al., 2013</xref>) with respect to chronological age can be seen in <xref ref-type="table" rid="app1table7">Appendix 1—table 7</xref>.</p></sec><sec id="s2-3"><title>Brain regions associated with aging</title><p>We computed the SHapley Additive exPlanation (SHAP) values, which reflect the marginal contribution of each brain region to the brain-age prediction, using the UK Biobank dataset. SHAP values interpret the impact in the prediction of the values of volume or cortical thickness for a given brain region. In other words, they reflect the most important features that consistently influenced the prediction of brain-age and whether the decrease or increase of each region impacted into predicting a higher or lower brain-age. The SHAP values were computed separately for females and males. We compared the regions with higher SHAP values for females and males, and vice-versa, by averaging the SHAP values within each sex separately and then subtracting the mean SHAP of males to the mean SHAP of females.</p><p>There were regions whose SHAP values were high in both females and males, including the volumes of the amygdala, nucleus accumbens, cerebellar white matter, lateral ventricles and the insula, as well as the cortical thickness of the superior-temporal cortex. All the brain regions with consistent highest SHAP values for females and males are shown in <xref ref-type="fig" rid="fig2">Figure 2a–b</xref>, as well as the effect of each region (larger or lower value) on predicting a higher brain-age. Conversely, the thickness of regions such as the transverse temporal cortex, the pars triangularis, the inferior parietal cortex and the left frontal pole thickness, as well as the volume of the left entorhinal cortex had higher SHAP values in females than in males, while the opposite occurred with the thickness of the left isthmus cingulate and the right cuneus and the cortical volume of the superior frontal and right rostral middle regions (<xref ref-type="fig" rid="fig2">Figure 2c</xref>).</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Significant SHAP-selected brain regions most important in prediction for (<bold>a</bold>) females and (<bold>b</bold>) males separately.</title><p>Significance was studied by assessing the stability of the region’s importance by performing subsampling of data over 1,000 permutations. Colored regions had a <italic>P</italic> &lt; 0.05 corrected for multiple comparisons using Bonferroni correction approach. Regions in red show larger volume or cortical thickness, while regions in blue show lower volume or cortical thickness. In (<bold>c</bold>), comparison for the regions with higher SHAP values that were significant for females (green) and males (purple). The color map shows the results from subtracting the males’ mean SHAP value to the female’s mean SHAP value for each region. In (<bold>d</bold>), examples of the fit of three significant SHAP-selected regions against chronological age for females and males. For visualization purposes, nonparametric smoothing spline functions were used to fit the data (mean ± 95%CI).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81067-fig2-v2.tif"/></fig><p>In <xref ref-type="fig" rid="fig2">Figure 2d</xref>, we can see the fit of three example regions whose SHAP values were different for females and males against chronological age. For example, the bi-lateral superior frontal volumes decreased more over the years within males than females. This result was seen as the interaction of sex with age (<italic>P<sub>interaction</sub></italic> &lt;0.001). We also found an interaction effect of sex and age for the isthmus cingulate thickness (<italic>P</italic><sub>interatcion</sub> &lt;0.001), by which the thickness of males decreased more over the years than from the females. On the contrary, we also found regions, such as the middle temporal thickness, whose slope was not different between for both sexes (<italic>P</italic><sub>interaction</sub> = 0.671), but which appeared to be lower for females than for males. All the results of this exploratory analysis can be seen in <xref ref-type="table" rid="app1table8">Appendix 1—table 8</xref>.</p></sec><sec id="s2-4"><title>Associations with AD biomarkers and risk factors</title><p>We studied the association between brain-age delta and AD biomarker classifications (Aβ status, AT stages) and <italic>APOE-</italic>ε4 status in all the independent cohorts pooled together, with a linear model adjusting for the effect of age and sex (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="table" rid="table4">Table 4</xref>). Aβ status was defined by CSF (ALFA+, ADNI, and EPAD) or amyloid PET (OASIS) using pre-established cut-off values (<xref ref-type="bibr" rid="bib41">Hansson et al., 2018</xref>; <xref ref-type="bibr" rid="bib60">Milà-Alomà et al., 2020</xref>; <xref ref-type="bibr" rid="bib71">Salvadó et al., 2019</xref>; <xref ref-type="bibr" rid="bib73">Schindler et al., 2018</xref>). Brain-age delta was higher in MCI with respect to CU individuals (<italic>P<sub>FDR</sub></italic> &lt;0.001). In both CU and MCI, a higher brain-age delta was significantly associated with abnormal Aβ status (CU: <italic>P<sub>FDR</sub></italic> &lt;0.001 and MCI: <italic>P<sub>FDR</sub></italic> &lt;0.001) and with progressive AT stages (CU: <italic>P<sub>FDR</sub></italic> &lt;0.001 and MCI: <italic>P<sub>FDR</sub></italic> &lt;0.001) (see <xref ref-type="table" rid="table4">Table 4</xref> and <xref ref-type="table" rid="app1table9">Appendix 1—table 9</xref> for more details). The mean brain-age delta values for the different Aβ status and AT stages can be found in <xref ref-type="table" rid="app1table10">Appendix 1—table 10</xref>. The brain-age effect on AT stages was progressive, as that of the A+T- group was larger than that of A-T-, while the brain-age delta of A+T + was larger than those of the other two previous stages (<xref ref-type="table" rid="table4">Table 4</xref> and <xref ref-type="fig" rid="fig3">Figure 3a</xref>). Brain-age delta was also significantly associated with <italic>APOE</italic> status (CU: <italic>P<sub>FDR</sub></italic> = 0.002 and MCI: <italic>P</italic>=0.017, <italic>P<sub>FDR</sub></italic> = 0.040). In particular, <italic>APOE</italic>-ε4 carriers had larger brain-age deltas (i.e. older-appearing brains than expected for their chronological age) compared to <italic>APOE</italic>-ε33 individuals for both CU (<italic>β</italic>=0.173, <italic>P<sub>FDR</sub></italic> = 0.003) and MCI (<italic>β</italic>=0.273, <italic>P<sub>FDR</sub></italic> = 0.008; see <xref ref-type="table" rid="table4">Table 4</xref> and <xref ref-type="fig" rid="fig3">Figure 3</xref>). The mean brain-age delta values for the different <italic>APOE</italic> status can be found in <xref ref-type="table" rid="app1table7">Appendix 1—table 7</xref>. These results were consistent with the results from the within-cohort analyses (see <xref ref-type="table" rid="app1table11">Appendix 1—table 11</xref>).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>In (<bold>a</bold>) and (<bold>b</bold>), the standardized associations (<italic>β</italic>±95% CI) between measures of brain-age delta validation variables for (<bold>a</bold>) CU individuals and (<bold>b</bold>) MCI individuals.</title><p>Variables include AD biomarkers and risk factors: amyloid-β status, AT stages and APOE status; and neurodegeneration markers (available in ALFA + and ADNI): CSF NfL, plasma NfL and aging signature change. The analyses included age and sex as covariates. Sample size for each variable can be seen in <xref ref-type="table" rid="table4">Table 4</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81067-fig3-v2.tif"/></fig><table-wrap id="table4" position="float"><label>Table 4.</label><caption><title>Relationships between validation variables and brain-age delta for all CU and MCI individuals.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" colspan="2">Model</th><th align="left" valign="top">β</th><th align="left" valign="top">SE</th><th align="left" valign="top"><italic>P</italic>-Value</th><th align="left" valign="top">[0.025]</th><th align="left" valign="top">[0.975]</th><th align="left" valign="top">N</th><th align="left" valign="top">Effect size</th><th align="left" valign="top">FDR corr <italic>P</italic>-Value</th></tr></thead><tbody><tr><td align="left" valign="top" colspan="9"><bold>CU Individuals</bold></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top" colspan="2"><bold>Amyloid-β pathology (ref: A-)</bold></td><td align="char" char="." valign="top">0.234</td><td align="char" char="." valign="top">0.047</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="char" char="." valign="top">0.140</td><td align="char" char="." valign="top">0.325</td><td align="char" char="." valign="top">1634</td><td align="char" char="." valign="top">0.222</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="top" rowspan="2"><bold>Amyloid-β / Tau pathology (ref: A-T-)</bold></td><td align="left" valign="top"><bold>A+T-</bold></td><td align="char" char="." valign="top">0.2023</td><td align="char" char="." valign="top">0.059</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="char" char="." valign="top">0.015</td><td align="char" char="." valign="top">0.394</td><td align="char" char="." valign="top" rowspan="2">1162</td><td align="char" char="." valign="top">0.275</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="top"><bold>A+T</bold> +</td><td align="char" char="." valign="top">0.310</td><td align="char" char="." valign="top">0.096</td><td align="char" char="." valign="top"><bold>0.003</bold></td><td align="char" char="." valign="top">0.101</td><td align="char" char="." valign="top">0.500</td><td align="char" char="." valign="top">0.300</td><td align="char" char="." valign="top"><bold>0.008</bold></td></tr><tr><td align="left" valign="top" rowspan="3"><bold><italic>APOE</italic> status (ref: <italic>APOE</italic>-ε33)</bold></td><td align="left" valign="top"><italic>APOE</italic>-ε2</td><td align="char" char="." valign="top">–0.124</td><td align="char" char="." valign="top">0.082</td><td align="char" char="." valign="top">0.130</td><td align="char" char="." valign="top">–0.321</td><td align="char" char="." valign="top">0.334</td><td align="char" char="." valign="top" rowspan="3">1634</td><td align="char" char="." valign="top">0.122</td><td align="char" char="." valign="top">0.227</td></tr><tr><td align="left" valign="top"><italic>APOE</italic>-ε4</td><td align="char" char="." valign="top">0.173</td><td align="char" char="." valign="top">0.052</td><td align="char" char="." valign="top"><bold>0.001</bold></td><td align="char" char="." valign="top">0.071</td><td align="char" char="." valign="top">0.274</td><td align="char" char="." valign="top">0.172</td><td align="char" char="." valign="top"><bold>0.003</bold></td></tr><tr><td align="left" valign="top"><italic>APOE</italic>-ε24</td><td align="char" char="." valign="top">0.012</td><td align="char" char="." valign="top">0.144</td><td align="char" char="." valign="top">0.936</td><td align="char" char="." valign="top">–0.271</td><td align="char" char="." valign="top">0.294</td><td align="char" char="." valign="top">0.011</td><td align="char" char="." valign="top">0.999</td></tr><tr><td align="left" valign="top" colspan="2"><bold>WMH volume</bold><xref ref-type="table-fn" rid="table4fn5"><sup>*</sup></xref></td><td align="char" char="." valign="top">0.160</td><td align="char" char="." valign="top">0.030</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="char" char="." valign="top">0.111</td><td align="char" char="." valign="top">0.231</td><td align="char" char="." valign="top">972</td><td align="char" char="." valign="top">0.028</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="top" colspan="2"><bold>CSF NfL</bold><xref ref-type="table-fn" rid="table4fn6"><sup>†</sup></xref></td><td align="char" char="." valign="top">0.079</td><td align="char" char="." valign="top">0.049</td><td align="char" char="." valign="top">0.112</td><td align="char" char="." valign="top">–0.019</td><td align="char" char="." valign="top">0.176</td><td align="char" char="." valign="top">378</td><td align="char" char="." valign="top">0.006</td><td align="char" char="." valign="top">0.209</td></tr><tr><td align="left" valign="top" colspan="2"><bold>Plasma NfL</bold><xref ref-type="table-fn" rid="table4fn6"><sup>†</sup></xref></td><td align="char" char="." valign="top">0.154</td><td align="char" char="." valign="top">0.045</td><td align="char" char="." valign="top"><bold>0.001</bold></td><td align="char" char="." valign="top">0.066</td><td align="char" char="." valign="top">0.242</td><td align="char" char="." valign="top">508</td><td align="char" char="." valign="top">0.024</td><td align="char" char="." valign="top"><bold>0.003</bold></td></tr><tr><td align="left" valign="top" colspan="2"><bold>Brain Atrophy</bold><xref ref-type="table-fn" rid="table4fn6"><sup>†</sup></xref></td><td align="char" char="." valign="top">0.053</td><td align="char" char="." valign="top">0.048</td><td align="char" char="." valign="top">0.272</td><td align="char" char="." valign="top">–0.041</td><td align="char" char="." valign="top">0.146</td><td align="char" char="." valign="top">152</td><td align="char" char="." valign="top">0.003</td><td align="char" char="." valign="top">0.415</td></tr><tr><td align="left" valign="top" colspan="9"><bold>MCI Individuals</bold></td><td align="left" valign="top"/></tr><tr><td align="left" valign="top" colspan="2"><bold>Amyloid-β pathology</bold></td><td align="char" char="." valign="top">0.640</td><td align="char" char="." valign="top">0.089</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="char" char="." valign="top">0.465</td><td align="char" char="." valign="top">0.816</td><td align="char" char="." valign="top">218</td><td align="char" char="." valign="top">0.665</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="top" rowspan="2"><bold>Amyloid-β / Tau pathology (ref: A-T-)</bold></td><td align="left" valign="top"><bold>A+T-</bold></td><td align="char" char="." valign="top">0.564</td><td align="char" char="." valign="top">0.109</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="char" char="." valign="top">0.350</td><td align="char" char="." valign="top">0.778</td><td align="char" char="." valign="top" rowspan="2">218</td><td align="char" char="." valign="top">0.592</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="top"><bold>A+T</bold> +</td><td align="char" char="." valign="top">0.720</td><td align="char" char="." valign="top">0.102</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="char" char="." valign="top">0.519</td><td align="char" char="." valign="top">0.920</td><td align="char" char="." valign="top">0.720</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="top" rowspan="3"><bold><italic>APOE</italic> status (ref: <italic>APOE</italic>-ε33)</bold></td><td align="left" valign="top"><italic>APOE</italic>-ε2</td><td align="char" char="." valign="top">0.007</td><td align="char" char="." valign="top">0.167</td><td align="char" char="." valign="top">0.968</td><td align="char" char="." valign="top">–0.273</td><td align="char" char="." valign="top">0.978</td><td align="char" char="." valign="top" rowspan="3">218</td><td align="char" char="." valign="top">0.001</td><td align="char" char="." valign="top">0.999</td></tr><tr><td align="left" valign="top"><italic>APOE</italic>-ε4</td><td align="char" char="." valign="top">0.273</td><td align="char" char="." valign="top">0.093</td><td align="char" char="." valign="top"><bold>0.003</bold></td><td align="char" char="." valign="top">0.091</td><td align="char" char="." valign="top">0.456</td><td align="char" char="." valign="top">0.281</td><td align="char" char="." valign="top"><bold>0.008</bold></td></tr><tr><td align="left" valign="top"><italic>APOE</italic>-ε24</td><td align="char" char="." valign="top">0.352</td><td align="char" char="." valign="top">0.319</td><td align="char" char="." valign="top">0.269</td><td align="char" char="." valign="top">–0.273</td><td align="char" char="." valign="top">0.978</td><td align="char" char="." valign="top">0.359</td><td align="char" char="." valign="top">0.415</td></tr><tr><td align="left" valign="top" colspan="2"><bold>WMH volume</bold></td><td align="char" char="." valign="top">0.222</td><td align="char" char="." valign="top">0.054</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="char" char="." valign="top">0.117</td><td align="char" char="." valign="top">0.327</td><td align="char" char="." valign="top">191</td><td align="char" char="." valign="top">0.040</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="top" colspan="2"><bold>Plasma NfL</bold><xref ref-type="table-fn" rid="table4fn7"><sup>‡</sup></xref></td><td align="char" char="." valign="top">0.242</td><td align="char" char="." valign="top">0.067</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="char" char="." valign="top">0.110</td><td align="char" char="." valign="top">0.374</td><td align="char" char="." valign="top">134</td><td align="char" char="." valign="top">0.046</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Notes: Relationships between validation variables and Brain-Age delta from all CU pooled subjects (including ALFA+, ADNI, EPAD and OASIS) and all MCI pooled subjects (including ADNI and EPAD). Results given by the linear model: brain-age delta ~each variable +chronological age+sex. The regression coefficients (β), standard errors (SE), P-value, 95% Confidence Interval, number of individuals (N) and effect size are depicted for each variable.</p></fn><fn><p>Significant values after FDR correction (<italic>P</italic>&lt;0.05) are marked in bold.</p></fn><fn><p>Effect size in categorical variables was calculated as Cohen’s D, while Cohens f<sup>2</sup> was calculated for continuous measurements. Amyloid-β status was defined by CSF (ALFA+, ADNI, and EPAD) or amyloid PET (OASIS). MCI individuals only contained individuals from ADNI and EPAD.</p></fn><fn><p>APOE, apolipoprotein E; WMH, White Matter Hyperintensities; CSF, cerebrospinal fluid; NfL, neurofilament light; ref, reference.</p></fn><fn id="table4fn5"><label>*</label><p>Contains data from ALFA+, ADNI and EPAD.</p></fn><fn id="table4fn6"><label>†</label><p>Contains data from ALFA +and ADNI.</p></fn><fn id="table4fn7"><label>‡</label><p>Contains data from ADNI.</p></fn></table-wrap-foot></table-wrap><p>We next studied the association between brain-age delta and AD biomarkers and risk factors stratified by sex (<xref ref-type="table" rid="table5">Table 5</xref>). In general, the same associations found with the whole sample was seen for females and males separately. However, although a higher brain-age delta was significantly associated with progressive AT stages both for females (CU: <italic>P<sub>FDR</sub></italic> = 0.002 and MCI: <italic>P<sub>FDR</sub></italic> &lt;0.001) and males (CU: <italic>P<sub>FDR</sub></italic> = 0.019 and MCI: <italic>P<sub>FDR</sub></italic> &lt;0.001), brain-age delta of A+T + was significantly larger than those of the other two previous stages (A-T- and A+T-) in CU females (<italic>β</italic>=0.431, <italic>P<sub>FDR</sub></italic> = 0.008) but not in CU males (<italic>β</italic>=0.139, <italic>P<sub>FDR</sub></italic> = 0.424). Brain-age delta was only significantly associated with <italic>APOE</italic> status in CU males (P<italic><sub>FDR</sub></italic> = 0.028), while this association was not seen in the rest of subgroups (CU and MCI females and MCI males). The rest of the associations tested with AD biomarkers, such as the interactions with sex, not reported here were non-significant.</p><table-wrap id="table5" position="float"><label>Table 5.</label><caption><title>Relationships between validation variables and brain-age delta stratified by sex for all CU and MCI individuals.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="3"/><th align="left" valign="bottom" colspan="6">Females</th><th align="left" valign="bottom" colspan="6">Males</th></tr></thead><tbody><tr><td align="left" valign="bottom" colspan="3"><bold>Model</bold></td><td align="left" valign="bottom"><bold>β (SE</bold>)</td><td align="left" valign="bottom"><bold><italic>P</italic>-Value</bold></td><td align="left" valign="bottom"><bold>[0.025, 0.075]</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Effect size</bold></td><td align="left" valign="bottom"><bold><italic>FDR corr P</italic>-Value corr</bold></td><td align="left" valign="bottom"><bold>β</bold></td><td align="left" valign="bottom"><bold><italic>P</italic>-Value</bold></td><td align="left" valign="bottom"><bold>[0.025, 0.075]</bold></td><td align="left" valign="bottom"><bold>N</bold></td><td align="left" valign="bottom"><bold>Effect size</bold></td><td align="left" valign="bottom"><bold>FDR corr <italic>P</italic>-Value</bold></td></tr><tr><td align="left" valign="bottom"/><td align="center" valign="bottom" colspan="13"><bold>CU Individuals</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom" colspan="3"><bold>Amyloid-β pathology (ref: A-)</bold></td><td align="left" valign="bottom">0.286 (0.065)</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">[0.160, 0.413]</td><td align="left" valign="bottom">966</td><td align="left" valign="bottom">0.288</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">0.341 (0.076)</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">[0.192, 0.490]</td><td align="left" valign="bottom">668</td><td align="left" valign="bottom">0.344</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom" rowspan="2" colspan="2"><bold>Amyloid-β / Tau pathology (ref: A-T-)</bold></td><td align="left" valign="bottom"><bold>A+T-</bold></td><td align="left" valign="bottom"><bold>0.250</bold> (<bold>0.082</bold>)</td><td align="left" valign="bottom"><bold>0.003</bold></td><td align="left" valign="bottom">[0.088, 0.411]</td><td align="left" valign="bottom" rowspan="2">688</td><td align="left" valign="bottom">0.252</td><td align="left" valign="bottom"><bold>0.008</bold></td><td align="left" valign="bottom">0.2978 (0.096)</td><td align="left" valign="bottom">0.<bold>002</bold></td><td align="left" valign="bottom">[0.110, 0.486]</td><td align="left" valign="bottom" rowspan="2">474</td><td align="left" valign="bottom">0.301</td><td align="left" valign="bottom"><bold>0.006</bold></td></tr><tr><td align="left" valign="bottom"><bold>A+T</bold> +</td><td align="left" valign="bottom"><bold>0.391</bold> (<bold>0.131</bold>)</td><td align="left" valign="bottom"><bold>0.003</bold></td><td align="left" valign="bottom">[0.134, 0.648]</td><td align="left" valign="bottom">0.385</td><td align="left" valign="bottom"><bold>0.008</bold></td><td align="left" valign="bottom">0.173 (0.163)</td><td align="left" valign="bottom">0.290</td><td align="left" valign="bottom">[–0.148, 0.494]</td><td align="left" valign="bottom">0.175</td><td align="left" valign="bottom">0.424</td></tr><tr><td align="left" valign="bottom" rowspan="3" colspan="2"><bold><italic>APOE</italic> status (ref: <italic>APOE</italic>-ε33)</bold></td><td align="left" valign="bottom"><italic>APOE</italic>-ε2</td><td align="left" valign="bottom">–0.175 (0.110)</td><td align="left" valign="bottom">0.112</td><td align="left" valign="bottom">[–0.391, 0.041]</td><td align="left" valign="bottom" rowspan="3">966</td><td align="left" valign="bottom">0.172</td><td align="left" valign="bottom">0.209</td><td align="left" valign="bottom">–0.061 (0.122)</td><td align="left" valign="bottom">0.615</td><td align="left" valign="bottom">[–0.301, 0.178]</td><td align="left" valign="bottom" rowspan="3">668</td><td align="left" valign="bottom">0.062</td><td align="left" valign="bottom">0.766</td></tr><tr><td align="left" valign="bottom"><italic>APOE</italic>-ε4</td><td align="left" valign="bottom">0.117 (0.067)</td><td align="left" valign="bottom">0.081</td><td align="left" valign="bottom">[–0.014, 0.248]</td><td align="left" valign="bottom">0.116</td><td align="left" valign="bottom">0.162</td><td align="left" valign="bottom">0.249 (0.082)</td><td align="left" valign="bottom">0.003</td><td align="left" valign="bottom">[0.087, 0.410]</td><td align="left" valign="bottom">0.249</td><td align="left" valign="bottom"><bold>0.008</bold></td></tr><tr><td align="left" valign="bottom"><italic>APOE</italic>-ε24</td><td align="left" valign="bottom">–0.011 (0.197)</td><td align="left" valign="bottom">0.958</td><td align="left" valign="bottom">[–0.337, 0.358]</td><td align="left" valign="bottom">0.011</td><td align="left" valign="bottom">0.999</td><td align="left" valign="bottom">0.044 (0.212)</td><td align="left" valign="bottom">0.836</td><td align="left" valign="bottom">[–0.372, 0.461]</td><td align="left" valign="bottom">0.045</td><td align="left" valign="bottom">0.976</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>WMH volume</bold><xref ref-type="table-fn" rid="table5fn4"><sup>*</sup></xref></td><td align="left" valign="bottom">0.263 (0.041)</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">[0.183, 0.342]</td><td align="left" valign="bottom">580</td><td align="left" valign="bottom">0.072</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">0.179 (0.050)</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">[0.790, 0.278]</td><td align="left" valign="bottom">392</td><td align="left" valign="bottom">0.032</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>CSF NfL</bold> ¥</td><td align="left" valign="bottom">0.129 (0.064)</td><td align="left" valign="bottom">0.046</td><td align="left" valign="bottom">[0.002, 0.256]</td><td align="left" valign="bottom">228</td><td align="left" valign="bottom">0.019</td><td align="left" valign="bottom">0.102</td><td align="left" valign="bottom">0.006 (0.078)</td><td align="left" valign="bottom">0.939</td><td align="left" valign="bottom">[–0.149, 0.161]</td><td align="left" valign="bottom">150</td><td align="left" valign="bottom">0.000</td><td align="left" valign="bottom">0.999</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>Plasma NfL</bold><xref ref-type="table-fn" rid="table5fn5"><sup>†</sup></xref></td><td align="left" valign="bottom">0.191 (0.059)</td><td align="left" valign="bottom"><bold>0.001</bold></td><td align="left" valign="bottom">[0.076, 0.306]</td><td align="left" valign="bottom">298</td><td align="left" valign="bottom">0.037</td><td align="left" valign="bottom"><bold>0.003</bold></td><td align="left" valign="bottom">0.110 (0.069)</td><td align="left" valign="bottom">0.119</td><td align="left" valign="bottom">[–0.029, 0.248]</td><td align="left" valign="bottom">210</td><td align="left" valign="bottom">0.012</td><td align="left" valign="bottom">0.217</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>Brain Atrophy</bold><xref ref-type="table-fn" rid="table5fn5"><sup>†</sup></xref></td><td align="left" valign="bottom">0.045 (0.063)</td><td align="left" valign="bottom">0.475</td><td align="left" valign="bottom">[–0.079, 0.169]</td><td align="left" valign="bottom">171</td><td align="left" valign="bottom">0.002</td><td align="left" valign="bottom">0.635</td><td align="left" valign="bottom">0.082 (0.074)</td><td align="left" valign="bottom">0.268</td><td align="left" valign="bottom">[–0.064, 0.228]</td><td align="left" valign="bottom">102</td><td align="left" valign="bottom">0.007</td><td align="left" valign="bottom">0.418</td></tr><tr><td align="left" valign="bottom"/><td align="center" valign="bottom" colspan="13"><bold>MCI Individuals</bold></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom" colspan="3"><bold>Amyloid-β pathology</bold></td><td align="left" valign="bottom">0.713 (0.131)</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">[0.455, 0.970]</td><td align="left" valign="bottom">217</td><td align="left" valign="bottom">0.751</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">0.581 (0.124)</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">[0.337, 0.824]</td><td align="left" valign="bottom">286</td><td align="left" valign="bottom">0.597</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom" rowspan="2" colspan="2"><bold>Amyloid-β / Tau pathology (ref: A-T-)</bold></td><td align="left" valign="bottom"><bold>A+T-</bold></td><td align="left" valign="bottom">0.556 (0.176)</td><td align="left" valign="bottom"><bold>0.002</bold></td><td align="left" valign="bottom">[0.210, 0.903]</td><td align="left" valign="bottom" rowspan="2">214</td><td align="left" valign="bottom">0.590</td><td align="left" valign="bottom"><bold>0.006</bold></td><td align="left" valign="bottom">0.543 (0.144)</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">[0.260, 0.827]</td><td align="left" valign="bottom" rowspan="2">284</td><td align="left" valign="bottom">0.558</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom"><bold>A+T</bold> +</td><td align="left" valign="bottom">0.809 (0.146)</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">[0.52, 1.098]</td><td align="left" valign="bottom">0.812</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">0.626 (0.145)</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">[0.342, 0.911]</td><td align="left" valign="bottom">0.633</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom" rowspan="3" colspan="2"><bold><italic>APOE</italic> status (ref: <italic>APOE</italic>-ε33)</bold></td><td align="left" valign="bottom"><italic>APOE</italic>-ε2</td><td align="left" valign="bottom">0.034 (0.295)</td><td align="left" valign="bottom">0.908</td><td align="left" valign="bottom">[–0.546, 0.614]</td><td align="left" valign="bottom" rowspan="3">217</td><td align="left" valign="bottom">0.033</td><td align="left" valign="bottom">0.999</td><td align="left" valign="bottom">–0.008 (0.206)</td><td align="left" valign="bottom">0.992</td><td align="left" valign="bottom">[–0.408, 0.404]</td><td align="left" valign="bottom" rowspan="3">286</td><td align="left" valign="bottom">0.002</td><td align="left" valign="bottom">0.999</td></tr><tr><td align="left" valign="bottom"><italic>APOE</italic>-ε4</td><td align="left" valign="bottom">0.254 (0.142)</td><td align="left" valign="bottom">0.0676</td><td align="left" valign="bottom">[–0.026, 0.535]</td><td align="left" valign="bottom">0.267</td><td align="left" valign="bottom">0.155</td><td align="left" valign="bottom">0.287 (0.125)</td><td align="left" valign="bottom">0.<bold>023</bold></td><td align="left" valign="bottom">[0.040, 0.534]</td><td align="left" valign="bottom">0.289</td><td align="left" valign="bottom">0.052</td></tr><tr><td align="left" valign="bottom"><italic>APOE</italic>-ε24</td><td align="left" valign="bottom">0.290 (0.418)</td><td align="left" valign="bottom">0.489</td><td align="left" valign="bottom">[–0.535,1.115]</td><td align="left" valign="bottom">0.309</td><td align="left" valign="bottom">0.649</td><td align="left" valign="bottom">0.399 (0.507)</td><td align="left" valign="bottom">0.431</td><td align="left" valign="bottom">[–0.598, 1.398]</td><td align="left" valign="bottom">0.389</td><td align="left" valign="bottom">0.584</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>WMH volume</bold></td><td align="left" valign="bottom">0.158 (0.085)</td><td align="left" valign="bottom">0.063</td><td align="left" valign="bottom">[–0.009, 0.325]</td><td align="left" valign="bottom">181</td><td align="left" valign="bottom">0.020</td><td align="left" valign="bottom">0.133</td><td align="left" valign="bottom">0.300 (0.069)</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td><td align="left" valign="bottom">[0.164, 0.437]</td><td align="left" valign="bottom">252</td><td align="left" valign="bottom">0.075</td><td align="left" valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>Plasma NfL</bold><xref ref-type="table-fn" rid="table5fn6"><sup>‡</sup></xref></td><td align="left" valign="bottom">0.342 (0.098)</td><td align="left" valign="bottom"><bold>0.001</bold></td><td align="left" valign="bottom">[0.147, 0.536]</td><td align="left" valign="bottom">128</td><td align="left" valign="bottom">0.097</td><td align="left" valign="bottom"><bold>0.003</bold></td><td align="left" valign="bottom">0.164 (0.091)</td><td align="left" valign="bottom">0.068</td><td align="left" valign="bottom">[–0.012, 0.341]</td><td align="left" valign="bottom">173</td><td align="left" valign="bottom">0.020</td><td align="left" valign="bottom">0.137</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: Relationships between validation variables and Brain-Age delta from all CU pooled subjects (including ALFA+, ADNI, EPAD and OASIS) and all MCI pooled subjects (including ADNI and EPAD). Results given by the linear model: brain-age delta ~each variable +chronological age+sex. The standardized regression coefficients (β), standard errors (SE), P-value, 95% Confidence Interval, number of individuals (N) and effect size are depicted for each variable.</p></fn><fn><p>Significant values after FDR correction (p&lt;0.05) are marked in bold. Effect size in categorical variables was calculated as Cohen’s D, while Cohens f<sup>2</sup> was calculated for continuous measurements. Amyloid-β status was defined by CSF (ALFA+, ADNI, and EPAD) or amyloid PET (OASIS).</p></fn><fn><p>APOE, apolipoprotein E; WMH, White Matter Hyperintensities; CSF, cerebrospinal fluid; NfL, neurofilament light; ref, reference.</p></fn><fn id="table5fn4"><label>*</label><p>Contains data from ALFA+, ADNI and EPAD.</p></fn><fn id="table5fn5"><label>†</label><p>Contains data from ALFA +and ADNI.</p></fn><fn id="table5fn6"><label>‡</label><p>Contains data from ADNI.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2-5"><title>Associations with neurodegeneration biomarkers</title><p>We next tested the associations between brain-age delta and neurodegeneration biomarkers (<xref ref-type="fig" rid="fig3">Figure 3</xref> and <xref ref-type="table" rid="table4">Table 4</xref>). CSF NfL, plasma NfL and longitudinal change of the aging signature were available in ALFA + and ADNI. The positive associations between brain-age deltas and plasma NfL were significant within the CU (<italic>β</italic>=0.154, <italic>P<sub>FDR</sub></italic> = 0.003) and MCI individuals (<italic>β</italic>=242, <italic>P<sub>FDR</sub></italic> &lt;0.001). CSF NfL was not significantly associated with brain-age delta (<italic>β</italic>=0.079, <italic>P<sub>FDR</sub></italic> = 0.209). The association between the longitudinal change in the aging signature composite, which was obtained from the cortical thickness in aging-vulnerable regions, and brain-age delta was not statistically significant (<italic>β</italic>=0.053, <italic>P<sub>FDR</sub></italic> = 0.415).</p><p>We next studied the association between brain-age delta and neurodegeneration biomarkers stratified by sex (<xref ref-type="table" rid="table5">Table 5</xref>). The associations between brain-age delta and plasma NfL were significant within the CU and MCI females (CU: <italic>β</italic>=0.191, <italic>P<sub>FDR</sub></italic> = 0.003 and MCI: <italic>β</italic>=0.342, <italic>P<sub>FDR</sub></italic> = 0.003), but not within the males (CU: <italic>β</italic>=0.110, <italic>P<sub>FDR</sub></italic> = 0.217 and MCI: <italic>β</italic>=0.141, <italic>P<sub>FDR</sub></italic> = 0.137). However, the interaction effect of sex and CSF NfL on CU brain-age delta (<xref ref-type="fig" rid="fig4">Figure 4a</xref>) did not reach significance (CU: <italic>P<sub>interaction_FDR</sub></italic>=0.417 and MCI: <italic>P<sub>interaction_FDR</sub></italic>=0.393).</p><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>In (<bold>a</bold>) and (<bold>b</bold>), the associations of brain-age delta and continuous validation variables stratified by sex for (<bold>a</bold>) CU individuals and (<bold>b</bold>) MCI individuals.</title><p>Scatter plots representing the associations of CSF NfL, plasma NfL, brain atrophy and WMH with brain-age delta in females (green) and males (purple). Each point depicts the value of the validation biomarkers of an individual and the solid lines indicate the regression line for each of the groups. 95% Confidence intervals are shown in the shaded areas. The standardized regression coefficients (β) and the corrected p-values are shown, which were computed using a linear model adjusting for age and sex. Additionally, we also computed the ‘brain-age delta x sex’ interaction term. The sample size for each variable can be seen in <xref ref-type="table" rid="table5">Table 5</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81067-fig4-v2.tif"/></fig><p>The associations between brain-age delta and CSF NfL in CU females did not survive multiple comparisons correction (<italic>β</italic>=0.129, p=0.046, <italic>P<sub>FDR</sub></italic> = 0.102), and was also not significant in CU males (<italic>β</italic>=0.006, <italic>P<sub>FDR</sub></italic> = 0.999). There was not an interaction effect of sex and CSF NfL on CU brain-age delta (<xref ref-type="fig" rid="fig4">Figure 4a</xref>) (<italic>P<sub>interaction_FDR</sub></italic>=0.425). In the same line, the associations between brain-age delta and longitudinal aging signature in CU females and CU males were not significant (females: <italic>P<sub>FDR</sub></italic> = 0.613 and males: <italic>P<sub>FDR</sub></italic> = 0.417). The interaction effect of sex on this longitudinal biomarker was not significant (<italic>P<sub>interaction_FDR</sub></italic>=0.924).</p><p>In addition, we tested the interaction between age and brain age delta to predict these biomarkers, and further stratified these analyses by sex. We found a significant interaction effect of age and CU brain-age delta on CSF NfL (<italic>P</italic><sub>interaction_<italic>FDR</italic></sub>&lt;0.001) within the CU individuals (<xref ref-type="fig" rid="fig5">Figure 5a</xref>), by which the measures of CSF NfL were higher with age and with larger brain-age deltas (older-appearing brain). When stratifying by sex, this interaction effect of age was seen in females (<italic>P</italic><sub>interaction_<italic>FDR</italic></sub>&lt;0.001), but not in males (<italic>P</italic><sub>interaction_<italic>FDR</italic></sub>=0.393). Regarding plasma NfL (<xref ref-type="fig" rid="fig5">Figure 5b</xref>), although we found a similar direction in the associations by which the measures of plasma NfL were higher with age and with larger brain-age deltas for CU and MCI individuals, the interaction effects were not significant (<italic>P</italic><sub>interaction_<italic>FDR</italic></sub>=0.118 and MCI: <italic>P</italic><sub>interaction_<italic>FDR</italic></sub>=0.421). When stratifying by sex, this interaction effect of age on plasma NfL was seen in CU females (<italic>P</italic><sub>interaction_<italic>FDR</italic></sub>=0.040) and not in CU males (<italic>P</italic><sub>interaction_<italic>FDR</italic></sub>=0.999). On the contrary, the interaction effect of age and plasma NfL on brain-age delta did not survive multiple comparisons in MCI males (<italic>P</italic><sub>interaction</sub> = 0.022, <italic>P</italic><sub>interaction_<italic>FDR</italic></sub>=0.050). This interaction effect was also not found in MCI females (<italic>P</italic><sub>interaction</sub> = 0.605, <italic>P</italic><sub>interaction_<italic>FDR</italic></sub>=0.761). The rest of the associations with neurodegeneration biomarkers not reported here were non-significant.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>The associations of brain-age delta and (<bold>a</bold>) CSF NfL and (<bold>b</bold>) plasma NfL with chronological age for all CU and, when available, MCI individuals.</title><p>For visualization purposes, individuals were categorized into two groups according to their brain-age delta: ‘brain-age delta &lt;0’ representing decelerated brain aging (blue); and ‘brain-age delta &gt;0’ representing accelerated brain aging (red). Scatter plots representing the associations of CSF NfL, plasma NfL and WMH with age in individuals with brain-age delta &gt;0 and brain-age delta &lt;0. Each point depicts the value of the validation biomarkers of an individual and the solid lines indicate the regression line for each of the groups. The regression coefficients (β) and the FDR corrected p-values are shown, which were computed using a linear model adjusting for age and sex. Additionally, we also computed the ‘brain-age delta x sex’ interaction term. The sample size for each variable can be seen in <xref ref-type="table" rid="table5">Table 5</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81067-fig5-v2.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>The associations of (<bold>a</bold>) Aging signature change and (<bold>b</bold>) WMH with chronological age for all CU and, when available, MCI individuals.</title><p>The sample size for each variable can be seen in <xref ref-type="table" rid="table4">Table 4</xref> and <xref ref-type="table" rid="table5">Table 5</xref>. For visualization purposes, individuals were categorized into two groups according to their brain-age delta: ‘brain-age delta &lt;0’ representing decelerated brain aging (blue); and ‘brain-age delta &gt;0’ representing accelerated brain aging (red). Scatter plots representing the associations of CSF NfL, plasma NfL and WMH with age in individuals with brain-age delta &gt;0 and brain-age delta &lt;0. Each point depicts the value of the validation biomarkers of an individual and the solid lines indicate the regression line for each of the groups.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81067-fig5-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-6"><title>Associations with markers of cerebrovascular disease</title><p>We lastly tested the associations between brain-age delta and markers of cerebrovascular disease WMH; WMH data were available in ALFA+, ADNI and EPAD. In both CU and MCI, brain-age delta was significantly associated with WMH (CU: <italic>β</italic>=0.160, <italic>P<sub>FDR</sub></italic> &lt;0.001 and MCI: <italic>β</italic>=0.222, <italic>P<sub>FDR</sub></italic> &lt;0.001) (see <xref ref-type="table" rid="table4">Table 4</xref>). These results were consistent with the results from the within-cohort analyses (see <xref ref-type="table" rid="app1table11">Appendix 1—table 11</xref>).</p><p>When studying the association between brain-age delta and WMH stratified by sex (<xref ref-type="table" rid="table5">Table 5</xref>) we found that the brain-age delta was positively associated with WMH both in CU females (<italic>β</italic>=0.263, <italic>P<sub>FDR</sub></italic> &lt;0.001) and CU males (<italic>β</italic>=0.179, <italic>P<sub>FDR</sub></italic> &lt;0.001). The interaction effect of sex and WMH on CU brain-age delta (<xref ref-type="fig" rid="fig4">Figure 4a</xref>) was not significant (<italic>P</italic><sub>interaction_<italic>FDR</italic></sub>=0.223). Conversely, we found that the brain-age delta was positively associated with WMH MCI males (<italic>β</italic>=0.300, <italic>P<sub>FDR</sub></italic> &lt;0.001), but not in females (<italic>β</italic>=0.158, <italic>P<sub>FDR</sub></italic> = 0.133). The interaction effect of sex and WMH on MCI brain-age delta (<xref ref-type="fig" rid="fig4">Figure 4b</xref>) was also not significant (<italic>P</italic><sub>interaction_<italic>FDR</italic></sub>=0.209). The rest of the associations tested with WMH not reported here were non-significant.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we show that, in non-demented individuals, the predicted brain-age delta is associated with specific AD biomarkers (amyloid-<inline-formula><mml:math id="inf2"><mml:mi>β</mml:mi></mml:math></inline-formula> PET, CSF Aβ42 and CSF pTau) and risk factors (<italic>APOE</italic> genotype), as well as with unspecific neurodegeneration biomarkers (plasma NfL), and markers of cerebrovascular disease (WMH volume). However, our results do not show that variation in cross-sectional brain-age delta was able to capture longitudinal atrophy and, therefore, it is solely a cross-sectional analysis. Our results also indicate that there might be sex differences in the development of brain aging trajectories, which must be further characterized. Taken together, our findings validate the use of machine learning predicted brain-age delta as a non-invasive biomarker of brain aging, which is associated to AD pathology in non-demented individuals with abnormal levels of biomarkers of AD and axonal injury. The capacity of brain-age delta to de detect accelerated aging must be further studied.</p><p>We have studied the associations between brain-age delta and different biomarkers of AD pathology and neurodegeneration in CU individuals. We are aware of the complexity of disentangling the effects of aging and pathology in brain aging. In this work, we do not aim to disentangle to what extent the brain structural differences are caused by AD pathology (as measured by the biomarkers that we study) or aging. Here, we show that an unspecific estimation of biological brain aging, agnostic of the underlying mechanisms is associated with the specific biological process of AD.</p><p>Regarding the associations with AD biomarkers and risk factors, regression analyses revealed significant positive associations of brain-age delta with increased Aβ pathology and with AT stages for CU and MCI individuals. We also found significant associations with <italic>APOE</italic> status in the CU and MCI individuals, in which larger brain-age deltas were associated with the presence of <italic>APOE</italic>-ε4 allele. This result is in line with previous literature that has shown that <italic>APOE</italic>-ε4 carriership may accelerate AD-related brain atrophy (<xref ref-type="bibr" rid="bib30">Evans et al., 2014</xref>; <xref ref-type="bibr" rid="bib32">Filippini et al., 2011</xref>), as accelerated brain aging has also been found in MCI and AD patients (<xref ref-type="bibr" rid="bib6">Beheshti et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Kaufmann et al., 2019</xref>). The association of brain-age delta with <italic>APOE</italic>-ε4 was also previously studied, for which significant associations were found in MCI individuals (<xref ref-type="bibr" rid="bib21">Cole et al., 2018</xref>; <xref ref-type="bibr" rid="bib53">Löwe et al., 2016</xref>). Taken together, our results advocate for an effect of <italic>APOE</italic>-ε4 in physiological brain aging, albeit of a lesser magnitude than when AD pathology is present. These results with AD biomarkers and risk factors were highly reproducible in within-cohort analyses.</p><p>With the aim of studying the associations between brain-age delta and neurodegeneration, we computed the associations with NfL, a marker of neuro-axonal damage (<xref ref-type="bibr" rid="bib47">Khalil et al., 2018</xref>) which can be measured both in CSF and in plasma, and with longitudinal changes in the aging signature composite as marker of age-related brain atrophy. The particular use of NfL in this context is supported by its correlation with age throughout the lifespan, as well as its strong association with all-cause mortality in the elderly (<xref ref-type="bibr" rid="bib45">Kaeser et al., 2021</xref>). We found significant positive associations between brain-age delta and plasma NfL both in CU and MCI individuals, but we did not find significant associations between CSF NfL and CU brain-age delta. Even though we found NfL to be positively associated with chronological age in CU individuals, in line with previous studies (<xref ref-type="bibr" rid="bib6">Beheshti et al., 2018</xref>; <xref ref-type="bibr" rid="bib46">Kaufmann et al., 2019</xref>; <xref ref-type="bibr" rid="bib48">Khalil et al., 2020</xref>; <xref ref-type="bibr" rid="bib60">Milà-Alomà et al., 2020</xref>), the expected annual change of NfL in CU individuals whose mean age range was 65 years old is around 3.5% (<xref ref-type="bibr" rid="bib48">Khalil et al., 2020</xref>). Therefore, we expected to find weak associations with brain-age delta. Still, we found a significant interaction effect of age and CSF NfL on CU brain-age delta, for which the individuals with larger brain-age delta had increased CSF NfL over the years, whereas the decelerated ones remained more stable. Taken together, a strong association between brain-age delta and plasma NfL was observed across all individuals whereas the association on CU brain-age delta and CSF NfL was milder and could only be detected as an interaction with age. Overall, these mild associations between brain-age delta and NfL suggest that the morphological effects of aging in the brain are not fully driven by neurodegeneration. In this regard, it is worth noting that cortical thinning with age has also been linked to loss of volume of the neuropil and other non-neuronal processes which are not necessarily implicated in neurodegeneration (<xref ref-type="bibr" rid="bib82">Vidal-Pineiro et al., 2020</xref>). Conversely, brain-age delta was not associated with longitudinal change in aging signature. This might indicate, as previously shown (<xref ref-type="bibr" rid="bib82">Vidal-Pineiro et al., 2020</xref>), that brain-age delta might not reflect accelerated brain aging but instead early life factors. However, the lack of this association might also be influenced by the short amount of time between time visits (average of 3 years) or the measurement used to measure longitudinal atrophy (cortical aging signature). Therefore, further research is needed to determine the relative contribution of early life factors and accelerated aging to brain-age delta estimates.</p><p>We also studied the associations between brain-age delta and cerebrovascular disease. Regression analyses revealed significant associations of brain-age delta with increased WMH for both CU and MCI individuals. These results were expected, as the increase in WMH with age has been previously studied (<xref ref-type="bibr" rid="bib57">Maniega et al., 2015</xref>) and it has been shown that individuals with high WMH burden display spatial patterns of atrophy that partially overlap with those of brain aging (<xref ref-type="bibr" rid="bib11">Brugulat-Serrat et al., 2020a</xref>; <xref ref-type="bibr" rid="bib40">Habes et al., 2016</xref>). In addition, WMH have been linked to cognitive dysfunction and dementia (<xref ref-type="bibr" rid="bib12">Brugulat-Serrat et al., 2020b</xref>; <xref ref-type="bibr" rid="bib11">Brugulat-Serrat et al., 2020a</xref>; <xref ref-type="bibr" rid="bib57">Maniega et al., 2015</xref>) and a potential pathway has been proposed, in which small vessel cerebrovascular disease affects cognition by promoting neurodegenerative changes (<xref ref-type="bibr" rid="bib70">Rizvi et al., 2018</xref>). In summary, our results support an effect of cerebrovascular disease in physiological brain aging.</p><p>Brain structure aging-associated changes have been widely studied (<xref ref-type="bibr" rid="bib3">Bakkour et al., 2013</xref>; <xref ref-type="bibr" rid="bib34">Fjell et al., 2014</xref>). In our study, the brain regions that had highest impact on the machine learning prediction were similar to regions previously mentioned in literature (<xref ref-type="bibr" rid="bib1">Arenaza-Urquijo et al., 2019</xref>; <xref ref-type="bibr" rid="bib3">Bakkour et al., 2013</xref>). We found an overlap between some of our selected regions and regions included in the aging signature for both females and males, such as the precentral sulcus, insula, superior frontal and rostral middle frontal regions. In addition, the effect of sex on age-related changes in brain structure has also been studied in the recent years, with some studies reporting age–sex interactions in volumes of certain brain structures (<xref ref-type="bibr" rid="bib16">Coffey et al., 1998</xref>; <xref ref-type="bibr" rid="bib24">DeCarli et al., 2005</xref>), and others not finding such interactions (<xref ref-type="bibr" rid="bib39">Greenberg et al., 2008</xref>). In our study, we found that, even though most of the regions with highest impact were the same for males and females, there were some regions that were sex specific. In particular, we found reduction in the superior-frontal, isthmus-cingulate and pars orbitalis regions within males and regions such as inferior-parietal, pars triangularis and paracentral within females. Most of these sex-specific regions were in concordance with previous studies (<xref ref-type="bibr" rid="bib2">Armstrong et al., 2019</xref>; <xref ref-type="bibr" rid="bib67">Podgórski et al., 2021</xref>). The mechanisms underlying these sex-specific brain aging differences are not well-known. Sexual hormones such as estrogen, progesterone and androgen could play a role in brain atrophy <xref ref-type="bibr" rid="bib2">Armstrong et al., 2019</xref>; in the WHIMS-MRI study (<xref ref-type="bibr" rid="bib69">Resnick et al., 2009</xref>), women under menopausal hormone therapy were associated with greater brain atrophy. Others, however, have proposed that estrogen and progesterone may play a protective effect in women (<xref ref-type="bibr" rid="bib2">Armstrong et al., 2019</xref>; <xref ref-type="bibr" rid="bib38">Green and Simpkins, 2000</xref>). Other possible biological mechanisms influencing these results could be developmental (<xref ref-type="bibr" rid="bib4">Baron-Cohen et al., 2005</xref>) or the influence of a greater presence of adverse lifestyle-related factors in men (<xref ref-type="bibr" rid="bib24">DeCarli et al., 2005</xref>).</p><p>In line with the effect of sex on age-related changes in brain structure, we studied the effect of sex on the associations between brain-age delta and the above-mentioned variables. Regarding the AD biomarkers and risk factors, we found that the association between brain-age delta and a larger proportion of A+T + was only seen in females for the CU individuals, but the interaction effect of sex and AT stages on brain-age delta was not significant. Regarding the neurodegeneration variables, we found a positive association between brain-age delta and plasma NfL in CU and in MCI females. These associations were not seen in their male counterparts. However, the interaction effect of sex and CSF and plasma NfL on CU and MCI brain-age delta was not significant. In addition, we found a significant interaction effect of age and CSF and plasma NfL on brain-age delta, for which the CU females with larger brain-age delta had increased CSF and plasma NfL over the years, whereas the decelerated ones remained more stable. These results were expected, as females have higher chances of undergoing neurodegeneration and have showed to undergo faster cognitive decline than males (<xref ref-type="bibr" rid="bib31">Ferretti et al., 2018</xref>). Although the role of sex hormones still needs to be clarified, it has been suggested that the menopausal drop of estrogen increases vulnerability to neurological events (<xref ref-type="bibr" rid="bib38">Green and Simpkins, 2000</xref>; <xref ref-type="bibr" rid="bib56">Maioli et al., 2021</xref>). On the contrary, results suggest that morphological effects of aging in the CU males’ brain are not fully driven by neurodegeneration. Lastly, regarding the cerebrovascular disease biomarkers, we found a positive association between brain-age delta and WMH for both CU females and males, while no interaction effect of sex was found. Conversely, in MCI individuals, we only found positive associations between brain-age delta and WMH on males, but no interaction effect of sex was found in MCI individuals. Overall, we found cross-sectional sex differences in the associations between brain-age delta and markers of neurodegeneration and cerebrovascular disease. NfL was only positively associated with brain-age delta in females, while WMH were positively associated with both CU females and males. Positive associations between NfL and WMH have been previously demonstrated, for both CU and MCI (<xref ref-type="bibr" rid="bib63">Osborn et al., 2018</xref>), and the different AD stages (<xref ref-type="bibr" rid="bib84">Walsh et al., 2021</xref>). Moreover, it has been proposed that WMH may reflect two different pathological pathways, one including amyloid aggregation and another including axonal injury (<xref ref-type="bibr" rid="bib63">Osborn et al., 2018</xref>). Our results may suggest that brain aging in males might be driven more strongly by the former pathway, while brain aging in females might be driven more by the latter one. However, the lack of significant brain-age delta-by-sex interactions in our analyses reflect the limitations in the evidence for the above-mentioned sex-differences. Further work exploring these sex differences in detail is warranted.</p><p>Our purpose was to study the clinical validity of using the brain-age delta as a proxy biomarker of brain aging associated to AD and neurodegeneration. Therefore, our main aim was studying the characteristics of the individuals whose brain age is more accelerated or decelerated. One of the strengths of this study was the robustness of the brain-age delta measurement using a widely used segmentation atlas such as the Desikan-Killiany. Notably, we demonstrated the robustness of our method by training our model with one cohort and testing independently on four independent cohorts. The similar results obtained in all cohorts allowed us to seek associations in a large sample of participants with biomarker data and to further stratify the data by sex. This aspect is critical for this type of analyses as the effects of biological aging are necessarily very small, particularly in CU individuals of limited age range. This may explain why we could not detect significant effects versus longitudinal brain atrophy, as the available sample size for these analyses was smaller since this variable was not available in all cohorts. Another strength of our work was that we were able to include a wide range of different biomarkers of AD pathology allowing us to perform an in-depth analysis of the effect of these measurements with the brain-age delta. Conversely, our model used a smaller number of features and a training set with a more limited age range than other models seen in literature recently (<xref ref-type="bibr" rid="bib51">Liem et al., 2017</xref>; <xref ref-type="bibr" rid="bib64">Peng et al., 2021</xref>), leading to a performance which cannot be compared against these state-of-the-art models. However, the performance of age prediction was similar to other publications that used similar methodologies (<xref ref-type="bibr" rid="bib6">Beheshti et al., 2018</xref>; <xref ref-type="bibr" rid="bib23">Dafflon et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">de Lange et al., 2020a</xref>) and, most importantly, was successful in studying the utility of brain-age delta as biomarker of brain aging in non-demented individuals, which is impacted by abnormal levels of biomarkers of AD and neurodegeneration. Moreover, using a relatively restricted number of features allowed us to visualize and interpret in an easier way the contribution of different brain regions to the brain age prediction by means of SHAP values. This ensured that the model had neurobiological interpretability. However, it is important to note that SHAP values may not reflect the true relationship between the features and the model’s prediction in the presence of correlated features. This is an important consideration to bear in mind for correctly interpreting our results. In addition, future work should also focus on developing a model with larger number of features or a 3D model and should study the effect of these validation measurements for AD and neurodegeneration, as well as longitudinal changes, with the brain-age delta more in depth.</p><p>In conclusion, we validated that machine-learning based brain age prediction obtained from a widely used segmentation atlas can be used as a biomarker of biological brain aging associated with AD pathology, risk factors, and neurodegeneration. Moreover, our results confirm the presence of sex-related brain aging structural changes and suggest the prevalence of different neuropathological pathways involved in brain aging within females and males. Therefore, these results indicate the importance on considering different approaches for assessing aging and neurodegeneration differently for each sex.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Participants</title><p>We used a collection of T1-weighted brain MRI scans included in the UK Biobank (<ext-link ext-link-type="uri" xlink:href="https://www.ukbiobank.ac.uk">https://www.ukbiobank.ac.uk</ext-link>) cohort for training the proposed model and for calculating cross-validated brain age predictions. The dataset consisted of CU individuals (<inline-formula><mml:math id="inf3"><mml:mi>N</mml:mi><mml:mo>=</mml:mo></mml:math></inline-formula> 22,661), after excluding subjects with ICD-9 and ICD-10 diagnosis, covering individuals of ages 44–81.</p><p>We also used four different cohorts to investigate the association between brain-age deltas with different sets of biomarker and AD risk factor measurements. Inclusion criteria for the independent cohorts consisted of: (i) availability of T1-weighted MRI brain scans; (ii) and availability of apolipoprotein E (<italic>APOE</italic>) categories and of CSF or PET measures for amyloid-<inline-formula><mml:math id="inf4"><mml:mi>β</mml:mi></mml:math></inline-formula> pathology acquired in less than a year from the MRI acquisition. These cohorts included individuals with different diagnosis: CU and MCI. ADNI cohort included CU and MCI individuals from ADNI 1,2 and 3 (N=751, CU = 253, MCI = 498), the EPAD cohort included CU and MCI individuals (N=808, CU = 653, MCI = 155), the ALFA + cohort included only CU individuals (N=380) and the OASIS cohort included CU individuals (N=407). MCI individuals, which were only included from ADNI and EPAD cohorts, were specified by a Clinical Dementia Rating = 0.5. We did not include individuals with a dementia diagnosis in the AD continuum because we wanted to focus on assessing the impact of abnormal AD biomarkers and risk factors on brain-age estimates in preclinical and prodromal AD stages.</p><p>All the individuals had available data for the following clinical variables: chronological age, sex, MMSE and years of education, which will be referred as clinical variables from now on. A more detailed description of the clinical variables of these datasets is given in <xref ref-type="table" rid="table1">Table 1</xref>. Regarding AD-related variables, ALFA+, ADNI and EPAD cohorts included CSF Aβ42 measurements for categorizing Aβ pathology status, AT status determined by CSF Aβ42 and CSF p-tau, <italic>APOE</italic> categories and WMH. OASIS, meanwhile, only had data available for Aβ PET and <italic>APOE</italic> categories. In addition, ALFA + and ADNI included biomarkers of neurodegeneration such as CSF NfL, plasma NfL and cortical atrophy measured by longitudinal changes in the so-called aging signature (<xref ref-type="bibr" rid="bib3">Bakkour et al., 2013</xref>). The combination of available AD-related variables and neurodegeneration biomarkers will be referred as validation variables from so on. A more detailed description of the validation variables can be seen in <xref ref-type="table" rid="table2">Table 2</xref>.</p></sec><sec id="s4-2"><title>Image acquisition and preprocessing</title><p>The UK Biobank, ADNI and OASIS datasets had available T1-weighted magnetic resonance (MR) images that had already been segmented with Freesurfer and had been parcellated using the FreeSurfer’s cortical Desikan-Killiany (<xref ref-type="bibr" rid="bib29">Desikan et al., 2006</xref>) and subcortical aseg (<xref ref-type="bibr" rid="bib33">Fischl et al., 2002</xref>) labeling pipelines, which had undergone a quality control procedure. Taking advantage of this available data, we decided to use the same segmentation pipeline with the ALFA + and EPAD cohorts. All the image acquisition and preprocessing done is as follows.</p><p>The UK Biobank dataset consisted of T1-weighted magnetic resonance (MR) images, all collected using a 3T Siemens Skyra scanner and preprocessed as previously explained in more detail (<ext-link ext-link-type="uri" xlink:href="https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/brain_mri.pdf">https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/brain_mri.pdf</ext-link>). Images were previously segmented with Freesurfer 6.0 and underwent a quality control procedure.</p><p>For ADNI participants (<xref ref-type="bibr" rid="bib65">Petersen et al., 2010</xref>), MRI acquisition methods are described in more detail elsewhere (<ext-link ext-link-type="uri" xlink:href="http://adni.loni.usc.edu/methods/documents/">http://adni.loni.usc.edu/methods/documents/</ext-link>). In brief, most of the T1-weighted MR were MP-RAGE, acquired with 1.5T or 3T scanners. Images were segmented with Freesurfer 5.1 and 6.0 and subjected to a quality control procedure. When possible, we also included a second T1-weighted MRI image sequence for the participants that underwent another MRI visit 3 years later. These scans were also segmented following the previously explained procedure.</p><p>For the OASIS subjects (<xref ref-type="bibr" rid="bib58">Marcus et al., 2007</xref>), the MRI scans were acquired on 1.5T or on 3.0T scanners. T1-weighted magnetization-prepared rapid gradient echo (MP-RAGE) scans were obtained according to previously explained protocol (<ext-link ext-link-type="uri" xlink:href="https://theunitedconsortium.com/wp-content/uploads/2021/07/OASIS-3_Imaging_Data_Dictionary_v1.8.pdf">https://theunitedconsortium.com/wp-content/uploads/2021/07/OASIS-3_Imaging_Data_Dictionary_v1.8.pdf</ext-link>). All MRI sessions were segmented using FreeSurfer 5.1 or 5.3 and followed quality control measures. The PET images were acquired with [11 C]PIB Pittsburgh’s compound 60-min dynamic PET scan in 3D mode and the corresponding analysis analyses were performed using the PET unified pipeline (PUP, <ext-link ext-link-type="uri" xlink:href="https://github.com/ysu001/PUP">https://github.com/ysu001/PUP</ext-link>) (<xref ref-type="bibr" rid="bib77">Su, 2018</xref>). Mean standardized uptake value (SUVR) values were converted to Centiloid scale as previously explained, using the whole cerebellum as reference region.</p><p>For the ALFA + participants, a high-resolution 3D T1-weighted MRI sequence was acquired in a 3T Philips Ingenia CX scanner (TE/TR = 4.6/9.9ms, Flip Angle = 8°; voxel size = 0.75 × 0.75 x0.75 mm). Images were segmented with Freesurfer 6.0 and subjected to a quality control procedure to identify and remove incidental findings (<xref ref-type="bibr" rid="bib10">Brugulat-Serrat et al., 2017</xref>) and segmentation errors (<xref ref-type="bibr" rid="bib43">Huguet et al., 2021</xref>). Some of these ALFA + subjects (N=187) underwent a second MRI visit 3 years after the initial visit, where another T1-weighted MRI sequence was acquired and segmented following the same procedure as in the first visit.</p><p>For the EPAD cohort (<xref ref-type="bibr" rid="bib76">Solomon et al., 2018</xref>), which is a multisite study, T1-weighted MRIs were inversion-recovery prepare 3D gradient-echo sequences, acquired with 3T scanners. Images were segmented with Freesurfer 6.0 and subjected to a quality control procedure (<xref ref-type="bibr" rid="bib52">Lorenzini et al., 2021</xref>).</p><p>For all the cohorts, subsequent to the FreeSurfer segmentation, tissue regions were parcellated into 183 different anatomical regions of interest (ROI)s using the widely-used FreeSurfer’s cortical Desikan-Killiany (<xref ref-type="bibr" rid="bib29">Desikan et al., 2006</xref>) and subcortical aseg (<xref ref-type="bibr" rid="bib33">Fischl et al., 2002</xref>) labeling pipelines. As mentioned before, we used the available FreeSurfer segmentations from UK Biobank, ADNI, and OASIS cohorts. All volumes were residualized with respect to total intracranial volume (TIV) and to scanning site, while all cortical thicknesses were residualized with respect to scanning site, using linear models. Lastly, we performed a standardization procedure by computing z-score measurements feature-wise within each cohort, as previously performed (<xref ref-type="bibr" rid="bib14">Casamitjana et al., 2018</xref>; <xref ref-type="bibr" rid="bib79">Subramaniapillai et al., 2021</xref>; <xref ref-type="bibr" rid="bib81">Ten Kate et al., 2018</xref>). We then assessed that there were not statistical differences in mean cortical thickness and volumes between the cohorts (see <xref ref-type="fig" rid="app1fig1">Appendix 1—figure 1</xref>).</p></sec><sec id="s4-3"><title>Biomarkers</title><sec id="s4-3-1"><title>CSF and plasma collection, processing and biomarkers measurements</title><p>CSF and blood collection, processing and storage in the ALFA + study have been described previously (<xref ref-type="bibr" rid="bib60">Milà-Alomà et al., 2020</xref>; <xref ref-type="bibr" rid="bib78">Suárez-Calvet et al., 2020</xref>). CSF p-tau181 was measured using the Elecsys Phospho-Tau (181 P) CSF electrochemiluminescence immunoassay on a fully automated cobas e 601 instrument (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). CSF Aβ42 and NfL were measured with the NeuroToolKit on a cobas e 411 or cobas e 601 instrument (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). Plasma NfL was measured using the commercial Quanterix assay (Simoa NF-light Kit cat. no. 103186) on a HD-X analyzer following the manufacturer’s instructions (Quanterix, Billerica, MA, USA). All these measurements were previously reported (<xref ref-type="bibr" rid="bib60">Milà-Alomà et al., 2020</xref>; <xref ref-type="bibr" rid="bib78">Suárez-Calvet et al., 2020</xref>). All measurements were performed at the Clinical Neurochemistry Laboratory, University of Gothenburg, Mölndal, Sweden, by laboratory technicians and scientists blinded to participants’ clinical information.</p><p>In the ADNI study, CSF samples were measured according to the kit manufacturer’s instructions and as described in previous studies (<xref ref-type="bibr" rid="bib9">Bittner et al., 2016</xref>), using the Elecsys β-amyloid(1–42) CSF (<xref ref-type="bibr" rid="bib9">Bittner et al., 2016</xref>), and the Elecsys Phospho-Tau (181 P) and Elecsys Total-Tau CSF immunoassays on a cobas e 601 analyzer at the Biomarker Research Laboratory, University of Pennsylvania, USA. Plasma NfL was measured on an in-house <ext-link ext-link-type="uri" xlink:href="https://www.sciencedirect.com/topics/medicine-and-dentistry/immunoassay">immunoassay</ext-link> on the single-molecule array (Simoa) platform, using the same methodology as described previously, at the Clinical Neurochemistry Laboratory, University of Gothenburg, Mölndal, Sweden.</p><p>In the EPAD study, CSF was measured using the Elecsys β-amyloid (1–42) and the Elecsys Phospho-Tau (181 P) CSF electrochemiluminescence immunoassay on a fully automated cobas e 601 instrument (Roche Diagnostics International Ltd.). All measurements were performed at the Clinical Neurochemistry Laboratory, University of Gothenburg, Mölndal, Sweden, by laboratory technicians and scientists blinded to participants’ clinical information. Concentrations of CSF Aβ42 and p-tau181 were determined according to the manufacturer’s instructions (<xref ref-type="bibr" rid="bib76">Solomon et al., 2018</xref>).</p></sec></sec><sec id="s4-4"><title>Amyloid-β positivity cutoffs</title><p>For ALFA+, ADNI and EPAD, AT stages were defined by CSF Aβ42 and CSF p-tau, respectively. Previously used cut-offs were applied to each cohort, consisting of 1098 pg/mL for CSF Aβ42 for ALFA + and EPAD (<xref ref-type="bibr" rid="bib73">Schindler et al., 2018</xref>) and of 880 pg/mL for CSF Aβ42 for ADNI (<xref ref-type="bibr" rid="bib41">Hansson et al., 2018</xref>) and of 24 pg/mL for p-tau for the three cohorts (<xref ref-type="bibr" rid="bib60">Milà-Alomà et al., 2020</xref>). For OASIS, we used the cut-off value of 17 Centiloids from literature (<xref ref-type="bibr" rid="bib71">Salvadó et al., 2019</xref>).</p></sec><sec id="s4-5"><title>WMH volumes</title><p>WMH volumes were generated for ALFA + and EPAD cohorts using Bayesian Model Selection (BaMoS) procedure (<xref ref-type="bibr" rid="bib80">Sudre et al., 2015</xref>), which has been provided previously. We also obtained the already available WMH volumes for ADNI cohort, in which the method of WMH volumetric quantification was performed using probabilistic models in a Markov Random Field framework, as previously provided (<xref ref-type="bibr" rid="bib74">Schwarz et al., 2009</xref>). For each cohort, total WMH volumes were derived by summing and multiplying the number of labeled voxels by voxel dimensions. Total WMH volumes were natural log transformed and residualized with respect to TIV using linear models.</p></sec><sec id="s4-6"><title>Aging signature measurements</title><p>For ALFA + and ADNI, we computed the weighted Dickerson’s aging signature (<xref ref-type="bibr" rid="bib3">Bakkour et al., 2013</xref>), which has been used as a proxy measurement for brain aging. The aging signature is a map of specific brain regions that undergo cortical atrophy in normal aging. This meta-ROI is composed of the surface-area weighted average of the mean cortical thickness in the following individual ROIs: calcarine, caudal fusiform, caudal insula, cuneus, inferior frontal gyrus, medial superior frontal and precentral cortices. A Z-score of this aging-specific measure was calculated based on the mean and standard deviation of the CU individuals, as done previously (<xref ref-type="bibr" rid="bib3">Bakkour et al., 2013</xref>). This is referred as Aging Signature V1.</p><p>In addition, we also computed this measurement on the scanners from the second MRI visit, referred as Aging Signature V2. We then computed a longitudinal brain atrophy measurement by computing the aging signature change over the years between the MRI acquisitions. Therefore, longitudinal aging signature change, or brain atrophy, was computed as:<disp-formula id="equ1"><mml:math id="m1"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">A</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">c</mml:mi><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">V</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mspace width="thinmathspace"/><mml:mn>2</mml:mn></mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">g</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mi mathvariant="normal">a</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">u</mml:mi><mml:mi mathvariant="normal">r</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">V</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mspace width="thinmathspace"/><mml:mn>1</mml:mn></mml:mrow></mml:mrow><mml:mrow><mml:mi mathvariant="normal">T</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">m</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">b</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">w</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">n</mml:mi><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">s</mml:mi><mml:mi mathvariant="normal">i</mml:mi><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">s</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula></p><p>For a secondary analysis shown in <xref ref-type="table" rid="app1table7">Appendix 1—table 7</xref>, we also computed the aging signature (Aging Signature V1) for the remaining independent cohorts: EPAD and OASIS.</p></sec><sec id="s4-7"><title>Brain-age prediction</title><sec id="s4-7-1"><title>Regression model</title><sec id="s4-7-1-1"><title>Model workflow</title><p>For the current study, we used a gradient boosting framework: the XGBoost regressor model from the XGBoost python package (<ext-link ext-link-type="uri" xlink:href="https://xgboost.readthedocs.io/en/">https://xgboost.readthedocs.io/en/</ext-link>) to run the brain age prediction. This regressor, which is based on a decision-tree based ensemble algorithm, was selected due to its speed and performance and its advanced regularization to reduce overfitting (<xref ref-type="bibr" rid="bib15">Chen and Guestrin, 2016</xref>). In addition, large-scale brain age studies have demonstrated its adequacy (<xref ref-type="bibr" rid="bib5">Bashyam et al., 2020</xref>; <xref ref-type="bibr" rid="bib25">de Lange et al., 2019</xref>; <xref ref-type="bibr" rid="bib27">de Lange et al., 2020b</xref>; <xref ref-type="bibr" rid="bib46">Kaufmann et al., 2019</xref>). As it has been shown that there are sex-related trajectories in normal aging (<xref ref-type="bibr" rid="bib67">Podgórski et al., 2021</xref>), we trained separate models for females and males. For each model, we first performed Bayesian parameter optimization based on a cross-validation scheme with ten folds repeated ten times using the FreeSurfer volumes and thickness of the UK Biobank as input. For the optimization we used HYPEROPT (<xref ref-type="bibr" rid="bib8">Bergstra et al., 2013</xref>), with which we scanned for maximum depth, number of estimators, learning rate, alpha regularization, lambda regularization, subsample, gamma and colsample by tree. The optimized parameters were maximum depth = 4, number of estimators = 800, learning rate = 0.03, alpha regularization = 4, lambda regularization = 1, subsample = 0.36, gamma = 3 and colsample by tree = 0.89 for the males model; and maximum depth = 4, number of estimators = 850, learning rate = 0.03, alpha regularization = 8.5, lambda regularization = 14.5, subsample = 0.449, gamma = 3.5 and colsample by tree = 0.72 for the females model. We trained these two models and performed the brain-age prediction on the independent cohorts. We decided to compute a ROI based model using these 183 FreeSurfer regions because they are widely used and available in most of the neuroimaging datasets. Therefore, our aim was not to compare our performance to the one achieved by a model trained with larger number of ROIs or with the full 3D images, but to study the generalizability and the relevance of our model in the AD field.</p></sec></sec></sec><sec id="s4-8"><title>Contribution of brain regions in prediction</title><p>We computed SHAP (SHapley Additive exPlanation) values (<ext-link ext-link-type="uri" xlink:href="https://github.com/slundberg/shap">https://github.com/slundberg/shap</ext-link>) (<xref ref-type="bibr" rid="bib54">Lundberg et al., 2020</xref>) to measure the contribution of each brain region in the prediction of age for each subject. SHAP assigns an importance value within the prediction to each feature (in this case, brain region), which is based on its unique consistent and locally accurate attribution (<xref ref-type="bibr" rid="bib54">Lundberg et al., 2020</xref>). We calculated the average SHAP value for each region for all females and males of the UK Biobank cohort.</p><p>In addition, to assess that the regions with highest SHAP values were stable, we performed a permutation approach to study the significance of each region, separately for females and males. With this aim we compared the averaged SHAP value (region-specific) obtained when using the entire train set on the model to a null distribution calculated from 1,000 permutations performing subsample of the subjects, in which we trained and tested the model using 80% and 20% of the individuals, respectively.</p></sec><sec id="s4-9"><title>Brain-age delta estimation</title><p>We predicted brain-age on the independent cohorts separately: ALFA+, EPAD, ADNI, and OASIS, using the previously trained model. To investigate the prediction performance, correlation analyses were run for predicted brain-age versus chronological age, R<sup>2</sup>, root mean square error (RMSE), and mean absolute error (MAE) were calculated for each independent cohort separately, as well as for females and males separate pooled from all independent cohorts. We also investigated the prediction performance on the UK Biobank cohort by computing the average latter metrics from a cross-validation with 10 splits and 10 repetitions.</p><p>As recent research has shown that brain-age estimation involves a proportional bias (<xref ref-type="bibr" rid="bib26">de Lange et al., 2020a</xref>; <xref ref-type="bibr" rid="bib49">Le et al., 2018</xref>; <xref ref-type="bibr" rid="bib50">Liang et al., 2019</xref>; <xref ref-type="bibr" rid="bib75">Smith et al., 2019</xref>), we applied a well-established age-bias correction procedure to our data (<xref ref-type="bibr" rid="bib26">de Lange et al., 2020a</xref>; <xref ref-type="bibr" rid="bib49">Le et al., 2018</xref>). This correction, as originally proposed (<xref ref-type="bibr" rid="bib28">de Lange and Cole, 2020c</xref>; <xref ref-type="bibr" rid="bib49">Le et al., 2018</xref>), consists of a linear regression between age (Ω) and brain-predicted age (<inline-formula><mml:math id="inf5"><mml:mi>Y</mml:mi></mml:math></inline-formula>) on each of the independent cohorts, <inline-formula><mml:math id="inf6"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mi>Y</mml:mi><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:mspace width="thinmathspace"/><mml:mo>×</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">Ω</mml:mi><mml:mspace width="thinmathspace"/><mml:mo>+</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>β</mml:mi></mml:mrow></mml:mstyle></mml:math></inline-formula>. The derived values of slope (α) and intercept (β) from the training set were used to correct the predicted brain-age in each test set by applying: <inline-formula><mml:math id="inf7"><mml:mstyle displaystyle="true" scriptlevel="0"><mml:mrow><mml:mrow><mml:mi mathvariant="normal">C</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">o</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mrow><mml:mi mathvariant="normal">P</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">t</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">d</mml:mi></mml:mrow><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">B</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">r</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">a</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">i</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">n</mml:mi></mml:mrow><mml:mrow><mml:mtext> </mml:mtext></mml:mrow><mml:mrow><mml:mi mathvariant="normal">A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">g</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">e</mml:mi></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mo>×</mml:mo><mml:mrow><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow><mml:mo>+</mml:mo><mml:mrow><mml:mi>β</mml:mi></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:math></inline-formula>. By subtracting the chronological age from the Corrected Predicted Brain Age, we obtained the brain-age delta which was used to test the associations with the validation measurements.</p></sec><sec id="s4-10"><title>Statistical analyses</title><p>All statistical analyses were conducted using Python 3.7.0. We tested for normality of the distribution for each biomarker using the Kolmogorov-Smirnov test and visual inspection of histograms. CSF NfL and plasma NfL did not follow a normal distribution and were thus natural log transformed. In addition, to compare the measurements for CSF NfL and for plasma NfL coming from different cohorts (ALFA +and ADNI), CSF and plasma NfL was converted to z-scores.</p><p>To study the performance and accuracy of the brain-age prediction for each cohort, correlation analyses were run for predicted brain-age versus chronological age. We also computed R<sup>2</sup>, RMSE and MAE for each cohort, as well as the age bias of the prediction after bias correction. We assessed statistically whether the accuracy of the predicted brain-age was different between cohorts by using Fisher’s z-transformation for correlation coefficients. In addition, we computed these performance metrics to assess the differences in the model for females and males in the pooled cohorts. Results from another secondary analysis are also shown in <xref ref-type="table" rid="app1table7">Appendix 1—table 7</xref>, in which we assessed the performance and accuracy of the aging signature for all cohorts, by performing correlation analyses between the aging signature versus chronological age and computing the R<sup>2</sup> and RMSE. In this secondary analyses, we also studied whether the performance obtained for the predicted brain-age was better than the aging signature by performing the William’s test (<xref ref-type="bibr" rid="bib85">Williams, 1959</xref>) for the Pearson’s correlation coefficient and a F-test to assess which model was statistically better (<xref ref-type="table" rid="app1table7">Appendix 1—table 7</xref>).</p><p>We used the brain-age delta as a measure of brain aging to study the associations between this measurement and the different AD and neurodegeneration biomarkers and risk factors. With this aim, we pooled all the subjects from all cohorts together and computed linear regression models for each validation variable, in which chronological age and sex were included as covariates. Local effect size of each of the continuous validation variables was calculated using Cohen’s f<sup>2</sup> (<xref ref-type="bibr" rid="bib17">Cohen, 2013</xref>). The mean brain age delta among Aβ pathology, AT stages and <italic>APOE</italic> status, were assessed by a one-way analysis of covariance (ANCOVA) adjusting for age and sex. Effect size of the different levels was calculated by dividing the estimated difference in the brain-age delta between the different categories by the estimated standard deviation. We also stratified the individuals by sex and studied the associations between brain-age delta and the different validation variables by computing linear regression models in which chronological age was included as covariate. We next tested for interactions between sex and the validation variables on brain-age delta using linear regression models and including chronological age as covariate. Lastly, we tested for interactions between age and the validation variables on brain-age delta for CU and MCI individuals, as well as for females and males. Correction for multiple comparisons was performed using false discovery rate correction (FDR) (<xref ref-type="bibr" rid="bib7">Benjamini and Hochberg, 1995</xref>). The number of tests for which we corrected was 125.</p><p>We also performed two different secondary and exploratory analyses. First, we assessed whether the brain regions (volumes and cortical thickness) that contributed the most to the prediction of females and males in the UK Biobank were different for each sex. With this aim we performed regression models to study the interaction effect of sex for each of the selected ROIs by including a sex-age interaction term.</p><p>Secondly, we wanted to identify the individuals whose predicted brain-age deviate the most from chronological aging, that is, individuals with the highest positive or lowest negative brain-age deltas, to study the above-mentioned associations. The aim of this secondary analysis was to examine the impact of these extreme individuals on the overall relationships observed in our sample, in the expectation that the observed effect would be small. Even though this procedure implies that some of the data is discarded, we expected that the resulting analyses may be more sensitive. With this aim, we selected the individuals whose brain-age delta was included within the 10th and 90th percentile of the distribution for each independent cohort and studied the differences between these groups. The methodology and the results of this analysis can be found in Appendix 1.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>is currently a full-time employee of H. Lundbeck A/S and previously has served as a consultant or on advisory boards for the following for-profit companies or has given lectures in symposia sponsored by the following for-profit companies: Roche Diagnostics, Genentech, Novartis, Lundbeck, Oryzon, Biogen, Lilly, Janssen, Green Valley, MSD, Eisai, Alector, BioCross, GE Healthcare, and ProMIS Neurosciences</p></fn><fn fn-type="COI-statement" id="conf3"><p>Employee of Takeda Pharmaceutical Company Ltd</p></fn><fn fn-type="COI-statement" id="conf4"><p>Is a full-time employee and shareholder of Roche Diagnostics International Ltd</p></fn><fn fn-type="COI-statement" id="conf5"><p>Is a full-time employee of Roche Diagnostics GmbH</p></fn><fn fn-type="COI-statement" id="conf6"><p>Is a full-time employee and shareholder of Roche Diagnostics GmbH</p></fn><fn fn-type="COI-statement" id="conf7"><p>Has served as a consultant and at advisory boards for Roche Diagnostics International Ltd and has given lectures in symposia sponsored by Roche Diagnostics, S.L.U, Roche Farma, S.A and Roche Sistemas de Diagnósticos, Sociedade Unipessoal, Lda</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con2"><p>Data curation, Software, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Resources, Data curation, Software, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Resources, Data curation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Resources, Data curation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Validation, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Resources, Data curation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Resources, Data curation, Software, Writing – review and editing</p></fn><fn fn-type="con" id="con9"><p>Resources, Data curation, Software, Writing – review and editing</p></fn><fn fn-type="con" id="con10"><p>Resources, Data curation, Software, Writing – review and editing</p></fn><fn fn-type="con" id="con11"><p>Validation, Investigation, Visualization, Writing – review and editing</p></fn><fn fn-type="con" id="con12"><p>Resources, Data curation, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con13"><p>Resources, Data curation, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Validation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con15"><p>Resources, Validation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con16"><p>Resources, Validation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con17"><p>Resources, Validation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con18"><p>Resources, Validation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con19"><p>Resources, Validation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con20"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con21"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con22"><p>Resources, Writing – review and editing</p></fn><fn fn-type="con" id="con23"><p>Resources, Data curation, Validation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con24"><p>Resources, Data curation, Validation, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con25"><p>Conceptualization, Data curation, Validation, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con26"><p>Conceptualization, Supervision, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con27"><p>Conceptualization, Supervision, Validation, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con28"><p>Resources</p></fn><fn fn-type="con" id="con29"><p>Resources</p></fn><fn fn-type="con" id="con30"><p>Resources</p></fn><fn fn-type="con" id="con31"><p>Resources</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Clinical trial registration Clinicaltrials.gov Identifier: NCT01835717.</p></fn><fn fn-type="other"><p>Human subjects: ALFA ethics: All participants were enrolled in the ALFA (ALzheimer and FAmilies) study (Clinicaltrials.gov Identifier: NCT01835717). The study was approved by the Independent Ethics Committee &quot;Parc de Salut Mar,&quot; Barcelona, and all participants gave written informed consent.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-81067-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>UK Biobank data availability at <ext-link ext-link-type="uri" xlink:href="https://www.ukbiobank.ac.uk/">https://www.ukbiobank.ac.uk/</ext-link> ADNI data availability at <ext-link ext-link-type="uri" xlink:href="https://adni.loni.usc.edu/">https://adni.loni.usc.edu/</ext-link> EPAD data availability at <ext-link ext-link-type="uri" xlink:href="https://ep-ad.org/">https://ep-ad.org/</ext-link> ALFA: data availability through GAAIN at <ext-link ext-link-type="uri" xlink:href="https://www.gaaindata.org/partners/online.html">https://www.gaaindata.org/partners/online.html</ext-link> Fully steps and instructions on data access can be found in the following links: UK Biobank: <ext-link ext-link-type="uri" xlink:href="https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access">https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access</ext-link> ADNI: <ext-link ext-link-type="uri" xlink:href="https://adni.loni.usc.edu/data-samples/access-data/EPAD">https://adni.loni.usc.edu/data-samples/access-data/EPAD</ext-link>: <ext-link ext-link-type="uri" xlink:href="https://ep-ad.org/open-access-data/access/">https://ep-ad.org/open-access-data/access/</ext-link> ALFA: <ext-link ext-link-type="uri" xlink:href="https://www.gaaindata.org/partner/ALFA">https://www.gaaindata.org/partner/ALFA</ext-link>.</p></sec><ack id="ack"><title>Acknowledgements</title><p>This publication is part of the ALFA study (ALzheimer and FAmilies). The authors would like to express their most sincere gratitude to the ALFA project participants, without whom this research would have not been possible. Authors would like to thank Roche Diagnostics International Ltd. for kindly providing the kits for the CSF analysis of ALFA + participants and GE Healthcare for kindly providing [18 F] flutemetamol doses of ALFA + participants. Collaborators of the ALFA Study are: Müge Akinci, Annabella Beteta, Alba Cañas, Irene Cumplido, Carme Deulofeu, Ruth Dominguez, Maria Emilio, Karine Fauria, Sherezade Fuentes, Oriol Grau-Rivera, Laura Hernandez, Gema Huesa, Jordi Huguet, Eider M Arenaza-Urquijo, Eva M Palacios, Paula Marne, Tania Menchón, Carolina Minguillon, Eleni Palpatzis, Cleofé Peña-Gómez, Albina Polo, Sandra Pradas, Blanca Rodríguez-Fernández, Aleix Sala-Vila, Gemma Salvadó, Mahnaz Shekari, Anna Soteras, Laura Stankeviciute, Marc Vilanova and Natalia Vilor-Tejedor.</p><p>The project leading to these results has received funding from “la Caixa” Foundation (ID 100010434), under agreement LCF/PR/GN17/50300004 and the Alzheimer’s Association and an international anonymous charity foundation through the TriBEKa Imaging Platform project (TriBEKa-17–519007). Additional support has been received from the Universities and Research Secretariat, Ministry of Business and Knowledge of the Catalan Government under the grant no. 2017-SGR-892 and the Spanish Research Agency (AEI) under project PID2020-116907RB-I00 of the call MCIN/ AEI /10.13039/501100011033. FB is supported by the NIHR biomedical research center at UCLH. MSC receives funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme (Grant agreement No. 948677), the Instituto de Salud Carlos III (PI19/00155), and from a fellowship from ”la Caixa” Foundation (ID 100010434) and from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 847648 (LCF/BQ/PR21/11840004).</p><p>COBAS, COBAS E and ELECSYS are trademarks of Roche. All other product names and trademarks are the property of their respective owners. The Roche NeuroToolKit is a panel of exploratory prototype assays designed to robustly evaluate biomarkers associated with key pathologic events characteristic of AD and other neurological disorders, used for research purposes only and not approved for clinical use.</p><p>The authors would like to thank the reviewers for their constructive input on this manuscript.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arenaza-Urquijo</surname><given-names>EM</given-names></name><name><surname>Przybelski</surname><given-names>SA</given-names></name><name><surname>Lesnick</surname><given-names>TL</given-names></name><name><surname>Graff-Radford</surname><given-names>J</given-names></name><name><surname>Machulda</surname><given-names>MM</given-names></name><name><surname>Knopman</surname><given-names>DS</given-names></name><name><surname>Schwarz</surname><given-names>CG</given-names></name><name><surname>Lowe</surname><given-names>VJ</given-names></name><name><surname>Mielke</surname><given-names>MM</given-names></name><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Jack</surname><given-names>CR</given-names></name><name><surname>Vemuri</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The metabolic brain signature of cognitive resilience in the 80+: beyond alzheimer pathologies</article-title><source>Brain</source><volume>142</volume><fpage>1134</fpage><lpage>1147</lpage><pub-id pub-id-type="doi">10.1093/brain/awz037</pub-id><pub-id pub-id-type="pmid">30851100</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>NM</given-names></name><name><surname>An</surname><given-names>Y</given-names></name><name><surname>Beason-Held</surname><given-names>L</given-names></name><name><surname>Doshi</surname><given-names>J</given-names></name><name><surname>Erus</surname><given-names>G</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Davatzikos</surname><given-names>C</given-names></name><name><surname>Resnick</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sex differences in brain aging and predictors of neurodegeneration in cognitively healthy older adults</article-title><source>Neurobiology of Aging</source><volume>81</volume><fpage>146</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2019.05.020</pub-id><pub-id pub-id-type="pmid">31280118</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakkour</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Wolk</surname><given-names>DA</given-names></name><name><surname>Dickerson</surname><given-names>BC</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The effects of aging and alzheimer’s disease on cerebral cortical anatomy: specificity and differential relationships with cognition</article-title><source>NeuroImage</source><volume>76</volume><fpage>332</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2013.02.059</pub-id><pub-id pub-id-type="pmid">23507382</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baron-Cohen</surname><given-names>S</given-names></name><name><surname>Knickmeyer</surname><given-names>RC</given-names></name><name><surname>Belmonte</surname><given-names>MK</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Sex differences in the brain: implications for explaining autism</article-title><source>Science</source><volume>310</volume><fpage>819</fpage><lpage>823</lpage><pub-id pub-id-type="doi">10.1126/science.1115455</pub-id><pub-id pub-id-type="pmid">16272115</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bashyam</surname><given-names>VM</given-names></name><name><surname>Erus</surname><given-names>G</given-names></name><name><surname>Doshi</surname><given-names>J</given-names></name><name><surname>Habes</surname><given-names>M</given-names></name><name><surname>Nasrallah</surname><given-names>I</given-names></name><name><surname>Truelove-Hill</surname><given-names>M</given-names></name><name><surname>Srinivasan</surname><given-names>D</given-names></name><name><surname>Mamourian</surname><given-names>L</given-names></name><name><surname>Pomponio</surname><given-names>R</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Launer</surname><given-names>LJ</given-names></name><name><surname>Masters</surname><given-names>CL</given-names></name><name><surname>Maruff</surname><given-names>P</given-names></name><name><surname>Zhuo</surname><given-names>C</given-names></name><name><surname>Völzke</surname><given-names>H</given-names></name><name><surname>Johnson</surname><given-names>SC</given-names></name><name><surname>Fripp</surname><given-names>J</given-names></name><name><surname>Koutsouleris</surname><given-names>N</given-names></name><name><surname>Satterthwaite</surname><given-names>TD</given-names></name><name><surname>Wolf</surname><given-names>D</given-names></name><name><surname>Gur</surname><given-names>RE</given-names></name><name><surname>Gur</surname><given-names>RC</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><name><surname>Albert</surname><given-names>MS</given-names></name><name><surname>Grabe</surname><given-names>HJ</given-names></name><name><surname>Resnick</surname><given-names>S</given-names></name><name><surname>Bryan</surname><given-names>RN</given-names></name><name><surname>Wolk</surname><given-names>DA</given-names></name><name><surname>Shou</surname><given-names>H</given-names></name><name><surname>Davatzikos</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>MRI signatures of brain age and disease over the lifespan based on a deep brain network and 14 468 individuals worldwide</article-title><source>Brain</source><volume>143</volume><fpage>2312</fpage><lpage>2324</lpage><pub-id pub-id-type="doi">10.1093/brain/awaa160</pub-id><pub-id pub-id-type="pmid">32591831</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beheshti</surname><given-names>I</given-names></name><name><surname>Maikusa</surname><given-names>N</given-names></name><name><surname>Matsuda</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The association between “brain-age score” (BAS) and traditional neuropsychological screening tools in alzheimer’s disease</article-title><source>Brain and Behavior</source><volume>8</volume><elocation-id>e01020</elocation-id><pub-id pub-id-type="doi">10.1002/brb3.1020</pub-id><pub-id pub-id-type="pmid">29931756</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Benjamini</surname><given-names>Y</given-names></name><name><surname>Hochberg</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Controlling the false discovery rate: A practical and powerful approach to multiple testing</article-title><source>Journal of the Royal Statistical Society</source><volume>57</volume><fpage>289</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1111/j.2517-6161.1995.tb02031.x</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Bergstra</surname><given-names>J</given-names></name><name><surname>Yamins</surname><given-names>D</given-names></name><name><surname>Cox</surname><given-names>DD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Making a Science of Model Search: Hyperparameter Optimization in Hundreds of Dimensions for Vision Architectures. Proc. of the</article-title><conf-name>Proc.of the 30th International Conference on Machine Learning</conf-name></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bittner</surname><given-names>T</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Teunissen</surname><given-names>CE</given-names></name><name><surname>Ostlund</surname><given-names>RE</given-names></name><name><surname>Militello</surname><given-names>M</given-names></name><name><surname>Andreasson</surname><given-names>U</given-names></name><name><surname>Hubeek</surname><given-names>I</given-names></name><name><surname>Gibson</surname><given-names>D</given-names></name><name><surname>Chu</surname><given-names>DC</given-names></name><name><surname>Eichenlaub</surname><given-names>U</given-names></name><name><surname>Heiss</surname><given-names>P</given-names></name><name><surname>Kobold</surname><given-names>U</given-names></name><name><surname>Leinenbach</surname><given-names>A</given-names></name><name><surname>Madin</surname><given-names>K</given-names></name><name><surname>Manuilova</surname><given-names>E</given-names></name><name><surname>Rabe</surname><given-names>C</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of β-amyloid (1-42) in human cerebrospinal fluid</article-title><source>Alzheimer’s &amp; Dementia</source><volume>12</volume><fpage>517</fpage><lpage>526</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2015.09.009</pub-id><pub-id pub-id-type="pmid">26555316</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brugulat-Serrat</surname><given-names>A</given-names></name><name><surname>Rojas</surname><given-names>S</given-names></name><name><surname>Bargalló</surname><given-names>N</given-names></name><name><surname>Conesa</surname><given-names>G</given-names></name><name><surname>Minguillón</surname><given-names>C</given-names></name><name><surname>Fauria</surname><given-names>K</given-names></name><name><surname>Gramunt</surname><given-names>N</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Gispert</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Incidental findings on brain MRI of cognitively normal first-degree descendants of patients with alzheimer’s disease: a cross-sectional analysis from the ALFA (alzheimer and families) project</article-title><source>BMJ Open</source><volume>7</volume><elocation-id>e013215</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2016-013215</pub-id><pub-id pub-id-type="pmid">28341686</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brugulat-Serrat</surname><given-names>A</given-names></name><name><surname>Salvadó</surname><given-names>G</given-names></name><name><surname>Operto</surname><given-names>G</given-names></name><name><surname>Cacciaglia</surname><given-names>R</given-names></name><name><surname>Sudre</surname><given-names>CH</given-names></name><name><surname>Grau-Rivera</surname><given-names>O</given-names></name><name><surname>Suárez-Calvet</surname><given-names>M</given-names></name><name><surname>Falcon</surname><given-names>C</given-names></name><name><surname>Sánchez-Benavides</surname><given-names>G</given-names></name><name><surname>Gramunt</surname><given-names>N</given-names></name><name><surname>Minguillon</surname><given-names>C</given-names></name><name><surname>Fauria</surname><given-names>K</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Gispert</surname><given-names>JD</given-names></name><collab>ALFA Study</collab></person-group><year iso-8601-date="2020">2020a</year><article-title>White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants</article-title><source>Human Brain Mapping</source><volume>41</volume><fpage>1309</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1002/hbm.24877</pub-id><pub-id pub-id-type="pmid">31778002</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brugulat-Serrat</surname><given-names>A</given-names></name><name><surname>Salvadó</surname><given-names>G</given-names></name><name><surname>Sudre</surname><given-names>CH</given-names></name><name><surname>Grau-Rivera</surname><given-names>O</given-names></name><name><surname>Suárez-Calvet</surname><given-names>M</given-names></name><name><surname>Falcon</surname><given-names>C</given-names></name><name><surname>Sánchez-Benavides</surname><given-names>G</given-names></name><name><surname>Gramunt</surname><given-names>N</given-names></name><name><surname>Fauria</surname><given-names>K</given-names></name><name><surname>Cardoso</surname><given-names>MJ</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Gispert</surname><given-names>JD</given-names></name><name><surname>Camí</surname><given-names>J</given-names></name><name><surname>Cacciaglia</surname><given-names>R</given-names></name><name><surname>Operto</surname><given-names>G</given-names></name><name><surname>Skouras</surname><given-names>S</given-names></name><name><surname>Minguillón</surname><given-names>C</given-names></name><name><surname>Polo</surname><given-names>A</given-names></name><name><surname>Huguet</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals</article-title><source>Brain Imaging and Behavior</source><volume>14</volume><fpage>2012</fpage><lpage>2023</lpage><pub-id pub-id-type="doi">10.1007/s11682-019-00151-2</pub-id><pub-id pub-id-type="pmid">31278650</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Buckley</surname><given-names>RF</given-names></name><name><surname>Mormino</surname><given-names>EC</given-names></name><name><surname>Rabin</surname><given-names>JS</given-names></name><name><surname>Hohman</surname><given-names>TJ</given-names></name><name><surname>Landau</surname><given-names>S</given-names></name><name><surname>Hanseeuw</surname><given-names>BJ</given-names></name><name><surname>Jacobs</surname><given-names>HIL</given-names></name><name><surname>Papp</surname><given-names>KV</given-names></name><name><surname>Amariglio</surname><given-names>RE</given-names></name><name><surname>Properzi</surname><given-names>MJ</given-names></name><name><surname>Schultz</surname><given-names>AP</given-names></name><name><surname>Kirn</surname><given-names>D</given-names></name><name><surname>Scott</surname><given-names>MR</given-names></name><name><surname>Hedden</surname><given-names>T</given-names></name><name><surname>Farrell</surname><given-names>M</given-names></name><name><surname>Price</surname><given-names>J</given-names></name><name><surname>Chhatwal</surname><given-names>J</given-names></name><name><surname>Rentz</surname><given-names>DM</given-names></name><name><surname>Villemagne</surname><given-names>VL</given-names></name><name><surname>Johnson</surname><given-names>KA</given-names></name><name><surname>Sperling</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Sex differences in the association of global amyloid and regional tau deposition measured by positron emission tomography in clinically normal older adults</article-title><source>JAMA Neurology</source><volume>76</volume><fpage>542</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2018.4693</pub-id><pub-id pub-id-type="pmid">30715078</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casamitjana</surname><given-names>A</given-names></name><name><surname>Petrone</surname><given-names>P</given-names></name><name><surname>Tucholka</surname><given-names>A</given-names></name><name><surname>Falcon</surname><given-names>C</given-names></name><name><surname>Skouras</surname><given-names>S</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Vilaplana</surname><given-names>V</given-names></name><name><surname>Gispert</surname><given-names>JD</given-names></name><collab>Alzheimer’s Disease Neuroimaging Initiative</collab></person-group><year iso-8601-date="2018">2018</year><article-title>MRI-based screening of preclinical alzheimer’s disease for prevention clinical trials</article-title><source>Journal of Alzheimer’s Disease</source><volume>64</volume><fpage>1099</fpage><lpage>1112</lpage><pub-id pub-id-type="doi">10.3233/JAD-180299</pub-id><pub-id pub-id-type="pmid">30010132</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Guestrin</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>XGBoost: A Scalable Tree Boosting System</article-title><conf-name>KDD ’16</conf-name><conf-loc>New York, NY, USA</conf-loc><fpage>785</fpage><lpage>794</lpage><pub-id pub-id-type="doi">10.1145/2939672.2939785</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coffey</surname><given-names>CE</given-names></name><name><surname>Lucke</surname><given-names>JF</given-names></name><name><surname>Saxton</surname><given-names>JA</given-names></name><name><surname>Ratcliff</surname><given-names>G</given-names></name><name><surname>Unitas</surname><given-names>LJ</given-names></name><name><surname>Billig</surname><given-names>B</given-names></name><name><surname>Bryan</surname><given-names>RN</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Sex differences in brain aging: A quantitative magnetic resonance imaging study</article-title><source>Archives of Neurology</source><volume>55</volume><fpage>169</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1001/archneur.55.2.169</pub-id><pub-id pub-id-type="pmid">9482358</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><source>Statistical Power Analysis for the Behavioral Sciences</source><publisher-name>Routledge</publisher-name><pub-id pub-id-type="doi">10.4324/9780203771587</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>JH</given-names></name><name><surname>Franke</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017a</year><article-title>Predicting age using neuroimaging: innovative brain ageing biomarkers</article-title><source>Trends in Neurosciences</source><volume>40</volume><fpage>681</fpage><lpage>690</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2017.10.001</pub-id><pub-id pub-id-type="pmid">29074032</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>JH</given-names></name><name><surname>Annus</surname><given-names>T</given-names></name><name><surname>Wilson</surname><given-names>LR</given-names></name><name><surname>Remtulla</surname><given-names>R</given-names></name><name><surname>Hong</surname><given-names>YT</given-names></name><name><surname>Fryer</surname><given-names>TD</given-names></name><name><surname>Acosta-Cabronero</surname><given-names>J</given-names></name><name><surname>Cardenas-Blanco</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>R</given-names></name><name><surname>Menon</surname><given-names>DK</given-names></name><name><surname>Zaman</surname><given-names>SH</given-names></name><name><surname>Nestor</surname><given-names>PJ</given-names></name><name><surname>Holland</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2017">2017b</year><article-title>Brain-predicted age in down syndrome is associated with beta amyloid deposition and cognitive decline</article-title><source>Neurobiology of Aging</source><volume>56</volume><fpage>41</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2017.04.006</pub-id><pub-id pub-id-type="pmid">28482213</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>JH</given-names></name><name><surname>Poudel</surname><given-names>RPK</given-names></name><name><surname>Tsagkrasoulis</surname><given-names>D</given-names></name><name><surname>Caan</surname><given-names>MWA</given-names></name><name><surname>Steves</surname><given-names>C</given-names></name><name><surname>Spector</surname><given-names>TD</given-names></name><name><surname>Montana</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2017">2017c</year><article-title>Predicting brain age with deep learning from raw imaging data results in a reliable and heritable biomarker</article-title><source>NeuroImage</source><volume>163</volume><fpage>115</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2017.07.059</pub-id><pub-id pub-id-type="pmid">28765056</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>JH</given-names></name><name><surname>Ritchie</surname><given-names>SJ</given-names></name><name><surname>Bastin</surname><given-names>ME</given-names></name><name><surname>Valdés Hernández</surname><given-names>MC</given-names></name><name><surname>Muñoz Maniega</surname><given-names>S</given-names></name><name><surname>Royle</surname><given-names>N</given-names></name><name><surname>Corley</surname><given-names>J</given-names></name><name><surname>Pattie</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>SE</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Wray</surname><given-names>NR</given-names></name><name><surname>Redmond</surname><given-names>P</given-names></name><name><surname>Marioni</surname><given-names>RE</given-names></name><name><surname>Starr</surname><given-names>JM</given-names></name><name><surname>Cox</surname><given-names>SR</given-names></name><name><surname>Wardlaw</surname><given-names>JM</given-names></name><name><surname>Sharp</surname><given-names>DJ</given-names></name><name><surname>Deary</surname><given-names>IJ</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Brain age predicts mortality</article-title><source>Molecular Psychiatry</source><volume>23</volume><fpage>1385</fpage><lpage>1392</lpage><pub-id pub-id-type="doi">10.1038/mp.2017.62</pub-id><pub-id pub-id-type="pmid">28439103</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Multimodality neuroimaging brain-age in UK biobank: relationship to biomedical, lifestyle, and cognitive factors</article-title><source>Neurobiology of Aging</source><volume>92</volume><fpage>34</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2020.03.014</pub-id><pub-id pub-id-type="pmid">32380363</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dafflon</surname><given-names>J</given-names></name><name><surname>Pinaya</surname><given-names>WHL</given-names></name><name><surname>Turkheimer</surname><given-names>F</given-names></name><name><surname>Cole</surname><given-names>JH</given-names></name><name><surname>Leech</surname><given-names>R</given-names></name><name><surname>Harris</surname><given-names>MA</given-names></name><name><surname>Cox</surname><given-names>SR</given-names></name><name><surname>Whalley</surname><given-names>HC</given-names></name><name><surname>McIntosh</surname><given-names>AM</given-names></name><name><surname>Hellyer</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>An automated machine learning approach to predict brain age from cortical anatomical measures</article-title><source>Human Brain Mapping</source><volume>41</volume><fpage>3555</fpage><lpage>3566</lpage><pub-id pub-id-type="doi">10.1002/hbm.25028</pub-id><pub-id pub-id-type="pmid">32415917</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>DeCarli</surname><given-names>C</given-names></name><name><surname>Massaro</surname><given-names>J</given-names></name><name><surname>Harvey</surname><given-names>D</given-names></name><name><surname>Hald</surname><given-names>J</given-names></name><name><surname>Tullberg</surname><given-names>M</given-names></name><name><surname>Au</surname><given-names>R</given-names></name><name><surname>Beiser</surname><given-names>A</given-names></name><name><surname>D’Agostino</surname><given-names>R</given-names></name><name><surname>Wolf</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Measures of brain morphology and infarction in the framingham heart study: establishing what is normal</article-title><source>Neurobiology of Aging</source><volume>26</volume><fpage>491</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2004.05.004</pub-id><pub-id pub-id-type="pmid">15653178</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lange</surname><given-names>A-MG</given-names></name><name><surname>Kaufmann</surname><given-names>T</given-names></name><name><surname>van der Meer</surname><given-names>D</given-names></name><name><surname>Maglanoc</surname><given-names>LA</given-names></name><name><surname>Alnæs</surname><given-names>D</given-names></name><name><surname>Moberget</surname><given-names>T</given-names></name><name><surname>Douaud</surname><given-names>G</given-names></name><name><surname>Andreassen</surname><given-names>OA</given-names></name><name><surname>Westlye</surname><given-names>LT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Population-based neuroimaging reveals traces of childbirth in the maternal brain</article-title><source>PNAS</source><volume>116</volume><fpage>22341</fpage><lpage>22346</lpage><pub-id pub-id-type="doi">10.1073/pnas.1910666116</pub-id><pub-id pub-id-type="pmid">31615888</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lange</surname><given-names>AMG</given-names></name><name><surname>Anatürk</surname><given-names>M</given-names></name><name><surname>Suri</surname><given-names>S</given-names></name><name><surname>Kaufmann</surname><given-names>T</given-names></name><name><surname>Cole</surname><given-names>JH</given-names></name><name><surname>Griffanti</surname><given-names>L</given-names></name><name><surname>Zsoldos</surname><given-names>E</given-names></name><name><surname>Jensen</surname><given-names>DEA</given-names></name><name><surname>Filippini</surname><given-names>N</given-names></name><name><surname>Singh-Manoux</surname><given-names>A</given-names></name><name><surname>Kivimäki</surname><given-names>M</given-names></name><name><surname>Westlye</surname><given-names>LT</given-names></name><name><surname>Ebmeier</surname><given-names>KP</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Multimodal brain-age prediction and cardiovascular risk: the whitehall II MRI sub-study</article-title><source>NeuroImage</source><volume>222</volume><elocation-id>117292</elocation-id><pub-id pub-id-type="doi">10.1016/j.neuroimage.2020.117292</pub-id><pub-id pub-id-type="pmid">32835819</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lange</surname><given-names>AMG</given-names></name><name><surname>Barth</surname><given-names>C</given-names></name><name><surname>Kaufmann</surname><given-names>T</given-names></name><name><surname>Maximov</surname><given-names>II</given-names></name><name><surname>van der Meer</surname><given-names>D</given-names></name><name><surname>Agartz</surname><given-names>I</given-names></name><name><surname>Westlye</surname><given-names>LT</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Women’s brain aging: effects of sex-hormone exposure, pregnancies, and genetic risk for alzheimer’s disease</article-title><source>Human Brain Mapping</source><volume>41</volume><fpage>5141</fpage><lpage>5150</lpage><pub-id pub-id-type="doi">10.1002/hbm.25180</pub-id><pub-id pub-id-type="pmid">32856754</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Lange</surname><given-names>AMG</given-names></name><name><surname>Cole</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2020">2020c</year><article-title>Commentary: correction procedures in brain-age prediction</article-title><source>NeuroImage. Clinical</source><volume>26</volume><elocation-id>102229</elocation-id><pub-id pub-id-type="doi">10.1016/j.nicl.2020.102229</pub-id><pub-id pub-id-type="pmid">32120292</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Desikan</surname><given-names>RS</given-names></name><name><surname>Ségonne</surname><given-names>F</given-names></name><name><surname>Fischl</surname><given-names>B</given-names></name><name><surname>Quinn</surname><given-names>BT</given-names></name><name><surname>Dickerson</surname><given-names>BC</given-names></name><name><surname>Blacker</surname><given-names>D</given-names></name><name><surname>Buckner</surname><given-names>RL</given-names></name><name><surname>Dale</surname><given-names>AM</given-names></name><name><surname>Maguire</surname><given-names>RP</given-names></name><name><surname>Hyman</surname><given-names>BT</given-names></name><name><surname>Albert</surname><given-names>MS</given-names></name><name><surname>Killiany</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest</article-title><source>NeuroImage</source><volume>31</volume><fpage>968</fpage><lpage>980</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2006.01.021</pub-id><pub-id pub-id-type="pmid">16530430</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>S</given-names></name><name><surname>Dowell</surname><given-names>NG</given-names></name><name><surname>Tabet</surname><given-names>N</given-names></name><name><surname>Tofts</surname><given-names>PS</given-names></name><name><surname>King</surname><given-names>SL</given-names></name><name><surname>Rusted</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cognitive and neural signatures of the APOE E4 allele in mid-aged adults</article-title><source>Neurobiology of Aging</source><volume>35</volume><fpage>1615</fpage><lpage>1623</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.01.145</pub-id><pub-id pub-id-type="pmid">24582638</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ferretti</surname><given-names>MT</given-names></name><name><surname>Iulita</surname><given-names>MF</given-names></name><name><surname>Cavedo</surname><given-names>E</given-names></name><name><surname>Chiesa</surname><given-names>PA</given-names></name><name><surname>Schumacher Dimech</surname><given-names>A</given-names></name><name><surname>Santuccione Chadha</surname><given-names>A</given-names></name><name><surname>Baracchi</surname><given-names>F</given-names></name><name><surname>Girouard</surname><given-names>H</given-names></name><name><surname>Misoch</surname><given-names>S</given-names></name><name><surname>Giacobini</surname><given-names>E</given-names></name><name><surname>Depypere</surname><given-names>H</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><collab>Women’s Brain Project and the Alzheimer Precision Medicine Initiative</collab></person-group><year iso-8601-date="2018">2018</year><article-title>Sex differences in alzheimer disease - the gateway to precision medicine</article-title><source>Nature Reviews. Neurology</source><volume>14</volume><fpage>457</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1038/s41582-018-0032-9</pub-id><pub-id pub-id-type="pmid">29985474</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Filippini</surname><given-names>N</given-names></name><name><surname>Ebmeier</surname><given-names>KP</given-names></name><name><surname>MacIntosh</surname><given-names>BJ</given-names></name><name><surname>Trachtenberg</surname><given-names>AJ</given-names></name><name><surname>Frisoni</surname><given-names>GB</given-names></name><name><surname>Wilcock</surname><given-names>GK</given-names></name><name><surname>Beckmann</surname><given-names>CF</given-names></name><name><surname>Smith</surname><given-names>SM</given-names></name><name><surname>Matthews</surname><given-names>PM</given-names></name><name><surname>Mackay</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Differential effects of the APOE genotype on brain function across the lifespan</article-title><source>NeuroImage</source><volume>54</volume><fpage>602</fpage><lpage>610</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.08.009</pub-id><pub-id pub-id-type="pmid">20705142</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischl</surname><given-names>B</given-names></name><name><surname>Salat</surname><given-names>DH</given-names></name><name><surname>Busa</surname><given-names>E</given-names></name><name><surname>Albert</surname><given-names>M</given-names></name><name><surname>Dieterich</surname><given-names>M</given-names></name><name><surname>Haselgrove</surname><given-names>C</given-names></name><name><surname>van der Kouwe</surname><given-names>A</given-names></name><name><surname>Killiany</surname><given-names>R</given-names></name><name><surname>Kennedy</surname><given-names>D</given-names></name><name><surname>Klaveness</surname><given-names>S</given-names></name><name><surname>Montillo</surname><given-names>A</given-names></name><name><surname>Makris</surname><given-names>N</given-names></name><name><surname>Rosen</surname><given-names>B</given-names></name><name><surname>Dale</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain</article-title><source>Neuron</source><volume>33</volume><fpage>341</fpage><lpage>355</lpage><pub-id pub-id-type="doi">10.1016/s0896-6273(02)00569-x</pub-id><pub-id pub-id-type="pmid">11832223</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fjell</surname><given-names>AM</given-names></name><name><surname>McEvoy</surname><given-names>L</given-names></name><name><surname>Holland</surname><given-names>D</given-names></name><name><surname>Dale</surname><given-names>AM</given-names></name><name><surname>Walhovd</surname><given-names>KB</given-names></name><collab>Alzheimer’s Disease Neuroimaging Initiative</collab></person-group><year iso-8601-date="2014">2014</year><article-title>What is normal in normal aging? effects of aging, amyloid and alzheimer’s disease on the cerebral cortex and the hippocampus</article-title><source>Progress in Neurobiology</source><volume>117</volume><fpage>20</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.pneurobio.2014.02.004</pub-id><pub-id pub-id-type="pmid">24548606</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>K</given-names></name><name><surname>Ziegler</surname><given-names>G</given-names></name><name><surname>Klöppel</surname><given-names>S</given-names></name><name><surname>Gaser</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Estimating the age of healthy subjects from T1-weighted MRI scans using kernel methods: exploring the influence of various parameters</article-title><source>NeuroImage</source><volume>50</volume><fpage>883</fpage><lpage>892</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2010.01.005</pub-id><pub-id pub-id-type="pmid">20070949</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franke</surname><given-names>K</given-names></name><name><surname>Gaser</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Ten years of <italic>brainage</italic> as a neuroimaging biomarker of brain aging: what insights have we gained?</article-title><source>Frontiers in Neurology</source><volume>10</volume><elocation-id>789</elocation-id><pub-id pub-id-type="doi">10.3389/fneur.2019.00789</pub-id><pub-id pub-id-type="pmid">31474922</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gennatas</surname><given-names>ED</given-names></name><name><surname>Avants</surname><given-names>BB</given-names></name><name><surname>Wolf</surname><given-names>DH</given-names></name><name><surname>Satterthwaite</surname><given-names>TD</given-names></name><name><surname>Ruparel</surname><given-names>K</given-names></name><name><surname>Ciric</surname><given-names>R</given-names></name><name><surname>Hakonarson</surname><given-names>H</given-names></name><name><surname>Gur</surname><given-names>RE</given-names></name><name><surname>Gur</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Age-related effects and sex differences in gray matter density, volume, mass, and cortical thickness from childhood to young adulthood</article-title><source>The Journal of Neuroscience</source><volume>37</volume><fpage>5065</fpage><lpage>5073</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3550-16.2017</pub-id><pub-id pub-id-type="pmid">28432144</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>PS</given-names></name><name><surname>Simpkins</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Neuroprotective effects of estrogens: potential mechanisms of action</article-title><source>International Journal of Developmental Neuroscience</source><volume>18</volume><fpage>347</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1016/s0736-5748(00)00017-4</pub-id><pub-id pub-id-type="pmid">10817919</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>DL</given-names></name><name><surname>Messer</surname><given-names>DF</given-names></name><name><surname>Payne</surname><given-names>ME</given-names></name><name><surname>Macfall</surname><given-names>JR</given-names></name><name><surname>Provenzale</surname><given-names>JM</given-names></name><name><surname>Steffens</surname><given-names>DC</given-names></name><name><surname>Krishnan</surname><given-names>RR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Aging, gender, and the elderly adult brain: an examination of analytical strategies</article-title><source>Neurobiology of Aging</source><volume>29</volume><fpage>290</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2006.09.016</pub-id><pub-id pub-id-type="pmid">17049410</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Habes</surname><given-names>M</given-names></name><name><surname>Erus</surname><given-names>G</given-names></name><name><surname>Toledo</surname><given-names>JB</given-names></name><name><surname>Zhang</surname><given-names>T</given-names></name><name><surname>Bryan</surname><given-names>N</given-names></name><name><surname>Launer</surname><given-names>LJ</given-names></name><name><surname>Rosseel</surname><given-names>Y</given-names></name><name><surname>Janowitz</surname><given-names>D</given-names></name><name><surname>Doshi</surname><given-names>J</given-names></name><name><surname>Van der Auwera</surname><given-names>S</given-names></name><name><surname>von Sarnowski</surname><given-names>B</given-names></name><name><surname>Hegenscheid</surname><given-names>K</given-names></name><name><surname>Hosten</surname><given-names>N</given-names></name><name><surname>Homuth</surname><given-names>G</given-names></name><name><surname>Völzke</surname><given-names>H</given-names></name><name><surname>Schminke</surname><given-names>U</given-names></name><name><surname>Hoffmann</surname><given-names>W</given-names></name><name><surname>Grabe</surname><given-names>HJ</given-names></name><name><surname>Davatzikos</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>White matter hyperintensities and imaging patterns of brain ageing in the general population</article-title><source>Brain</source><volume>139</volume><fpage>1164</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1093/brain/aww008</pub-id><pub-id pub-id-type="pmid">26912649</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>O</given-names></name><name><surname>Seibyl</surname><given-names>J</given-names></name><name><surname>Stomrud</surname><given-names>E</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Bittner</surname><given-names>T</given-names></name><name><surname>Lifke</surname><given-names>V</given-names></name><name><surname>Corradini</surname><given-names>V</given-names></name><name><surname>Eichenlaub</surname><given-names>U</given-names></name><name><surname>Batrla</surname><given-names>R</given-names></name><name><surname>Buck</surname><given-names>K</given-names></name><name><surname>Zink</surname><given-names>K</given-names></name><name><surname>Rabe</surname><given-names>C</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Shaw</surname><given-names>LM</given-names></name><collab>Swedish BioFINDER study group</collab></person-group><year iso-8601-date="2018">2018</year><article-title>CSF biomarkers of alzheimer’s disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in biofinder and ADNI cohorts</article-title><source>Alzheimer’s &amp; Dementia</source><volume>14</volume><fpage>1470</fpage><lpage>1481</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2018.01.010</pub-id><pub-id pub-id-type="pmid">29499171</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>D</given-names></name><name><surname>Shu</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Accelerated brain aging in amnestic mild cognitive impairment: relationships with individual cognitive decline, risk factors for alzheimer disease, and clinical progression</article-title><source>Radiology. Artificial Intelligence</source><volume>3</volume><elocation-id>e200171</elocation-id><pub-id pub-id-type="doi">10.1148/ryai.2021200171</pub-id><pub-id pub-id-type="pmid">34617021</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huguet</surname><given-names>J</given-names></name><name><surname>Falcon</surname><given-names>C</given-names></name><name><surname>Fusté</surname><given-names>D</given-names></name><name><surname>Girona</surname><given-names>S</given-names></name><name><surname>Vicente</surname><given-names>D</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Gispert</surname><given-names>JD</given-names></name><name><surname>Operto</surname><given-names>G</given-names></name><collab>ALFA Study</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Management and quality control of large neuroimaging datasets: developments from the barcelonaβeta brain research center</article-title><source>Frontiers in Neuroscience</source><volume>15</volume><elocation-id>633438</elocation-id><pub-id pub-id-type="doi">10.3389/fnins.2021.633438</pub-id><pub-id pub-id-type="pmid">33935631</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jack</surname><given-names>CR</given-names></name><name><surname>Bennett</surname><given-names>DA</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Carrillo</surname><given-names>MC</given-names></name><name><surname>Dunn</surname><given-names>B</given-names></name><name><surname>Haeberlein</surname><given-names>SB</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Jagust</surname><given-names>W</given-names></name><name><surname>Jessen</surname><given-names>F</given-names></name><name><surname>Karlawish</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>E</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Montine</surname><given-names>T</given-names></name><name><surname>Phelps</surname><given-names>C</given-names></name><name><surname>Rankin</surname><given-names>KP</given-names></name><name><surname>Rowe</surname><given-names>CC</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Siemers</surname><given-names>E</given-names></name><name><surname>Snyder</surname><given-names>HM</given-names></name><name><surname>Sperling</surname><given-names>R</given-names></name><collab>Contributors</collab></person-group><year iso-8601-date="2018">2018</year><article-title>NIA-AA research framework: toward a biological definition of alzheimer’s disease</article-title><source>Alzheimer’s &amp; Dementia</source><volume>14</volume><fpage>535</fpage><lpage>562</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2018.02.018</pub-id><pub-id pub-id-type="pmid">29653606</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaeser</surname><given-names>SA</given-names></name><name><surname>Lehallier</surname><given-names>B</given-names></name><name><surname>Thinggaard</surname><given-names>M</given-names></name><name><surname>Häsler</surname><given-names>LM</given-names></name><name><surname>Apel</surname><given-names>A</given-names></name><name><surname>Bergmann</surname><given-names>C</given-names></name><name><surname>Berdnik</surname><given-names>D</given-names></name><name><surname>Jeune</surname><given-names>B</given-names></name><name><surname>Christensen</surname><given-names>K</given-names></name><name><surname>Grönke</surname><given-names>S</given-names></name><name><surname>Partridge</surname><given-names>L</given-names></name><name><surname>Wyss-Coray</surname><given-names>T</given-names></name><name><surname>Mengel-From</surname><given-names>J</given-names></name><name><surname>Jucker</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A neuronal blood marker is associated with mortality in old age</article-title><source>Nature Aging</source><volume>1</volume><fpage>218</fpage><lpage>225</lpage><pub-id pub-id-type="doi">10.1038/s43587-021-00028-4</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufmann</surname><given-names>T</given-names></name><name><surname>van der Meer</surname><given-names>D</given-names></name><name><surname>Doan</surname><given-names>NT</given-names></name><name><surname>Schwarz</surname><given-names>E</given-names></name><name><surname>Lund</surname><given-names>MJ</given-names></name><name><surname>Agartz</surname><given-names>I</given-names></name><name><surname>Alnæs</surname><given-names>D</given-names></name><name><surname>Barch</surname><given-names>DM</given-names></name><name><surname>Baur-Streubel</surname><given-names>R</given-names></name><name><surname>Bertolino</surname><given-names>A</given-names></name><name><surname>Bettella</surname><given-names>F</given-names></name><name><surname>Beyer</surname><given-names>MK</given-names></name><name><surname>Bøen</surname><given-names>E</given-names></name><name><surname>Borgwardt</surname><given-names>S</given-names></name><name><surname>Brandt</surname><given-names>CL</given-names></name><name><surname>Buitelaar</surname><given-names>J</given-names></name><name><surname>Celius</surname><given-names>EG</given-names></name><name><surname>Cervenka</surname><given-names>S</given-names></name><name><surname>Conzelmann</surname><given-names>A</given-names></name><name><surname>Córdova-Palomera</surname><given-names>A</given-names></name><name><surname>Dale</surname><given-names>AM</given-names></name><name><surname>de Quervain</surname><given-names>DJF</given-names></name><name><surname>Di Carlo</surname><given-names>P</given-names></name><name><surname>Djurovic</surname><given-names>S</given-names></name><name><surname>Dørum</surname><given-names>ES</given-names></name><name><surname>Eisenacher</surname><given-names>S</given-names></name><name><surname>Elvsåshagen</surname><given-names>T</given-names></name><name><surname>Espeseth</surname><given-names>T</given-names></name><name><surname>Fatouros-Bergman</surname><given-names>H</given-names></name><name><surname>Flyckt</surname><given-names>L</given-names></name><name><surname>Franke</surname><given-names>B</given-names></name><name><surname>Frei</surname><given-names>O</given-names></name><name><surname>Haatveit</surname><given-names>B</given-names></name><name><surname>Håberg</surname><given-names>AK</given-names></name><name><surname>Harbo</surname><given-names>HF</given-names></name><name><surname>Hartman</surname><given-names>CA</given-names></name><name><surname>Heslenfeld</surname><given-names>D</given-names></name><name><surname>Hoekstra</surname><given-names>PJ</given-names></name><name><surname>Høgestøl</surname><given-names>EA</given-names></name><name><surname>Jernigan</surname><given-names>TL</given-names></name><name><surname>Jonassen</surname><given-names>R</given-names></name><name><surname>Jönsson</surname><given-names>EG</given-names></name><name><surname>Kirsch</surname><given-names>P</given-names></name><name><surname>Kłoszewska</surname><given-names>I</given-names></name><name><surname>Kolskår</surname><given-names>KK</given-names></name><name><surname>Landrø</surname><given-names>NI</given-names></name><name><surname>Le Hellard</surname><given-names>S</given-names></name><name><surname>Lesch</surname><given-names>K-P</given-names></name><name><surname>Lovestone</surname><given-names>S</given-names></name><name><surname>Lundervold</surname><given-names>A</given-names></name><name><surname>Lundervold</surname><given-names>AJ</given-names></name><name><surname>Maglanoc</surname><given-names>LA</given-names></name><name><surname>Malt</surname><given-names>UF</given-names></name><name><surname>Mecocci</surname><given-names>P</given-names></name><name><surname>Melle</surname><given-names>I</given-names></name><name><surname>Meyer-Lindenberg</surname><given-names>A</given-names></name><name><surname>Moberget</surname><given-names>T</given-names></name><name><surname>Norbom</surname><given-names>LB</given-names></name><name><surname>Nordvik</surname><given-names>JE</given-names></name><name><surname>Nyberg</surname><given-names>L</given-names></name><name><surname>Oosterlaan</surname><given-names>J</given-names></name><name><surname>Papalino</surname><given-names>M</given-names></name><name><surname>Papassotiropoulos</surname><given-names>A</given-names></name><name><surname>Pauli</surname><given-names>P</given-names></name><name><surname>Pergola</surname><given-names>G</given-names></name><name><surname>Persson</surname><given-names>K</given-names></name><name><surname>Richard</surname><given-names>G</given-names></name><name><surname>Rokicki</surname><given-names>J</given-names></name><name><surname>Sanders</surname><given-names>A-M</given-names></name><name><surname>Selbæk</surname><given-names>G</given-names></name><name><surname>Shadrin</surname><given-names>AA</given-names></name><name><surname>Smeland</surname><given-names>OB</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Sowa</surname><given-names>P</given-names></name><name><surname>Steen</surname><given-names>VM</given-names></name><name><surname>Tsolaki</surname><given-names>M</given-names></name><name><surname>Ulrichsen</surname><given-names>KM</given-names></name><name><surname>Vellas</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Westman</surname><given-names>E</given-names></name><name><surname>Ziegler</surname><given-names>GC</given-names></name><name><surname>Zink</surname><given-names>M</given-names></name><name><surname>Andreassen</surname><given-names>OA</given-names></name><name><surname>Westlye</surname><given-names>LT</given-names></name><collab>Karolinska Schizophrenia Project</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Common brain disorders are associated with heritable patterns of apparent aging of the brain</article-title><source>Nature Neuroscience</source><volume>22</volume><fpage>1617</fpage><lpage>1623</lpage><pub-id pub-id-type="doi">10.1038/s41593-019-0471-7</pub-id><pub-id pub-id-type="pmid">31551603</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>M</given-names></name><name><surname>Teunissen</surname><given-names>CE</given-names></name><name><surname>Otto</surname><given-names>M</given-names></name><name><surname>Piehl</surname><given-names>F</given-names></name><name><surname>Sormani</surname><given-names>MP</given-names></name><name><surname>Gattringer</surname><given-names>T</given-names></name><name><surname>Barro</surname><given-names>C</given-names></name><name><surname>Kappos</surname><given-names>L</given-names></name><name><surname>Comabella</surname><given-names>M</given-names></name><name><surname>Fazekas</surname><given-names>F</given-names></name><name><surname>Petzold</surname><given-names>A</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Kuhle</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Neurofilaments as biomarkers in neurological disorders</article-title><source>Nature Reviews. Neurology</source><volume>14</volume><fpage>577</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/s41582-018-0058-z</pub-id><pub-id pub-id-type="pmid">30171200</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalil</surname><given-names>M</given-names></name><name><surname>Pirpamer</surname><given-names>L</given-names></name><name><surname>Hofer</surname><given-names>E</given-names></name><name><surname>Voortman</surname><given-names>MM</given-names></name><name><surname>Barro</surname><given-names>C</given-names></name><name><surname>Leppert</surname><given-names>D</given-names></name><name><surname>Benkert</surname><given-names>P</given-names></name><name><surname>Ropele</surname><given-names>S</given-names></name><name><surname>Enzinger</surname><given-names>C</given-names></name><name><surname>Fazekas</surname><given-names>F</given-names></name><name><surname>Schmidt</surname><given-names>R</given-names></name><name><surname>Kuhle</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Serum neurofilament light levels in normal aging and their association with morphologic brain changes</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>812</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-14612-6</pub-id><pub-id pub-id-type="pmid">32041951</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Le</surname><given-names>TT</given-names></name><name><surname>Kuplicki</surname><given-names>RT</given-names></name><name><surname>McKinney</surname><given-names>BA</given-names></name><name><surname>Yeh</surname><given-names>HW</given-names></name><name><surname>Thompson</surname><given-names>WK</given-names></name><name><surname>Paulus</surname><given-names>MP</given-names></name><name><surname>Aupperle</surname><given-names>RL</given-names></name><name><surname>Bodurka</surname><given-names>J</given-names></name><name><surname>Cha</surname><given-names>YH</given-names></name><name><surname>Feinstein</surname><given-names>JS</given-names></name><name><surname>Khalsa</surname><given-names>SS</given-names></name><name><surname>Savitz</surname><given-names>J</given-names></name><name><surname>Simmons</surname><given-names>WK</given-names></name><name><surname>Victor</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>A nonlinear simulation framework supports adjusting for age when analyzing brainage</article-title><source>Frontiers in Aging Neuroscience</source><volume>10</volume><elocation-id>317</elocation-id><pub-id pub-id-type="doi">10.3389/fnagi.2018.00317</pub-id><pub-id pub-id-type="pmid">30405393</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Niu</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Investigating systematic bias in brain age estimation with application to post-traumatic stress disorders</article-title><source>Human Brain Mapping</source><volume>40</volume><fpage>3143</fpage><lpage>3152</lpage><pub-id pub-id-type="doi">10.1002/hbm.24588</pub-id><pub-id pub-id-type="pmid">30924225</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liem</surname><given-names>F</given-names></name><name><surname>Varoquaux</surname><given-names>G</given-names></name><name><surname>Kynast</surname><given-names>J</given-names></name><name><surname>Beyer</surname><given-names>F</given-names></name><name><surname>Kharabian Masouleh</surname><given-names>S</given-names></name><name><surname>Huntenburg</surname><given-names>JM</given-names></name><name><surname>Lampe</surname><given-names>L</given-names></name><name><surname>Rahim</surname><given-names>M</given-names></name><name><surname>Abraham</surname><given-names>A</given-names></name><name><surname>Craddock</surname><given-names>RC</given-names></name><name><surname>Riedel-Heller</surname><given-names>S</given-names></name><name><surname>Luck</surname><given-names>T</given-names></name><name><surname>Loeffler</surname><given-names>M</given-names></name><name><surname>Schroeter</surname><given-names>ML</given-names></name><name><surname>Witte</surname><given-names>AV</given-names></name><name><surname>Villringer</surname><given-names>A</given-names></name><name><surname>Margulies</surname><given-names>DS</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Predicting brain-age from multimodal imaging data captures cognitive impairment</article-title><source>NeuroImage</source><volume>148</volume><fpage>179</fpage><lpage>188</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2016.11.005</pub-id><pub-id pub-id-type="pmid">27890805</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="preprint"><person-group person-group-type="author"><name><surname>Lorenzini</surname><given-names>L</given-names></name><name><surname>Ingala</surname><given-names>S</given-names></name><name><surname>Wink</surname><given-names>AM</given-names></name><name><surname>Kuijer</surname><given-names>JP</given-names></name><name><surname>Wottschel</surname><given-names>V</given-names></name><name><surname>Dijsselhof</surname><given-names>M</given-names></name><name><surname>Sudre</surname><given-names>CH</given-names></name><name><surname>Haller</surname><given-names>S</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Gispert</surname><given-names>JD</given-names></name><name><surname>Cash</surname><given-names>DM</given-names></name><name><surname>Thomas</surname><given-names>DL</given-names></name><name><surname>Vos</surname><given-names>SB</given-names></name><name><surname>Prados</surname><given-names>F</given-names></name><name><surname>Petr</surname><given-names>J</given-names></name><name><surname>Wolz</surname><given-names>R</given-names></name><name><surname>Palombit</surname><given-names>A</given-names></name><name><surname>Schwarz</surname><given-names>AJ</given-names></name><name><surname>Gael</surname><given-names>C</given-names></name><name><surname>Payoux</surname><given-names>P</given-names></name><name><surname>Di Perri</surname><given-names>C</given-names></name><name><surname>Wardlaw</surname><given-names>J</given-names></name><name><surname>Frisoni</surname><given-names>GB</given-names></name><name><surname>Foley</surname><given-names>C</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Ritchie</surname><given-names>C</given-names></name><name><surname>Pernet</surname><given-names>C</given-names></name><name><surname>Waldman</surname><given-names>A</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Mutsaerts</surname><given-names>HJ</given-names></name><collab>for the EPAD consortium</collab></person-group><year iso-8601-date="2021">2021</year><article-title>The European Prevention of Alzheimer’s Dementia (EPAD) MRI Dataset and Processing Workflow</article-title><source>bioRxiv</source><pub-id pub-id-type="doi">10.1101/2021.09.29.462349</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Löwe</surname><given-names>LC</given-names></name><name><surname>Gaser</surname><given-names>C</given-names></name><name><surname>Franke</surname><given-names>K</given-names></name><collab>Alzheimer’s Disease Neuroimaging Initiative</collab></person-group><year iso-8601-date="2016">2016</year><article-title>The effect of the APOE genotype on individual brainage in normal aging, mild cognitive impairment, and alzheimer’s disease</article-title><source>PLOS ONE</source><volume>11</volume><elocation-id>e0157514</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0157514</pub-id><pub-id pub-id-type="pmid">27410431</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lundberg</surname><given-names>SM</given-names></name><name><surname>Erion</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>DeGrave</surname><given-names>A</given-names></name><name><surname>Prutkin</surname><given-names>JM</given-names></name><name><surname>Nair</surname><given-names>B</given-names></name><name><surname>Katz</surname><given-names>R</given-names></name><name><surname>Himmelfarb</surname><given-names>J</given-names></name><name><surname>Bansal</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>SI</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>From local explanations to global understanding with explainable AI for trees</article-title><source>Nature Machine Intelligence</source><volume>2</volume><fpage>56</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1038/s42256-019-0138-9</pub-id><pub-id pub-id-type="pmid">32607472</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ly</surname><given-names>M</given-names></name><name><surname>Yu</surname><given-names>GZ</given-names></name><name><surname>Karim</surname><given-names>HT</given-names></name><name><surname>Muppidi</surname><given-names>NR</given-names></name><name><surname>Mizuno</surname><given-names>A</given-names></name><name><surname>Klunk</surname><given-names>WE</given-names></name><name><surname>Aizenstein</surname><given-names>HJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Improving brain age prediction models: incorporation of amyloid status in alzheimer’s disease</article-title><source>Neurobiology of Aging</source><volume>87</volume><fpage>44</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2019.11.005</pub-id><pub-id pub-id-type="pmid">31843257</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maioli</surname><given-names>S</given-names></name><name><surname>Leander</surname><given-names>K</given-names></name><name><surname>Nilsson</surname><given-names>P</given-names></name><name><surname>Nalvarte</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Estrogen receptors and the aging brain</article-title><source>Essays in Biochemistry</source><volume>65</volume><fpage>913</fpage><lpage>925</lpage><pub-id pub-id-type="doi">10.1042/EBC20200162</pub-id><pub-id pub-id-type="pmid">34623401</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maniega</surname><given-names>SM</given-names></name><name><surname>Valdés Hernández</surname><given-names>MC</given-names></name><name><surname>Clayden</surname><given-names>JD</given-names></name><name><surname>Royle</surname><given-names>NA</given-names></name><name><surname>Murray</surname><given-names>C</given-names></name><name><surname>Morris</surname><given-names>Z</given-names></name><name><surname>Aribisala</surname><given-names>BS</given-names></name><name><surname>Gow</surname><given-names>AJ</given-names></name><name><surname>Starr</surname><given-names>JM</given-names></name><name><surname>Bastin</surname><given-names>ME</given-names></name><name><surname>Deary</surname><given-names>IJ</given-names></name><name><surname>Wardlaw</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>White matter hyperintensities and normal-appearing white matter integrity in the aging brain</article-title><source>Neurobiology of Aging</source><volume>36</volume><fpage>909</fpage><lpage>918</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2014.07.048</pub-id><pub-id pub-id-type="pmid">25457555</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcus</surname><given-names>DS</given-names></name><name><surname>Wang</surname><given-names>TH</given-names></name><name><surname>Parker</surname><given-names>J</given-names></name><name><surname>Csernansky</surname><given-names>JG</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Buckner</surname><given-names>RL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Open access series of imaging studies (OASIS): cross-sectional MRI data in young, middle aged, nondemented, and demented older adults</article-title><source>Journal of Cognitive Neuroscience</source><volume>19</volume><fpage>1498</fpage><lpage>1507</lpage><pub-id pub-id-type="doi">10.1162/jocn.2007.19.9.1498</pub-id><pub-id pub-id-type="pmid">17714011</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mielke</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Consideration of sex differences in the measurement and interpretation of alzheimer disease-related biofluid-based biomarkers</article-title><source>The Journal of Applied Laboratory Medicine</source><volume>5</volume><fpage>158</fpage><lpage>169</lpage><pub-id pub-id-type="doi">10.1373/jalm.2019.030023</pub-id><pub-id pub-id-type="pmid">31811073</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milà-Alomà</surname><given-names>M</given-names></name><name><surname>Salvadó</surname><given-names>G</given-names></name><name><surname>Gispert</surname><given-names>JD</given-names></name><name><surname>Vilor-Tejedor</surname><given-names>N</given-names></name><name><surname>Grau-Rivera</surname><given-names>O</given-names></name><name><surname>Sala-Vila</surname><given-names>A</given-names></name><name><surname>Sánchez-Benavides</surname><given-names>G</given-names></name><name><surname>Arenaza-Urquijo</surname><given-names>EM</given-names></name><name><surname>Crous-Bou</surname><given-names>M</given-names></name><name><surname>González-de-Echávarri</surname><given-names>JM</given-names></name><name><surname>Minguillon</surname><given-names>C</given-names></name><name><surname>Fauria</surname><given-names>K</given-names></name><name><surname>Simon</surname><given-names>M</given-names></name><name><surname>Kollmorgen</surname><given-names>G</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Suárez-Calvet</surname><given-names>M</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><collab>ALFA study</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the alzheimer’s continuum</article-title><source>Alzheimer’s &amp; Dementia</source><volume>16</volume><fpage>1358</fpage><lpage>1371</lpage><pub-id pub-id-type="doi">10.1002/alz.12131</pub-id><pub-id pub-id-type="pmid">32573951</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Millar</surname><given-names>PR</given-names></name><name><surname>Gordon</surname><given-names>BA</given-names></name><name><surname>Luckett</surname><given-names>PH</given-names></name><name><surname>Benzinger</surname><given-names>TL</given-names></name><name><surname>Cruchaga</surname><given-names>C</given-names></name><name><surname>Fagan</surname><given-names>AM</given-names></name><name><surname>Hassenstab</surname><given-names>JJ</given-names></name><name><surname>Perrin</surname><given-names>RJ</given-names></name><name><surname>Schindler</surname><given-names>SE</given-names></name><name><surname>Allegri</surname><given-names>RF</given-names></name><name><surname>Day</surname><given-names>GS</given-names></name><name><surname>Farlow</surname><given-names>MR</given-names></name><name><surname>Mori</surname><given-names>H</given-names></name><name><surname>Nübling</surname><given-names>G</given-names></name><name><surname>Bateman</surname><given-names>RJ</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Ances</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Multimodal brain age estimates relate to Alzheimer disease biomarkers and cognition in early stages: a cross-sectional observational study</article-title><source>eLife</source><volume>12</volume><elocation-id>e81869</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.81869</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nebel</surname><given-names>RA</given-names></name><name><surname>Aggarwal</surname><given-names>NT</given-names></name><name><surname>Barnes</surname><given-names>LL</given-names></name><name><surname>Gallagher</surname><given-names>A</given-names></name><name><surname>Goldstein</surname><given-names>JM</given-names></name><name><surname>Kantarci</surname><given-names>K</given-names></name><name><surname>Mallampalli</surname><given-names>MP</given-names></name><name><surname>Mormino</surname><given-names>EC</given-names></name><name><surname>Scott</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>WH</given-names></name><name><surname>Maki</surname><given-names>PM</given-names></name><name><surname>Mielke</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Understanding the impact of sex and gender in alzheimer’s disease: A call to action</article-title><source>Alzheimer’s &amp; Dementia</source><volume>14</volume><fpage>1171</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2018.04.008</pub-id><pub-id pub-id-type="pmid">29907423</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osborn</surname><given-names>KE</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Samuels</surname><given-names>LR</given-names></name><name><surname>Moore</surname><given-names>EE</given-names></name><name><surname>Cambronero</surname><given-names>FE</given-names></name><name><surname>Acosta</surname><given-names>LMY</given-names></name><name><surname>Bell</surname><given-names>SP</given-names></name><name><surname>Babicz</surname><given-names>MA</given-names></name><name><surname>Gordon</surname><given-names>EA</given-names></name><name><surname>Pechman</surname><given-names>KR</given-names></name><name><surname>Davis</surname><given-names>LT</given-names></name><name><surname>Gifford</surname><given-names>KA</given-names></name><name><surname>Hohman</surname><given-names>TJ</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Jefferson</surname><given-names>AL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cerebrospinal fluid β-amyloid<sub>42</sub> and neurofilament light relate to white matter hyperintensities</article-title><source>Neurobiology of Aging</source><volume>68</volume><fpage>18</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2018.03.028</pub-id><pub-id pub-id-type="pmid">29702372</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>H</given-names></name><name><surname>Gong</surname><given-names>W</given-names></name><name><surname>Beckmann</surname><given-names>CF</given-names></name><name><surname>Vedaldi</surname><given-names>A</given-names></name><name><surname>Smith</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Accurate brain age prediction with lightweight deep neural networks</article-title><source>Medical Image Analysis</source><volume>68</volume><elocation-id>101871</elocation-id><pub-id pub-id-type="doi">10.1016/j.media.2020.101871</pub-id><pub-id pub-id-type="pmid">33197716</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petersen</surname><given-names>RC</given-names></name><name><surname>Aisen</surname><given-names>PS</given-names></name><name><surname>Beckett</surname><given-names>LA</given-names></name><name><surname>Donohue</surname><given-names>MC</given-names></name><name><surname>Gamst</surname><given-names>AC</given-names></name><name><surname>Harvey</surname><given-names>DJ</given-names></name><name><surname>Jack</surname><given-names>CR</given-names></name><name><surname>Jagust</surname><given-names>WJ</given-names></name><name><surname>Shaw</surname><given-names>LM</given-names></name><name><surname>Toga</surname><given-names>AW</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Weiner</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Alzheimer’s disease neuroimaging initiative (adni): clinical characterization</article-title><source>Neurology</source><volume>74</volume><fpage>201</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1212/WNL.0b013e3181cb3e25</pub-id><pub-id pub-id-type="pmid">20042704</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pichet Binette</surname><given-names>A</given-names></name><name><surname>Gonneaud</surname><given-names>J</given-names></name><name><surname>Vogel</surname><given-names>JW</given-names></name><name><surname>La Joie</surname><given-names>R</given-names></name><name><surname>Rosa-Neto</surname><given-names>P</given-names></name><name><surname>Collins</surname><given-names>DL</given-names></name><name><surname>Poirier</surname><given-names>J</given-names></name><name><surname>Breitner</surname><given-names>JCS</given-names></name><name><surname>Villeneuve</surname><given-names>S</given-names></name><name><surname>Vachon-Presseau</surname><given-names>E</given-names></name><collab>Alzheimer’s Disease Neuroimaging Initiative</collab><collab>PREVENT-AD Research Group</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Morphometric network differences in ageing versus alzheimer’s disease dementia</article-title><source>Brain</source><volume>143</volume><fpage>635</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.1093/brain/awz414</pub-id><pub-id pub-id-type="pmid">32040564</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Podgórski</surname><given-names>P</given-names></name><name><surname>Bladowska</surname><given-names>J</given-names></name><name><surname>Sasiadek</surname><given-names>M</given-names></name><name><surname>Zimny</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Novel volumetric and surface-based magnetic resonance indices of the aging brain - does male and female brain age in the same way?</article-title><source>Frontiers in Neurology</source><volume>12</volume><elocation-id>645729</elocation-id><pub-id pub-id-type="doi">10.3389/fneur.2021.645729</pub-id><pub-id pub-id-type="pmid">34163419</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popescu</surname><given-names>SG</given-names></name><name><surname>Whittington</surname><given-names>A</given-names></name><name><surname>Gunn</surname><given-names>RN</given-names></name><name><surname>Matthews</surname><given-names>PM</given-names></name><name><surname>Glocker</surname><given-names>B</given-names></name><name><surname>Sharp</surname><given-names>DJ</given-names></name><name><surname>Cole</surname><given-names>JH</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Nonlinear biomarker interactions in conversion from mild cognitive impairment to alzheimer’s disease</article-title><source>Human Brain Mapping</source><volume>41</volume><fpage>4406</fpage><lpage>4418</lpage><pub-id pub-id-type="doi">10.1002/hbm.25133</pub-id><pub-id pub-id-type="pmid">32643852</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Resnick</surname><given-names>SM</given-names></name><name><surname>Espeland</surname><given-names>MA</given-names></name><name><surname>Jaramillo</surname><given-names>SA</given-names></name><name><surname>Hirsch</surname><given-names>C</given-names></name><name><surname>Stefanick</surname><given-names>ML</given-names></name><name><surname>Murray</surname><given-names>AM</given-names></name><name><surname>Ockene</surname><given-names>J</given-names></name><name><surname>Davatzikos</surname><given-names>MC</given-names></name><name><surname>Resnick</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Postmenopausal hormone therapy and regional brain volumes: the WHIMS-MRI study</article-title><source>Neurology</source><volume>72</volume><fpage>135</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1212/01.wnl.0000339037.76336.cf</pub-id><pub-id pub-id-type="pmid">19139364</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizvi</surname><given-names>B</given-names></name><name><surname>Narkhede</surname><given-names>A</given-names></name><name><surname>Last</surname><given-names>BS</given-names></name><name><surname>Budge</surname><given-names>M</given-names></name><name><surname>Tosto</surname><given-names>G</given-names></name><name><surname>Manly</surname><given-names>JJ</given-names></name><name><surname>Schupf</surname><given-names>N</given-names></name><name><surname>Mayeux</surname><given-names>R</given-names></name><name><surname>Brickman</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The effect of white matter hyperintensities on cognition is mediated by cortical atrophy</article-title><source>Neurobiology of Aging</source><volume>64</volume><fpage>25</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2017.12.006</pub-id><pub-id pub-id-type="pmid">29328963</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Salvadó</surname><given-names>G</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Brugulat-Serrat</surname><given-names>A</given-names></name><name><surname>Falcon</surname><given-names>C</given-names></name><name><surname>Grau-Rivera</surname><given-names>O</given-names></name><name><surname>Suárez-Calvet</surname><given-names>M</given-names></name><name><surname>Pavia</surname><given-names>J</given-names></name><name><surname>Niñerola-Baizán</surname><given-names>A</given-names></name><name><surname>Perissinotti</surname><given-names>A</given-names></name><name><surname>Lomeña</surname><given-names>F</given-names></name><name><surname>Minguillon</surname><given-names>C</given-names></name><name><surname>Fauria</surname><given-names>K</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Gispert</surname><given-names>JD</given-names></name><collab>Alzheimer’s Disease Neuroimaging Initiative, for the ALFA Study</collab></person-group><year iso-8601-date="2019">2019</year><article-title>Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers</article-title><source>Alzheimer’s Research &amp; Therapy</source><volume>11</volume><elocation-id>27</elocation-id><pub-id pub-id-type="doi">10.1186/s13195-019-0478-z</pub-id><pub-id pub-id-type="pmid">30902090</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanford</surname><given-names>N</given-names></name><name><surname>Ge</surname><given-names>R</given-names></name><name><surname>Antoniades</surname><given-names>M</given-names></name><name><surname>Modabbernia</surname><given-names>A</given-names></name><name><surname>Haas</surname><given-names>SS</given-names></name><name><surname>Whalley</surname><given-names>HC</given-names></name><name><surname>Galea</surname><given-names>L</given-names></name><name><surname>Popescu</surname><given-names>SG</given-names></name><name><surname>Cole</surname><given-names>JH</given-names></name><name><surname>Frangou</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Sex differences in predictors and regional patterns of brain age gap estimates</article-title><source>Human Brain Mapping</source><volume>43</volume><fpage>4689</fpage><lpage>4698</lpage><pub-id pub-id-type="doi">10.1002/hbm.25983</pub-id><pub-id pub-id-type="pmid">35790053</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindler</surname><given-names>SE</given-names></name><name><surname>Gray</surname><given-names>JD</given-names></name><name><surname>Gordon</surname><given-names>BA</given-names></name><name><surname>Xiong</surname><given-names>C</given-names></name><name><surname>Batrla-Utermann</surname><given-names>R</given-names></name><name><surname>Quan</surname><given-names>M</given-names></name><name><surname>Wahl</surname><given-names>S</given-names></name><name><surname>Benzinger</surname><given-names>TLS</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name><name><surname>Morris</surname><given-names>JC</given-names></name><name><surname>Fagan</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Cerebrospinal fluid biomarkers measured by elecsys assays compared to amyloid imaging</article-title><source>Alzheimer’s &amp; Dementia</source><volume>14</volume><fpage>1460</fpage><lpage>1469</lpage><pub-id pub-id-type="doi">10.1016/j.jalz.2018.01.013</pub-id><pub-id pub-id-type="pmid">29501462</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwarz</surname><given-names>C</given-names></name><name><surname>Fletcher</surname><given-names>E</given-names></name><name><surname>DeCarli</surname><given-names>C</given-names></name><name><surname>Carmichael</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Fully-automated white matter hyperintensity detection with anatomical prior knowledge and without FLAIR</article-title><source>Lecture Notes in Computer Science</source><volume>5636 LNCS</volume><fpage>239</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1007/978-3-642-02498-6</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>SM</given-names></name><name><surname>Vidaurre</surname><given-names>D</given-names></name><name><surname>Alfaro-Almagro</surname><given-names>F</given-names></name><name><surname>Nichols</surname><given-names>TE</given-names></name><name><surname>Miller</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Estimation of brain age delta from brain imaging</article-title><source>NeuroImage</source><volume>200</volume><fpage>528</fpage><lpage>539</lpage><pub-id pub-id-type="doi">10.1016/j.neuroimage.2019.06.017</pub-id><pub-id pub-id-type="pmid">31201988</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>A</given-names></name><name><surname>Kivipelto</surname><given-names>M</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Tom</surname><given-names>B</given-names></name><name><surname>Ritchie</surname><given-names>CW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>European prevention of alzheimer’s dementia longitudinal cohort study (EPAD LCS): study protocol</article-title><source>BMJ Open</source><volume>8</volume><elocation-id>e021017</elocation-id><pub-id pub-id-type="doi">10.1136/bmjopen-2017-021017</pub-id><pub-id pub-id-type="pmid">29678993</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Su</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>PhDyear</data-title><version designator="746dd5d">746dd5d</version><source>PUP</source><ext-link ext-link-type="uri" xlink:href="https://github.com/ysu001/PUP">https://github.com/ysu001/PUP</ext-link></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suárez-Calvet</surname><given-names>M</given-names></name><name><surname>Karikari</surname><given-names>TK</given-names></name><name><surname>Ashton</surname><given-names>NJ</given-names></name><name><surname>Lantero Rodríguez</surname><given-names>J</given-names></name><name><surname>Milà-Alomà</surname><given-names>M</given-names></name><name><surname>Gispert</surname><given-names>JD</given-names></name><name><surname>Salvadó</surname><given-names>G</given-names></name><name><surname>Minguillon</surname><given-names>C</given-names></name><name><surname>Fauria</surname><given-names>K</given-names></name><name><surname>Shekari</surname><given-names>M</given-names></name><name><surname>Grau-Rivera</surname><given-names>O</given-names></name><name><surname>Arenaza-Urquijo</surname><given-names>EM</given-names></name><name><surname>Sala-Vila</surname><given-names>A</given-names></name><name><surname>Sánchez-Benavides</surname><given-names>G</given-names></name><name><surname>González-de-Echávarri</surname><given-names>JM</given-names></name><name><surname>Kollmorgen</surname><given-names>G</given-names></name><name><surname>Stoops</surname><given-names>E</given-names></name><name><surname>Vanmechelen</surname><given-names>E</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Blennow</surname><given-names>K</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><collab>ALFA Study</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical alzheimer’s continuum when only subtle changes in Aβ pathology are detected</article-title><source>EMBO Molecular Medicine</source><volume>12</volume><elocation-id>e12921</elocation-id><pub-id pub-id-type="doi">10.15252/emmm.202012921</pub-id><pub-id pub-id-type="pmid">33169916</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramaniapillai</surname><given-names>S</given-names></name><name><surname>Rajagopal</surname><given-names>S</given-names></name><name><surname>Snytte</surname><given-names>J</given-names></name><name><surname>Otto</surname><given-names>AR</given-names></name><name><surname>Einstein</surname><given-names>G</given-names></name><name><surname>Rajah</surname><given-names>MN</given-names></name><collab>PREVENT-AD Research Group</collab></person-group><year iso-8601-date="2021">2021</year><article-title>Sex differences in brain aging among adults with family history of alzheimer’s disease and APOE4 genetic risk</article-title><source>NeuroImage. Clinical</source><volume>30</volume><elocation-id>102620</elocation-id><pub-id pub-id-type="doi">10.1016/j.nicl.2021.102620</pub-id><pub-id pub-id-type="pmid">33857772</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudre</surname><given-names>CH</given-names></name><name><surname>Cardoso</surname><given-names>MJ</given-names></name><name><surname>Bouvy</surname><given-names>WH</given-names></name><name><surname>Biessels</surname><given-names>GJ</given-names></name><name><surname>Barnes</surname><given-names>J</given-names></name><name><surname>Ourselin</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Bayesian model selection for pathological neuroimaging data applied to white matter lesion segmentation</article-title><source>IEEE Transactions on Medical Imaging</source><volume>34</volume><fpage>2079</fpage><lpage>2102</lpage><pub-id pub-id-type="doi">10.1109/TMI.2015.2419072</pub-id><pub-id pub-id-type="pmid">25850086</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ten Kate</surname><given-names>M</given-names></name><name><surname>Redolfi</surname><given-names>A</given-names></name><name><surname>Peira</surname><given-names>E</given-names></name><name><surname>Bos</surname><given-names>I</given-names></name><name><surname>Vos</surname><given-names>SJ</given-names></name><name><surname>Vandenberghe</surname><given-names>R</given-names></name><name><surname>Gabel</surname><given-names>S</given-names></name><name><surname>Schaeverbeke</surname><given-names>J</given-names></name><name><surname>Scheltens</surname><given-names>P</given-names></name><name><surname>Blin</surname><given-names>O</given-names></name><name><surname>Richardson</surname><given-names>JC</given-names></name><name><surname>Bordet</surname><given-names>R</given-names></name><name><surname>Wallin</surname><given-names>A</given-names></name><name><surname>Eckerstrom</surname><given-names>C</given-names></name><name><surname>Molinuevo</surname><given-names>JL</given-names></name><name><surname>Engelborghs</surname><given-names>S</given-names></name><name><surname>Van Broeckhoven</surname><given-names>C</given-names></name><name><surname>Martinez-Lage</surname><given-names>P</given-names></name><name><surname>Popp</surname><given-names>J</given-names></name><name><surname>Tsolaki</surname><given-names>M</given-names></name><name><surname>Verhey</surname><given-names>FRJ</given-names></name><name><surname>Baird</surname><given-names>AL</given-names></name><name><surname>Legido-Quigley</surname><given-names>C</given-names></name><name><surname>Bertram</surname><given-names>L</given-names></name><name><surname>Dobricic</surname><given-names>V</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Lovestone</surname><given-names>S</given-names></name><name><surname>Streffer</surname><given-names>J</given-names></name><name><surname>Bianchetti</surname><given-names>S</given-names></name><name><surname>Novak</surname><given-names>GP</given-names></name><name><surname>Revillard</surname><given-names>J</given-names></name><name><surname>Gordon</surname><given-names>MF</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Wottschel</surname><given-names>V</given-names></name><name><surname>Frisoni</surname><given-names>G</given-names></name><name><surname>Visser</surname><given-names>PJ</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>MRI predictors of amyloid pathology: results from the EMIF-AD multimodal biomarker discovery study</article-title><source>Alzheimer’s Research &amp; Therapy</source><volume>10</volume><elocation-id>100</elocation-id><pub-id pub-id-type="doi">10.1186/s13195-018-0428-1</pub-id><pub-id pub-id-type="pmid">30261928</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vidal-Pineiro</surname><given-names>D</given-names></name><name><surname>Parker</surname><given-names>N</given-names></name><name><surname>Shin</surname><given-names>J</given-names></name><name><surname>French</surname><given-names>L</given-names></name><name><surname>Grydeland</surname><given-names>H</given-names></name><name><surname>Jackowski</surname><given-names>AP</given-names></name><name><surname>Mowinckel</surname><given-names>AM</given-names></name><name><surname>Patel</surname><given-names>Y</given-names></name><name><surname>Pausova</surname><given-names>Z</given-names></name><name><surname>Salum</surname><given-names>G</given-names></name><name><surname>Sørensen</surname><given-names>Ø</given-names></name><name><surname>Walhovd</surname><given-names>KB</given-names></name><name><surname>Paus</surname><given-names>T</given-names></name><name><surname>Fjell</surname><given-names>AM</given-names></name><collab>Alzheimer’s Disease Neuroimaging Initiative and the Australian Imaging Biomarkers and Lifestyle flagship study of ageing</collab></person-group><year iso-8601-date="2020">2020</year><article-title>Cellular correlates of cortical thinning throughout the lifespan</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>21803</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-78471-3</pub-id><pub-id pub-id-type="pmid">33311571</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagen</surname><given-names>AZ</given-names></name><name><surname>Coath</surname><given-names>W</given-names></name><name><surname>Keshavan</surname><given-names>A</given-names></name><name><surname>James</surname><given-names>S-N</given-names></name><name><surname>Parker</surname><given-names>TD</given-names></name><name><surname>Lane</surname><given-names>CA</given-names></name><name><surname>Buchanan</surname><given-names>SM</given-names></name><name><surname>Keuss</surname><given-names>SE</given-names></name><name><surname>Storey</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>K</given-names></name><name><surname>Macdougall</surname><given-names>A</given-names></name><name><surname>Murray-Smith</surname><given-names>H</given-names></name><name><surname>Freiberger</surname><given-names>T</given-names></name><name><surname>Cash</surname><given-names>DM</given-names></name><name><surname>Malone</surname><given-names>IB</given-names></name><name><surname>Barnes</surname><given-names>J</given-names></name><name><surname>Sudre</surname><given-names>CH</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Pavisic</surname><given-names>IM</given-names></name><name><surname>Street</surname><given-names>R</given-names></name><name><surname>Crutch</surname><given-names>SJ</given-names></name><name><surname>Escott-Price</surname><given-names>V</given-names></name><name><surname>Leonenko</surname><given-names>G</given-names></name><name><surname>Zetterberg</surname><given-names>H</given-names></name><name><surname>Wellington</surname><given-names>H</given-names></name><name><surname>Heslegrave</surname><given-names>A</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Richards</surname><given-names>M</given-names></name><name><surname>Fox</surname><given-names>NC</given-names></name><name><surname>Cole</surname><given-names>JH</given-names></name><name><surname>Schott</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Life course, genetic, and neuropathological associations with brain age in the 1946 british birth cohort: a population-based study</article-title><source>The Lancet. Healthy Longevity</source><volume>3</volume><fpage>e607</fpage><lpage>e616</lpage><pub-id pub-id-type="doi">10.1016/S2666-7568(22)00167-2</pub-id><pub-id pub-id-type="pmid">36102775</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>P</given-names></name><name><surname>Sudre</surname><given-names>CH</given-names></name><name><surname>Fiford</surname><given-names>CM</given-names></name><name><surname>Ryan</surname><given-names>NS</given-names></name><name><surname>Lashley</surname><given-names>T</given-names></name><name><surname>Frost</surname><given-names>C</given-names></name><name><surname>Barnes</surname><given-names>J</given-names></name><collab>ADNI Investigators</collab></person-group><year iso-8601-date="2021">2021</year><article-title>The age-dependent associations of white matter hyperintensities and neurofilament light in early- and late-stage alzheimer’s disease</article-title><source>Neurobiology of Aging</source><volume>97</volume><fpage>10</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2020.09.008</pub-id><pub-id pub-id-type="pmid">33070094</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>EJ</given-names></name></person-group><year iso-8601-date="1959">1959</year><article-title>The comparison of regression variables</article-title><source>Journal of the Royal Statistical Society</source><volume>21</volume><fpage>396</fpage><lpage>399</lpage><pub-id pub-id-type="doi">10.1111/j.2517-6161.1959.tb00346.x</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhavoronkov</surname><given-names>A</given-names></name><name><surname>Mamoshina</surname><given-names>P</given-names></name><name><surname>Vanhaelen</surname><given-names>Q</given-names></name><name><surname>Scheibye-Knudsen</surname><given-names>M</given-names></name><name><surname>Moskalev</surname><given-names>A</given-names></name><name><surname>Aliper</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Artificial intelligence for aging and longevity research: recent advances and perspectives</article-title><source>Ageing Research Reviews</source><volume>49</volume><fpage>49</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/j.arr.2018.11.003</pub-id><pub-id pub-id-type="pmid">30472217</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1table1" position="float"><label>Appendix 1—table 1.</label><caption><title>Correlations between validation variables and chronological age.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top"/><th align="left" valign="top" colspan="2">Aging signature</th><th align="left" valign="top" colspan="2">Amyloid-β</th><th align="left" valign="top" colspan="2">Log WMH</th><th align="left" valign="top" colspan="2">Log Plasma NfL</th><th align="left" valign="top" colspan="2">Log CSF NfL</th></tr></thead><tbody><tr><td align="left" valign="top"/><td align="left" valign="top"><bold>R</bold></td><td align="left" valign="top"><bold>P-value</bold></td><td align="left" valign="top"><bold>R</bold></td><td align="left" valign="top"><bold>P-value</bold></td><td align="left" valign="top"><bold>R</bold></td><td align="left" valign="top"><bold>P-value</bold></td><td align="left" valign="top"><bold>R</bold></td><td align="left" valign="top"><bold>P-value</bold></td><td align="left" valign="top"><bold>R</bold></td><td align="left" valign="top"><bold>P-value</bold></td></tr><tr><td align="left" valign="top"><bold>ALFA+</bold></td><td align="char" char="." valign="top">–0.23</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="char" char="." valign="top">–0.12</td><td align="char" char="." valign="top">0.026</td><td align="char" char="." valign="top">0.25</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="char" char="." valign="top">0.322</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="char" char="." valign="top">0.403</td><td align="char" char="." valign="top">0.352</td></tr><tr><td align="left" valign="top"><bold>ADNI</bold></td><td align="char" char="." valign="top">–0.256</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="char" char="." valign="top">–0.100</td><td align="char" char="." valign="top">0.123</td><td align="char" char="." valign="top">0.370</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="char" char="." valign="top">0.441</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="left" valign="top">-</td><td align="left" valign="top">-</td></tr><tr><td align="left" valign="top"><bold>EPAD</bold></td><td align="char" char="." valign="top">–0.412</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="char" char="." valign="top">–0.04</td><td align="char" char="." valign="top">0.278</td><td align="char" char="." valign="top">0.401</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="left" valign="top">-</td><td align="left" valign="top">-</td><td align="left" valign="top">-</td><td align="left" valign="top">-</td></tr><tr><td align="left" valign="top"><bold>OASIS</bold></td><td align="char" char="." valign="top">–0.455</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="char" char="." valign="top">0.278</td><td align="char" char="." valign="top"><bold>&lt;0.001</bold></td><td align="left" valign="top">-</td><td align="left" valign="top">-</td><td align="left" valign="top">-</td><td align="left" valign="top">-</td><td align="left" valign="top">-</td><td align="left" valign="top">-</td></tr></tbody></table><table-wrap-foot><fn><p>The Pearson’s correlation coefficient (R) between different validation variables (aging signature, amyloid-β, WMH, plasma NfL, CSF NfL) and chronological age for the independent cohorts used: ALFA+, ADNI, EPAD and OASIS.</p></fn><fn><p>Significant values (<italic>P</italic>&lt;0.05) are marked in bold.</p></fn><fn><p>WMH, White Matter Hyperintensities; NfL, neurofilament light, CSF, cerebrospinal fluid.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app1table2" position="float"><label>Appendix 1—table 2.</label><caption><title>Comparison of prediction’s metrics across cohorts.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">Fisher’s z</th><th align="left" valign="bottom"><italic>P</italic>-Value</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>ALFA +vs ADNI</bold></td><td align="char" char="." valign="bottom">–2.446</td><td align="char" char="." valign="bottom">0.993</td></tr><tr><td align="left" valign="bottom"><bold>ALFA +vs_EPAD</bold></td><td align="char" char="." valign="bottom">–5.291</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom"><bold>ALFA +vs OASIS</bold></td><td align="char" char="." valign="bottom">–8.630</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom"><bold>ADNI vs EPAD</bold></td><td align="char" char="." valign="bottom">–1.817</td><td align="char" char="." valign="bottom">0.965</td></tr><tr><td align="left" valign="bottom"><bold>ADNI vs OASIS</bold></td><td align="char" char="." valign="bottom">–4.955</td><td align="char" char="." valign="bottom">1</td></tr><tr><td align="left" valign="bottom"><bold>EPAD vs OASIS</bold></td><td align="char" char="." valign="bottom">–4.166</td><td align="char" char="." valign="bottom">0.999</td></tr></tbody></table><table-wrap-foot><fn><p>Testing whether the Pearson’s correlation coefficients from the brain-age prediction against the chronological age is similar across all cohorts, via Fisher’s transformation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app1table3" position="float"><label>Appendix 1—table 3.</label><caption><title>Prediction metrics for different diagnostic groups in the different cohorts.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Cohorts</th><th align="left" valign="bottom" colspan="2">Correlation with age</th><th align="left" valign="bottom">MAE (y)</th><th align="left" valign="bottom" colspan="2">R<sup>2</sup></th><th align="left" valign="bottom" colspan="2">RMSE</th></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>R</bold></td><td align="left" valign="bottom"><bold>P-value</bold></td><td align="left" valign="bottom"/><td align="left" valign="bottom" colspan="2"/><td align="left" valign="bottom" colspan="2"/></tr><tr><td align="center" valign="bottom" colspan="8">CU individuals</td></tr><tr><td align="left" valign="bottom"><bold>ADNI</bold></td><td align="char" char="." valign="bottom">0.575</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">8.153</td><td align="char" char="." valign="bottom" colspan="2">0.331</td><td align="char" char="." valign="bottom" colspan="2">4.953</td></tr><tr><td align="left" valign="bottom"><bold>EPAD</bold></td><td align="char" char="." valign="bottom">0.634</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">4.494</td><td align="char" char="." valign="bottom" colspan="2">0.402</td><td align="char" char="." valign="bottom" colspan="2">5.456</td></tr><tr><td align="center" valign="bottom" colspan="8"><bold>MCI individuals</bold></td></tr><tr><td align="left" valign="bottom"><bold>ADNI</bold></td><td align="char" char="." valign="bottom">0.599</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">6.739</td><td align="char" char="." valign="bottom" colspan="2">0.358</td><td align="char" char="." valign="bottom" colspan="2">5.760</td></tr><tr><td align="left" valign="bottom"><bold>EPAD</bold></td><td align="char" char="." valign="bottom">0.557</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">5.22</td><td align="char" char="." valign="bottom" colspan="2">0.311</td><td align="char" char="." valign="bottom" colspan="2">5.871</td></tr></tbody></table><table-wrap-foot><fn><p>The Pearson’s correlation coefficient (R) between predicted brain-age and chronological age, R2 , root mean square error (RMSE), and mean absolute error (MAE) for CU and MCI individuals from ADNI and EPAD.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app1table4" position="float"><label>Appendix 1—table 4.</label><caption><title>Prediction metrics for females and males in training set.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top"/><th align="left" valign="top">MAE<sub>orig</sub></th><th align="left" valign="top">RMSE<sub>orig</sub></th><th align="left" valign="top">R<sup>2</sup><sub>orig</sub></th><th align="left" valign="top">MAE<sub>corr</sub></th><th align="left" valign="top">RMSE<sub>corr</sub></th><th align="left" valign="top">R<sup>2</sup><sub>corr</sub></th></tr></thead><tbody><tr><td align="left" valign="top"><bold>Female</bold></td><td align="char" char="." valign="top">4.221 (0.059)</td><td align="char" char="." valign="top">5.291 (0.062)</td><td align="char" char="." valign="top">0.696 (0.006)</td><td align="char" char="." valign="top">2.871 (0.062)</td><td align="char" char="." valign="top">3.554 (0.066)</td><td align="char" char="." valign="top">0.900 (0.004)</td></tr><tr><td align="left" valign="top"><bold>Male</bold></td><td align="char" char="." valign="top">4.175 (0.069)</td><td align="char" char="." valign="top">5.222 (0.070)</td><td align="char" char="." valign="top">0.728 (0.016)</td><td align="char" char="." valign="top">3.029 (0.069)</td><td align="char" char="." valign="top">3.764 (0.077)</td><td align="char" char="." valign="top">0.897 (0.004)</td></tr></tbody></table><table-wrap-foot><fn><p>The prediction metrics between predicted brain-age and chronological age for UK Biobank: R<sup>2</sup>, root mean square error (RMSE), and mean absolute error (MAE) for the train data using 10-fold cross validation with 10 repetitions per fold, given as mean (standard deviation).</p></fn><fn><p>Subindex <italic>orig</italic> refers to values before bias correction.</p></fn><fn><p>Subindex <italic>corr</italic> refers to values after bias correction.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app1table5" position="float"><label>Appendix 1—table 5.</label><caption><title>Prediction metrics for females and males in testing set.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="4">Pooled cohorts</th></tr></thead><tbody><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"><bold>MAE</bold></td><td align="left" valign="bottom"><bold>RMSE</bold></td><td align="left" valign="bottom"><bold>R<sup>2</sup></bold></td></tr><tr><td align="left" valign="bottom"><bold>Female</bold></td><td align="char" char="." valign="bottom">5.481</td><td align="char" char="." valign="bottom">6.013</td><td align="char" char="." valign="bottom">0.316</td></tr><tr><td align="left" valign="bottom"><bold>Male</bold></td><td align="char" char="." valign="bottom">6.201</td><td align="char" char="." valign="bottom">6.217</td><td align="char" char="." valign="bottom">0.364</td></tr></tbody></table><table-wrap-foot><fn><p>The prediction metrics before bias correction between predicted brain-age and chronological age for the testing cohorts pooled together: R<sup>2</sup>, root mean square error (RMSE), and mean absolute error (MAE) for females and males.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app1table6" position="float"><label>Appendix 1—table 6.</label><caption><title>Comparison of prediction’s metrics between females and males.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">Fisher’s z</th><th align="left" valign="bottom"><italic>P</italic>-Value</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>Females vs males</bold></td><td align="char" char="." valign="bottom">1.542</td><td align="char" char="." valign="bottom">0.123</td></tr></tbody></table><table-wrap-foot><fn><p>Testing whether the Pearson’s correlation coefficients from the brain-age prediction against the chronological age is similar between males and females pooled from all independent cohorts, via Fisher transformation.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app1table7" position="float"><label>Appendix 1—table 7.</label><caption><title>Prediction metrics for all independent cohorts using aging signature.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" colspan="6">Aging Signature – performance for brain age prediction</th></tr></thead><tbody><tr><td align="left" valign="top"/><td align="left" valign="top" colspan="2"><bold>Correlation with age</bold></td><td align="left" valign="top"><bold>MAE (y</bold>)</td><td align="left" valign="top"><bold>R<sup>2</sup></bold></td><td align="left" valign="top"><bold>RMSE</bold></td></tr><tr><td align="left" valign="top"><bold>Cohorts</bold></td><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top"><bold>ALFA+</bold></td><td align="char" char="." valign="top">–0.230</td><td align="char" char="." valign="top">&lt;0.001</td><td align="char" char="." valign="top">3.83</td><td align="char" char="." valign="top">0.06</td><td align="char" char="." valign="top">4.61</td></tr><tr><td align="left" valign="top"><bold>ADNI</bold></td><td align="char" char="." valign="top">–0.256</td><td align="char" char="." valign="top">&lt;0.001</td><td align="char" char="." valign="top">4.60</td><td align="char" char="." valign="top">0.07</td><td align="char" char="." valign="top">5.85</td></tr><tr><td align="left" valign="top"><bold>EPAD</bold></td><td align="char" char="." valign="top">–0.412</td><td align="char" char="." valign="top">&lt;0.001</td><td align="char" char="." valign="top">5.26</td><td align="char" char="." valign="top">0.17</td><td align="char" char="." valign="top">6.43</td></tr><tr><td align="left" valign="top"><bold>OASIS</bold></td><td align="char" char="." valign="top">–0.455</td><td align="char" char="." valign="top">&lt;0.001</td><td align="char" char="." valign="top">6.64</td><td align="char" char="." valign="top">0.21</td><td align="char" char="." valign="top">8.41</td></tr></tbody></table><table-wrap-foot><fn><p>We tested the linear association of the widely-used neuroanatomical aging signature (<xref ref-type="bibr" rid="bib3">Bakkour et al., 2013</xref>) with chronological age, to compare its performance with the XGboost brain-age prediction. The aging signature is a map of specific brain regions that undergo cortical atrophy in normal aging. Our brain-age estimation outperformed the aging signature (Pearson’s r [William’s test], <italic>P&lt;</italic>0.001; RMSE [F-test] <italic>P&lt;</italic>0.001, for all cohorts). These analyses were computed on the Pearson’s correlation coefficient (R) between predicted brain-age and chronological age, R<sup>2</sup>, root mean square error (RMSE), and mean absolute error (MAE) for each of the independent cohorts after bias correction.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app1table8" position="float"><label>Appendix 1—table 8.</label><caption><title>Interaction affects between age and sex effects for each signiciant SHAP-selected ROI.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="2">Cortical thickness</th><th align="left" valign="bottom" colspan="2">Subcortical Volumes</th><th align="left" valign="bottom" colspan="2">Cortical Volumes</th></tr></thead><tbody><tr><td align="left" valign="bottom"><bold>ROI</bold></td><td align="left" valign="bottom"><bold>P&gt;|t|</bold></td><td align="left" valign="bottom"><bold>ROI</bold></td><td align="left" valign="bottom"><bold>P&gt;|t|</bold></td><td align="left" valign="bottom"><bold>ROI</bold></td><td align="left" valign="bottom"><bold>P&gt;|t|</bold></td></tr><tr><td align="left" valign="bottom">L_frontalpole</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">3rd-Ventricle</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">L_entorhinal</td><td align="left" valign="bottom">0,019</td></tr><tr><td align="left" valign="bottom">L_inferiorparietal</td><td align="left" valign="bottom">0,104</td><td align="left" valign="bottom">4th-Ventricle</td><td align="left" valign="bottom">0,976</td><td align="left" valign="bottom">L_insula</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">L_isthmuscingulate</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">Brain-Stem</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">L_isthmuscingulate</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">L_lateraloccipital</td><td align="left" valign="bottom">0,235</td><td align="left" valign="bottom">CC_Anterior</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">L_middletemporal</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">L_lateralorbitofrontal</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">CC_Central</td><td align="left" valign="bottom">0,828</td><td align="left" valign="bottom">L_parsopercularis</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">L_middletemporal</td><td align="left" valign="bottom">0,285</td><td align="left" valign="bottom">CC_Mid_Posterior</td><td align="left" valign="bottom">0,685</td><td align="left" valign="bottom">L_parsorbitalis</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">L_paracentral</td><td align="left" valign="bottom">0,08</td><td align="left" valign="bottom">CC_Posterior</td><td align="left" valign="bottom">0,024</td><td align="left" valign="bottom">L_parstriangularis</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">L_parstriangularis</td><td align="left" valign="bottom">0,014</td><td align="left" valign="bottom">CSF</td><td align="left" valign="bottom">0,136</td><td align="left" valign="bottom">L_pericalcarine</td><td align="left" valign="bottom">0,007</td></tr><tr><td align="left" valign="bottom">L_precentral</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">Left-Accumbens-area</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">L_rostralmiddlefrontal</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">L_precuneus</td><td align="left" valign="bottom">0,007</td><td align="left" valign="bottom">Left-Amygdala</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">L_superiorfrontal</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">L_superiorfrontal</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">Left-Caudate</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">R_entorhinal</td><td align="left" valign="bottom">0,006</td></tr><tr><td align="left" valign="bottom">L_superiortemporal</td><td align="left" valign="bottom">0,071</td><td align="left" valign="bottom">Left-Cerebellum-Cortex</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">R_fusiform</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">L_transversetemporal</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">Left-Cerebellum-White-Matter</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">R_insula</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">R_caudalanteriorcingulate</td><td align="left" valign="bottom">0,452</td><td align="left" valign="bottom">Left-Hippocampus</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">R_middletemporal</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">R_cuneus</td><td align="left" valign="bottom">0,235</td><td align="left" valign="bottom">Left-Inf-Lat-Vent</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">R_parsorbitalis</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">R_frontalpole</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">Left-Lateral-Ventricle</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">R_parstriangularis</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">R_inferiorparietal</td><td align="left" valign="bottom">0,379</td><td align="left" valign="bottom">Left-Putamen</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">R_pericalcarine</td><td align="left" valign="bottom">0,258</td></tr><tr><td align="left" valign="bottom">R_lateraloccipital</td><td align="left" valign="bottom">0,212</td><td align="left" valign="bottom">Left-Thalamus-Proper</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">R_postcentral</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">R_lateralorbitofrontal</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">Left-VentralDC</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">R_rostralmiddlefrontal</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">R_lingual</td><td align="left" valign="bottom">0,789</td><td align="left" valign="bottom">Left-choroid-plexus</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">R_superiorfrontal</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">R_middletemporal</td><td align="left" valign="bottom">0,205</td><td align="left" valign="bottom">Optic-Chiasm</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">R_supramarginal</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">R_paracentral</td><td align="left" valign="bottom">0,301</td><td align="left" valign="bottom">Right-Amygdala</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">R_transversetemporal</td><td align="left" valign="bottom">&lt;0.0001</td></tr><tr><td align="left" valign="bottom">R_parstriangularis</td><td align="left" valign="bottom">0,088</td><td align="left" valign="bottom">Right-Caudate</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">R_pericalcarine</td><td align="left" valign="bottom">0,086</td><td align="left" valign="bottom">Right-Cerebellum-Cortex</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">R_posteriorcingulate</td><td align="left" valign="bottom">0,003</td><td align="left" valign="bottom">Right-Cerebellum-White-Matter</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">R_precentral</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">Right-Hippocampus</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">R_precuneus</td><td align="left" valign="bottom">0,215</td><td align="left" valign="bottom">Right-Inf-Lat-Vent</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">R_rostralmiddlefrontal</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">Right-Lateral-Ventricle</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">R_superiorfrontal</td><td align="left" valign="bottom">0,003</td><td align="left" valign="bottom">Right-Pallidum</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">R_superiortemporal</td><td align="left" valign="bottom">0,183</td><td align="left" valign="bottom">Right-Putamen</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">R_transversetemporal</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom">Right-Thalamus-Proper</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">Right-VentralDC</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">Right-choroid-plexus</td><td align="left" valign="bottom">&lt;0.0001</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><table-wrap id="app1table9" position="float"><label>Appendix 1—table 9.</label><caption><title>Comparison of brain-age deltas for the different amyloid-β, AT and <italic>APOE</italic> status.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom"/><th align="left" valign="bottom">Mean square</th><th align="left" valign="bottom">F</th><th align="left" valign="bottom"><italic>P-</italic>Value</th></tr></thead><tbody><tr><td align="center" valign="bottom" colspan="4"><bold>CU</bold></td></tr><tr><td align="left" valign="bottom"><bold>Amyloid-β status</bold></td><td align="char" char="." valign="bottom">35.787</td><td align="char" char="." valign="bottom">39.369</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom"><bold>AT Stage</bold></td><td align="char" char="." valign="bottom">21.550</td><td align="char" char="." valign="bottom">11.626</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom"><bold><italic>APOE</italic> status</bold></td><td align="char" char="." valign="bottom">16.218</td><td align="char" char="." valign="bottom">5.862</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="center" valign="bottom" colspan="4"><bold>MCI</bold></td></tr><tr><td align="left" valign="bottom"><bold>Amyloid-β status</bold></td><td align="char" char="." valign="bottom">47.166</td><td align="char" char="." valign="bottom">52.412</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom"><bold>AT Stage</bold></td><td align="char" char="." valign="bottom">50.064</td><td align="char" char="." valign="bottom">27.701</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td></tr><tr><td align="left" valign="bottom"><bold><italic>APOE</italic> status</bold></td><td align="char" char="." valign="bottom">10.049</td><td align="char" char="." valign="bottom">3.425</td><td align="char" char="." valign="bottom"><bold>0.017</bold></td></tr></tbody></table><table-wrap-foot><fn><p>Brain-age deltas for pooled CU and MCI individuals were compared for the different amyloid-β, AT and <italic>APOE</italic> status with ANCOVA models adjusted by age and sex.</p></fn><fn><p>Amyloid-β status was defined by CSF (ALFA+, ADNI and EPAD) or amyloid PET (OASIS).</p></fn><fn><p>Significant values (<italic>P</italic>&lt;0.05) are marked in bold.</p></fn><fn><p>APOE, apolipoprotein E; ANCOVA, analysis of covariance.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app1table10" position="float"><label>Appendix 1—table 10.</label><caption><title>Mean brain-age delta values for the different amyloid-β, AT and <italic>APOE</italic> status.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="2"/><th align="left" valign="bottom">CU brain-age delta, M (95% CI)</th><th align="left" valign="bottom">MCI brain-age delta, M (95% CI)</th></tr></thead><tbody><tr><td align="left" valign="bottom" rowspan="2"><bold>Amyloid-β status</bold></td><td align="left" valign="bottom"><bold>Aβ-</bold></td><td align="left" valign="bottom">–0.468 (-0.708,–0.228)</td><td align="left" valign="bottom">–1.618 (-2.231,–1.005)</td></tr><tr><td align="left" valign="bottom"><bold>Aβ+</bold></td><td align="left" valign="bottom">0.802 (0.485, 1.119)</td><td align="left" valign="bottom">1.033 (0.577, 1.490)</td></tr><tr><td align="left" valign="bottom" rowspan="3"><bold>AT Stage</bold></td><td align="left" valign="bottom"><bold>A-T-</bold></td><td align="left" valign="bottom">–0.214 (-0.507, 0.078)</td><td align="left" valign="bottom">–1.623 (-2.239,–1.007)</td></tr><tr><td align="left" valign="bottom"><bold>A+T-</bold></td><td align="left" valign="bottom">0.916 (0.506, 1.325)</td><td align="left" valign="bottom">0.561 (-0.066, 1.188)</td></tr><tr><td align="left" valign="bottom"><bold>A+T</bold> +</td><td align="left" valign="bottom">0.945 (0.140, 1.750)</td><td align="left" valign="bottom">1.410 (-0.753, 2.066)</td></tr><tr><td align="left" valign="bottom" rowspan="4"><bold><italic>APOE</italic> status</bold></td><td align="left" valign="bottom"><bold><italic>APOE</italic>-ε2</bold></td><td align="left" valign="bottom">–0.726 (-1.298,–0.153)</td><td align="left" valign="bottom">–0.660 (-2.234, 0.914)</td></tr><tr><td align="left" valign="bottom"><bold><italic>APOE</italic>-ε33</bold></td><td align="left" valign="bottom">–0.225 (-0.506, 0.056)</td><td align="left" valign="bottom">–0.522 (-1.0750, 0.031)</td></tr><tr><td align="left" valign="bottom"><bold><italic>APOE</italic>-ε4</bold></td><td align="left" valign="bottom">0.503 (0.193, 0.813)</td><td align="left" valign="bottom">0.617 (0.050, 1.184)</td></tr><tr><td align="left" valign="bottom"><bold><italic>APOE</italic>-ε24</bold></td><td align="left" valign="bottom">–0.092 (-1.109, 0.924)</td><td align="left" valign="bottom">1.257 (-1.067, 3.581)</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: brain-age delta are expressed as mean (M) and 95% confidence interval (CI).</p></fn><fn><p>Amyloid-β status was defined by CSF (ALFA+, ADNI and EPAD) or amyloid PET (OASIS). Abbreviations: APOE, apolipoprotein E.</p></fn></table-wrap-foot></table-wrap><table-wrap id="app1table11" position="float"><label>Appendix 1—table 11.</label><caption><title>Relationships between validation variables and brain-age delta across independent cohorts.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom" colspan="4">Model</th><th align="left" valign="bottom">β</th><th align="left" valign="bottom">SE</th><th align="left" valign="bottom"><italic>P</italic>-Value</th><th align="left" valign="bottom">[0.025]</th><th align="left" valign="bottom">[0.975]</th><th align="left" valign="bottom">N</th><th align="left" valign="bottom">Effect size</th></tr></thead><tbody><tr><td align="center" valign="bottom" colspan="11"><bold>ALFA+</bold></td></tr><tr><td align="left" valign="bottom" colspan="4"><bold>Amyloid-β pathology</bold></td><td align="char" char="." valign="bottom">0.796</td><td align="char" char="." valign="bottom">0.377</td><td align="char" char="." valign="bottom"><bold>0.035</bold></td><td align="char" char="." valign="bottom">0.056</td><td align="char" char="." valign="bottom">1.537</td><td align="char" char="." valign="bottom">355</td><td align="char" char="." valign="bottom">0.217</td></tr><tr><td align="left" valign="bottom" rowspan="2"><bold>Amyloid-β / Tau pathology (ref: A-T-)</bold></td><td align="left" valign="bottom" colspan="3">A+T-</td><td align="char" char="." valign="bottom">1.028</td><td align="char" char="." valign="bottom">0.409</td><td align="char" char="." valign="bottom"><bold>0.013</bold></td><td align="char" char="." valign="bottom">0.222</td><td align="char" char="." valign="bottom">1.832</td><td align="char" char="." valign="bottom">355</td><td align="char" char="." valign="bottom">0.225</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>A+T</bold> +</td><td align="char" char="." valign="bottom">0.855</td><td align="char" char="." valign="bottom">0.929</td><td align="char" char="." valign="bottom">0.358</td><td align="char" char="." valign="bottom">–0.973</td><td align="char" char="." valign="bottom">2.682</td><td align="char" char="." valign="bottom">355</td><td align="char" char="." valign="bottom">0.225</td></tr><tr><td align="left" valign="bottom" rowspan="3"><bold>APOE status (ref:</bold> <italic><bold>APOE</bold></italic><bold>-e33)</bold></td><td align="left" valign="bottom" colspan="3"><italic>APOE</italic>-ε2</td><td align="char" char="." valign="bottom">–1.278</td><td align="char" char="." valign="bottom">0.780</td><td align="char" char="." valign="bottom">0.102</td><td align="char" char="." valign="bottom">–2.811</td><td align="char" char="." valign="bottom">0.255</td><td align="char" char="." valign="bottom" rowspan="3">355</td><td align="char" char="." valign="bottom">0.325</td></tr><tr><td align="left" valign="bottom" colspan="3"><italic>APOE</italic>-ε4</td><td align="char" char="." valign="bottom">0.002</td><td align="char" char="." valign="bottom">0.397</td><td align="char" char="." valign="bottom">0.996</td><td align="char" char="." valign="bottom">–0.231</td><td align="char" char="." valign="bottom">0.817</td><td align="char" char="." valign="bottom">0.001</td></tr><tr><td align="left" valign="bottom" colspan="3"><italic>APOE</italic>-ε24</td><td align="char" char="." valign="bottom">–0.294</td><td align="char" char="." valign="bottom">1.273</td><td align="char" char="." valign="bottom">0.817</td><td align="char" char="." valign="bottom">–2.797</td><td align="char" char="." valign="bottom">2.797</td><td align="char" char="." valign="bottom">0.075</td></tr><tr><td align="left" valign="bottom" colspan="4"><bold>WMH</bold></td><td align="char" char="." valign="bottom">0.724</td><td align="char" char="." valign="bottom">0.236</td><td align="char" char="." valign="bottom"><bold>0.002</bold></td><td align="char" char="." valign="bottom">0.260</td><td align="char" char="." valign="bottom">1.187</td><td align="char" char="." valign="bottom">337</td><td align="char" char="." valign="bottom">0.028</td></tr><tr><td align="left" valign="bottom" colspan="4"><bold>CSF NfL</bold></td><td align="char" char="." valign="bottom">0.106</td><td align="char" char="." valign="bottom">0.199</td><td align="char" char="." valign="bottom">0.593</td><td align="char" char="." valign="bottom">–0.284</td><td align="char" char="." valign="bottom">0.497</td><td align="char" char="." valign="bottom">357</td><td align="char" char="." valign="bottom">0.001</td></tr><tr><td align="left" valign="bottom" colspan="4"><bold>Plasma NfL</bold></td><td align="char" char="." valign="bottom">0.116</td><td align="char" char="." valign="bottom">0.217</td><td align="char" char="." valign="bottom">0.594</td><td align="char" char="." valign="bottom">–0.311</td><td align="char" char="." valign="bottom">0.543</td><td align="char" char="." valign="bottom">343</td><td align="char" char="." valign="bottom">0.001</td></tr><tr><td align="left" valign="bottom" colspan="4"><bold>Aging signature change</bold></td><td align="char" char="." valign="bottom">0.082</td><td align="char" char="." valign="bottom">0.234</td><td align="char" char="." valign="bottom">0.728</td><td align="char" char="." valign="bottom">–0.378</td><td align="char" char="." valign="bottom">0.542</td><td align="char" char="." valign="bottom">236</td><td align="char" char="." valign="bottom">0.001</td></tr><tr><td align="center" valign="bottom" colspan="11"><bold>ADNI</bold></td></tr><tr><td align="left" valign="bottom" colspan="4"><bold>Amyloid-β</bold></td><td align="char" char="." valign="bottom">0.182</td><td align="char" char="." valign="bottom">0.525</td><td align="char" char="." valign="bottom">0.730</td><td align="char" char="." valign="bottom">–0.852</td><td align="char" char="." valign="bottom">1.216</td><td align="char" char="." valign="bottom">233</td><td align="char" char="." valign="bottom">0.047</td></tr><tr><td align="left" valign="bottom" rowspan="2"><bold>Amyloid-β / Tau pathology (ref: A-T-)</bold></td><td align="left" valign="bottom" colspan="3"><bold>A+T-</bold></td><td align="char" char="." valign="bottom">–0.375</td><td align="char" char="." valign="bottom">0.620</td><td align="char" char="." valign="bottom">0.546</td><td align="char" char="." valign="bottom">–1.597</td><td align="char" char="." valign="bottom">0.847</td><td align="char" char="." valign="bottom">232</td><td align="char" char="." valign="bottom">0.096</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>A+T</bold> +</td><td align="char" char="." valign="bottom">0.855</td><td align="char" char="." valign="bottom">0.711</td><td align="char" char="." valign="bottom">0.230</td><td align="char" char="." valign="bottom">–0.546</td><td align="char" char="." valign="bottom">2.255</td><td align="char" char="." valign="bottom">232</td><td align="char" char="." valign="bottom">0.225</td></tr><tr><td align="left" valign="bottom" rowspan="3"><bold>APOE status (ref:</bold> <italic><bold>APOE</bold></italic><bold>-e33)</bold></td><td align="left" valign="bottom" colspan="3"><italic>APOE</italic>-ε2</td><td align="char" char="." valign="bottom">0.525</td><td align="char" char="." valign="bottom">0.801</td><td align="char" char="." valign="bottom">0.513</td><td align="char" char="." valign="bottom">–1.055</td><td align="char" char="." valign="bottom">2.104</td><td align="char" char="." valign="bottom" rowspan="3">233</td><td align="char" char="." valign="bottom">0.142</td></tr><tr><td align="left" valign="bottom" colspan="3"><italic>APOE</italic>-ε4</td><td align="char" char="." valign="bottom">0.137</td><td align="char" char="." valign="bottom">0.579</td><td align="char" char="." valign="bottom">0.813</td><td align="char" char="." valign="bottom">–1.003</td><td align="char" char="." valign="bottom">1.278</td><td align="char" char="." valign="bottom">0.034</td></tr><tr><td align="left" valign="bottom" colspan="3"><italic>APOE</italic>-ε24</td><td align="char" char="." valign="bottom">–1.183</td><td align="char" char="." valign="bottom">2.811</td><td align="char" char="." valign="bottom">0.674</td><td align="char" char="." valign="bottom">–6.722</td><td align="char" char="." valign="bottom">4.356</td><td align="char" char="." valign="bottom">0.000</td></tr><tr><td align="left" valign="bottom" colspan="4"><bold>WMH</bold></td><td align="char" char="." valign="bottom">0.483</td><td align="char" char="." valign="bottom">0.243</td><td align="char" char="." valign="bottom"><bold>0.040</bold></td><td align="char" char="." valign="bottom">0.004</td><td align="char" char="." valign="bottom">0.963</td><td align="char" char="." valign="bottom">218</td><td align="char" char="." valign="bottom">0.018</td></tr><tr><td align="left" valign="bottom" colspan="4"><bold>CSF NfL</bold></td><td align="char" char="." valign="bottom">0.707</td><td align="char" char="." valign="bottom">0.784</td><td align="char" char="." valign="bottom">0.380</td><td align="char" char="." valign="bottom">–0.947</td><td align="char" char="." valign="bottom">2.361</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">0.048</td></tr><tr><td align="left" valign="bottom" colspan="4"><bold>Plasma NfL</bold></td><td align="char" char="." valign="bottom">0.195</td><td align="char" char="." valign="bottom">0.331</td><td align="char" char="." valign="bottom">0.557</td><td align="char" char="." valign="bottom">–0.459</td><td align="char" char="." valign="bottom">0.849</td><td align="char" char="." valign="bottom">165</td><td align="char" char="." valign="bottom">0.002</td></tr><tr><td align="left" valign="bottom" colspan="4"><bold>Aging signature change</bold></td><td align="char" char="." valign="bottom">0.343</td><td align="char" char="." valign="bottom">0.713</td><td align="char" char="." valign="bottom">0.634</td><td align="char" char="." valign="bottom">–1.108</td><td align="char" char="." valign="bottom">1.794</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">0.007</td></tr><tr><td align="center" valign="bottom" colspan="11"><bold>EPAD</bold></td></tr><tr><td align="left" valign="bottom" colspan="4"><bold>Amyloid-β</bold></td><td align="char" char="." valign="bottom">1.410</td><td align="char" char="." valign="bottom">0.311</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.800</td><td align="char" char="." valign="bottom">2.020</td><td align="char" char="." valign="bottom">601</td><td align="char" char="." valign="bottom">0.377</td></tr><tr><td align="left" valign="bottom" rowspan="2"><bold>Amyloid-β / Tau pathology (ref: A-T-)</bold></td><td align="left" valign="bottom" colspan="3"><bold>A+T-</bold></td><td align="char" char="." valign="bottom">1.109</td><td align="char" char="." valign="bottom">0.348</td><td align="char" char="." valign="bottom"><bold>0.002</bold></td><td align="char" char="." valign="bottom">0.474</td><td align="char" char="." valign="bottom">2.719</td><td align="char" char="." valign="bottom">575</td><td align="char" char="." valign="bottom">0.298</td></tr><tr><td align="left" valign="bottom" colspan="3"><bold>A+T</bold> +</td><td align="char" char="." valign="bottom">1.59</td><td align="char" char="." valign="bottom">0.572</td><td align="char" char="." valign="bottom"><bold>0.005</bold></td><td align="char" char="." valign="bottom">0.474</td><td align="char" char="." valign="bottom">2.719</td><td align="char" char="." valign="bottom">575</td><td align="char" char="." valign="bottom">0.417</td></tr><tr><td align="left" valign="bottom" rowspan="3"><bold>APOE status (ref:</bold> <italic><bold>APOE</bold></italic><bold>-e33)</bold></td><td align="left" valign="bottom" colspan="3"><italic>APOE</italic>-ε2</td><td align="char" char="." valign="bottom">–0.318</td><td align="char" char="." valign="bottom">0.573</td><td align="char" char="." valign="bottom">0.573</td><td align="char" char="." valign="bottom">–1.555</td><td align="char" char="." valign="bottom">0.579</td><td align="char" char="." valign="bottom" rowspan="3">601</td><td align="char" char="." valign="bottom">0.008</td></tr><tr><td align="left" valign="bottom" colspan="3"><italic>APOE</italic>-ε4</td><td align="char" char="." valign="bottom">0.292</td><td align="char" char="." valign="bottom">0.340</td><td align="char" char="." valign="bottom">0.390</td><td align="char" char="." valign="bottom">–0.375</td><td align="char" char="." valign="bottom">0.959</td><td align="char" char="." valign="bottom">0.076</td></tr><tr><td align="left" valign="bottom" colspan="3"><italic>APOE</italic>-ε24</td><td align="char" char="." valign="bottom">–0.506</td><td align="char" char="." valign="bottom">0.807</td><td align="char" char="." valign="bottom">0.531</td><td align="char" char="." valign="bottom">–2.090</td><td align="char" char="." valign="bottom">1.078</td><td align="char" char="." valign="bottom">0.131</td></tr><tr><td align="left" valign="bottom" colspan="4"><bold>WMH</bold></td><td align="char" char="." valign="bottom">0.783</td><td align="char" char="." valign="bottom">0.182</td><td align="char" char="." valign="bottom"><bold>&lt;0.001</bold></td><td align="char" char="." valign="bottom">0.426</td><td align="char" char="." valign="bottom">1.140</td><td align="char" char="." valign="bottom">417</td><td align="char" char="." valign="bottom">0.045</td></tr><tr><td align="center" valign="bottom" colspan="11"><bold>OASIS</bold></td></tr><tr><td align="left" valign="bottom" colspan="4"><bold>Amyloid-β</bold></td><td align="char" char="." valign="bottom">0.917</td><td align="char" char="." valign="bottom">0.441</td><td align="char" char="." valign="bottom"><bold>0.038</bold></td><td align="char" char="." valign="bottom">0.051</td><td align="char" char="." valign="bottom">1.784</td><td align="char" char="." valign="bottom">407</td><td align="char" char="." valign="bottom">0.246</td></tr><tr><td align="left" valign="bottom" rowspan="3"><bold>APOE status (ref:</bold> <italic><bold>APOE</bold></italic><bold>-e33)</bold></td><td align="left" valign="bottom" colspan="3"><italic>APOE</italic>-ε2</td><td align="char" char="." valign="bottom">–0.228</td><td align="char" char="." valign="bottom">0.532</td><td align="char" char="." valign="bottom">0.668</td><td align="char" char="." valign="bottom">–1.272</td><td align="char" char="." valign="bottom">0.817</td><td align="char" char="." valign="bottom" rowspan="3">407</td><td align="char" char="." valign="bottom">0.060</td></tr><tr><td align="left" valign="bottom" colspan="3"><italic>APOE</italic>-ε4</td><td align="char" char="." valign="bottom">1.238</td><td align="char" char="." valign="bottom">0.419</td><td align="char" char="." valign="bottom"><bold>0.003</bold></td><td align="char" char="." valign="bottom">0.415</td><td align="char" char="." valign="bottom">2.061</td><td align="char" char="." valign="bottom">0.335</td></tr><tr><td align="left" valign="bottom" colspan="3"><italic>APOE</italic>-ε24</td><td align="char" char="." valign="bottom">0.412</td><td align="char" char="." valign="bottom">1.086</td><td align="char" char="." valign="bottom">0.702</td><td align="char" char="." valign="bottom">–1.719</td><td align="char" char="." valign="bottom">2.550</td><td align="char" char="." valign="bottom">0.111</td></tr></tbody></table><table-wrap-foot><fn><p>Notes: Relationships between validation variables and brain-age delta for all CU subjects from each cohort. Results given by the linear model: brain-age delta ~each variable +chronological age+sex. The regression coefficients (β), standard errors (SE), <italic>P</italic>-value, 95% Confidence Interval, number of individuals (N) and effect size are depicted for each variable.</p></fn><fn><p>Significant values (<italic>P</italic>&lt;0.05) are marked in bold.</p></fn><fn><p>Effect size in categorical variables was calculated as Cohen’s D, while Cohens f2 was calculated for continuous measurements.</p></fn><fn><p>Amyloid-β status was defined by CSF (ALFA+, ADNI and EPAD) or amyloid PET (OASIS).</p></fn><fn><p>APOE, apolipoprotein E; WMH, White Matter Hyperintensities; CSF, cerebrospinal fluid; NfL, neurofilament light.</p></fn></table-wrap-foot></table-wrap><fig id="app1fig1" position="float"><label>Appendix 1—figure 1.</label><caption><title>Median (and interquartile range) cortical thickness for all individuals from all cohorts (UK Biobank (UKB), ALFA+, ADNI, EPAD and OASIS), without any correction (left) and after the standardization procedure (right).</title><p>The sample size can be seen in <xref ref-type="table" rid="table1">Table 1</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-81067-app1-fig1-v2.tif"/></fig><sec sec-type="appendix" id="s8"><title>Secondary analysis: Selection of Extreme Subjects</title><sec sec-type="appendix" id="s8-1"><title>Methods</title><p>The cohorts included in this study include mainly CU individuals with mean age 65–70 years and ranges of around 10 years. Therefore, we expected to find small differences in the biomarkers’ values used as validation measurements in these subjects. In addition, the effects of these biomarkers on the brain-age should be subtle, as many other processes and factors can influence the predicted brain age. Therefore, we wanted to identify the individuals whose predicted brain-age deviate the most from chronological aging, i.e., individuals with the highest positive or lowest negative brain-age deltas, to study the mentioned associations. With this aim, we selected the individuals whose brain-age delta was included within the 10th and 90th percentile of the distribution for each independent cohort. We then pooled together these selected individuals, who will be referred from now on as extreme subjects with decelerated brain-aging and accelerated brain-aging.</p><p>Once selecting these extreme subjects, we performed between groups comparison for the clinical and validation measurements, between the decelerated brain aging subjects and the accelerated brain aging subjects. For this we performed independent t tests or Mann–Whitney U tests for continuous variables and chi-square tests for categorical variables. We also tested for interactions between age and the validation variables on brain-age delta. Lastly, we stratified the decelerated and the accelerated brain aging subjects by sex and performed the same between groups comparison to study the sex differences of the composition of the demographics and validation variables found in the decelerated and accelerated brain-aging subjects. We also tested for interactions between sex and the validation variables on brain-age delta.</p></sec><sec sec-type="appendix" id="s8-2"><title>Results</title><p>Finally, we investigated whether individuals with extreme brain age phenotypes differed in their demographical and clinical characteristics as well as in the AD and neurodegeneration-related biomarkers and risk factors. The extreme phenotypes were defined as those individuals at the 10<sup>th</sup> percentile of brain-age delta (henceforth, decelerated brain aging) and 90<sup>th</sup> percentile of brain-age delta (accelerated brain aging). The extreme groups were defined, firstly, including both sexes and, secondly, separately in females and males.</p><p>Across the four cohorts, including both sexes, we found that Mini-Mental State Examination (MMSE) was significantly lower in the accelerated brain aging group for both the CU and the MCI individuals (CU: <italic>P</italic>=0.006, D=0.300 and MCI: <italic>P</italic>&lt;0.001, D=0.883). Years of education, percentage of females and males, and chronological age were not significantly different between the extreme groups.</p><p>For both CU and MCI, in the accelerated brain aging group, we found a higher proportion of Aβ-positive individuals (CU: <italic>P</italic>&lt;0.001, V=0.231 and MCI: <italic>P</italic>&lt;0.001, V=0.502), more advanced AT stages (CU: <italic>P</italic>&lt;0.001, V=0.239 and MCI: <italic>P</italic>&lt;0.001, V=0.531), and larger WMH total volume (CU: <italic>P</italic>&lt;0.001, D=0.707 and MCI: <italic>P</italic>=0.044, D=0.430). In the MCI group, a higher proportion of <italic>APOE</italic>-ε4 carriers in the accelerated brain aging group was found with respect to the decelerated brain aging group (<italic>P</italic>&lt;0.001, D=0.455). When studying the differences of neurodegeneration markers across the two extreme groups, we found significantly higher plasma NfL in the accelerated brain aging group only among MCI individuals (MCI: <italic>P</italic>=0.007, D=0.696). In addition, we found a significant interaction effect of age and plasma NfL on CU brain-age delta (<italic>P</italic><sub>interaction</sub> = 0.034) within the CU individuals, by which the measures of plasma NfL were higher with age in the accelerated brain-aging group. CSF NfL was only available in the ALFA +cohort (N=82) and a similar trend to that of plasma NfL was observed, but without reaching statistical significance.</p><p>We next compared the extreme brain age phenotypes calculated separately for CU females and males. In both CU females and males defined extreme groups, we found higher proportion of Aβ-positive individuals, higher proportion of more advanced AT stages, larger WMH and lower aging signature values (that is, reduced cortical thickness in aging-vulnerable regions) in the accelerated brain aging groups. Effect sizes showed that the increased WMH in the accelerated brain aging group was larger in females than in males. On the contrary, the effect of the proportion of Aβ-positive individuals in the accelerated brain aging group was stronger in males than in females. We also found lower MMSE scores in the CU accelerated brain aging males. In addition, we found a significant interaction effect of sex and plasma NfL on CU brain-age delta (<italic>P</italic><sub>interaction</sub> = 0.038) within the CU extremes individuals, by which the measures of plasma NfL were larger in females in the accelerated brain-aging group.</p></sec></sec></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81067.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Miller</surname><given-names>Karla L</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.06.23.22276492" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.06.23.22276492"/></front-stub><body><p>The study has significance for the field of dementia research and neurodegenerative diseases more broadly. Using the brain-age paradigm, the main findings are that having an older-appearing brain is associated with more advanced stages of amyloid and tau pathology, higher white matter hyperintensities, higher plasma NfL and carrying the APOE-e34 allele. Findings were broadly similar in cognitively normal people and people with mild cognitive impairment and there is also some evidence for sex differences.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81067.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Miller</surname><given-names>Karla L</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Boyle</surname><given-names>Rory</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/002pd6e78</institution-id><institution>Massachusetts General Hospital, Harvard Medical School</institution></institution-wrap><country>United States</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Cole</surname><given-names>James</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02jx3x895</institution-id><institution>Centre for Medical Image Computing, Department of Computer Science, University College London; Dementia Research Centre, Institute of Neurology, University College London, London</institution></institution-wrap><country>United Kingdom</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.06.23.22276492">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2022.06.23.22276492v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;Prediction Using Machine Learning on Structural Neuroimaging Data: Multi-Cohort Validation Against Biomarkers of Alzheimer's Disease and Neurodegeneration stratified by sex&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Jeannie Chin as the Senior Editor. The following individuals involved in the review of your submission have agreed to reveal their identity: Rory Boyle (Reviewer #2); James Cole (Reviewer #3).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Given the large number of tests conducted, the lack of multiple comparison correction means that some apparently significant associations may be statistically inflated.</p><p>2) Claims regarding sex differences should be tempered to be more in line with the strength of evidence.</p><p>3) Reviewers noted that brain-age δ was not associated with longitudinal brain change and that the current study is solely a cross-sectional analysis. The implications for this should be discussed – specifically, whether it indicates that brain-age δ does not reflect accelerated brain aging but instead early life factors.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>– ADNI dataset includes participants with a dementia diagnosis and many of those are in the AD continuum. What was the reason for not including those cases in this study?</p><p>– When correcting brain-age estimates for bias, the bias regression line was estimated for each cohort separately. I believe cohort refers to CU vs MCI cases in this context. Is there a rationale for expecting disease stage-dependent bias in brain-age estimates?</p><p>– Please clarify the use of the term 'cohort'. does it refer to CU vs MCI diagnostic groups or does it refer to different datasets? if lateral, then I think certain analyses should have been performed by cohort and diagnostic groups since the brain age behavior might be different at different disease stages. for instance, since UKBioBank is all CU participants, it is highly likely that the model performance within ADNI CU and within ADNI MCI cases might be different in terms of R2 and MAE.</p><p>– Once the brain-age estimates are corrected for bias based on regression against chronological age, including age as a covariate in linear regression models for each validation variable might lead to double correction for age bias.</p><p>– In reference to the paragraph: &quot;We also studied the differences in volumes and cortical thickness between females and males in the UKBioBank for the brain regions that contributed the most to the prediction according to the SHAP values. With this aim we performed regression models for each ROI with sex as a predictor variable, in which linear and quadratic expansions of age, site, and TIV (only included for volume ROIs), were included as covariates.&quot;, it is not clear why this regression modeling was necessary if SHAP was used to identify regions contributing the most to brain age prediction. Furthermore, ROI volumes were initially residualized for site and TIV and similarly, thickness values were residualized for site effects. If that's the case, why include site and TIV as a covariate in this analysis? Also, this is the only analysis that higher order age associations were considered. What was the rationale for pursuing non-linear age associations in this case but not in other models?</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>This is very nice work but I think that the findings could be really strengthened by addressing the limitations highlighted in the public review. I can definitely appreciate the impressive amount of work that has already gone into this study and I do not lightly ask for additional work. My concerns would be addressed by correcting your findings for multiple comparisons, re-interpreting your results after correction for multiple comparisons, and discussing the other limitations in-text that can address my concerns.</p><p>I have two other main concerns that can be addressed by text edits. First, the novelty of this work is overstated and does not fairly represent the brain-age δ literature. The authors incorrectly state that &quot;there are no comprehensive studies validating this measurement in association with specific biological markers of AD pathology (i.e. Amyloid-B [Ab] and tau pathology), neurodegeneration and cerebrovascular disease. Various studies have reported associations between brain-age δ and biomarkers of amyloid-B, tau, neurodegeneration, and cerebrovascular disease (Cole et al., 2017 Neurobiology of Aging; Huang et al., 2021 Radiology Artificial Intelligence; Millar et al., 2022 bioRxiv; Popescu et al., 2020 Human Brain Mapping; Wagen et al., 2022 Lancet Healthy Longevity). Therefore, this particular emphasis on novelty is not correct and is not representative of the literature. Can the authors please de-emphasize this novelty and acknowledge the good work carried out by other researchers that have addressed some of these questions previously?</p><p>Second, &quot;trend&quot; or &quot;trending&quot; is used in the manuscript to refer to findings that are nearly statistically significant. For example, see Lines 333-336, Lines 291-294, and Line 444. However, this is not a meaningful description of a statistical result as we do not know which way these results are 'trending'. It can give the impression that the results are likely significant but did not reach significance for some unstated reason. However, the distance between the sex*plasma interaction in CU (P=.092) than reaching statistical significance (.092 –.05 = .042) is further than the distance of the significant result for APOE-e4 carriers vs APOE-e33 carriers of P = .032 reaching 'non-significance' (.05 –.032 = .018). Likewise for the A+T+*sex interaction (P=.071). In that sense, if you are using language such as the trend to describe findings, you could equally use it to describe findings showing a trend towards non-significance. As such, please avoid using this language and state your results as they are.</p><p>References:</p><p>Cole et al., 2017 Neurobiology of Aging: https://doi.org/10.1016/j.neurobiolaging.2017.04.006</p><p>Huang et al., 2021 Radiology Artificial Intelligence: https://doi.org/10.1148/ryai.2021200171</p><p>Millar et al., 2022 bioRxiv: https://doi.org/10.1101/2022.08.25.505251</p><p>Popescu et al., 2020 Human Brain Mapping: https://doi.org/10.1002/hbm.25133</p><p>Wagen et al., 2022 Lancet Healthy Longevity: https://doi.org/10.1016/S2666-7568(22)00167-2</p><p>Sanford et al., 2022, Human Brain Mapping: https://doi.org/10.1002/hbm.25983</p><p>Subpramaniapillai et al., 2021 NeuroImage Clinical: https://doi.org/10.1016/j.nicl.2021.102620</p><p>Vidal-Pineiro et al. 2021 <italic>eLife</italic>: https://doi.org/10.7554/<italic>eLife</italic>.69995</p><p><italic>Reviewer #3 (Recommendations for the authors):</italic></p><p>– Consider the impact that the number of tests run has on the interpretation.</p><p>– It was not entirely clear from the Methods how MCI was defined in each cohort. If these definitions are not consistent between cohorts, this should be highlighted as a limitation.</p><p>– It is inappropriate to report accuracy performance metrics after correction for brain-age bias (e.g., Table 3). The point of the correction process is not to improve model performance post hoc, but instead to improve the interpretability of the metrics by removing residual correlation with age. All performance metrics 'after bias correction' should be removed from the manuscript</p><p>– Figure 4. It was not obvious what the interactions related to. Of the 9 interactions reported, one is by sex, the other by age. Also, why were the points grouped and coloured by positive versus negative brain-age δ? Generally, this figure could be improved for the sake of clarity.</p><p>– Why was the 'aging signature' included? Please provide stronger motivation for why this was relevant.</p><p>– The analysis on the top and bottom 10% of participants were not well motivated. Why include this when regression models have already by used that assess 100% of the data, instead of 20%? It was not clear where these results were reported either, so I would recommend omitting this analysis.</p><p>– Avoid drawing interpretations that males and females are different in cases where there is no statistical test of this hypothesis. Being non-identical does not necessarily mean that sex differences are statistically significant (e.g., Figure 1d).</p><p>– I recommend reporting confidence intervals whenever you report an effect size. This facilitates the comparison of effect sizes between tests.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.81067.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Given the large number of tests conducted, the lack of multiple comparison correction means that some apparently significant associations may be statistically inflated.</p></disp-quote><p>The reviewer’s suggestion is well received. To address this issue, we have now corrected p-values by the False Discovery Rate (FDR) to control the overall type I error rate in the multiple comparisons made in the study.</p><disp-quote content-type="editor-comment"><p>2) Claims regarding sex differences should be tempered to be more in line with the strength of evidence.</p></disp-quote><p>We agree with the reviewer’s comment that sex differences should be better characterized in the manuscript. We have revised our language to accurately reflect the strength of evidence for these findings. Examples of this are shown below:</p><p>Discussion, page 21, lines 477-479: “Our results also indicate that there might be sex differences in the development of brain aging trajectories, which must be further characterized.”</p><p>Discussion, page 23, lines 609-611: “However, the lack of significant brain-age δ-by-sex interactions in our analyses reflect the limitations in the evidence for the above-mentioned sex-differences. Further work exploring these sex differences in detail is warranted”.</p><disp-quote content-type="editor-comment"><p>3) Reviewers noted that brain-age δ was not associated with longitudinal brain change and that the current study is solely a cross-sectional analysis. The implications for this should be discussed – specifically, whether it indicates that brain-age δ does not reflect accelerated brain aging but instead early life factors.</p></disp-quote><p>The reviewer raises an important point. We did not expect the brain-age δ to have a strong impact on longitudinal brain changes, given the short follow-up time (3 years, approximately) which is comparable to the observed variability of our brain-age δ in the cross-sectional analysis. By definition, the cross-sectional analysis reflects the accumulated effect of biological factors on brain aging for about 60 years (the average age of our samples).</p><p>We agree with the reviewer that these points deserved further attention in the discussion. In light of this, we have added a discussion in the manuscript’s main text to address the implications of the longitudinal results. We have considered potential explanations for the findings, including the possibility that brain-age δ reflects early life factors rather than accelerated brain aging (as previous literature has suggested) and the possibility that a 3-year interval may not be sufficient for brain-age δ to capture longitudinal changes. We also note that brain-age δ is expected to account for small variability in the processes that contribute to aging and that a longer time difference may be needed to detect longitudinal changes. Examples of this are shown below:</p><p>Discussion, page 21, lines 475-477: “However, our results do not show that variation in cross-sectional brain-age δ was able to capture longitudinal atrophy and, therefore, it is solely a cross-sectional analysis.”</p><p>Discussion, page 21, lines 482-483: “The capacity of brain-age δ to de detect accelerated aging must be further studied.”</p><p>Discussion, page 22, lines 530-537: “Conversely, brain-age δ was not associated with longitudinal aging signature change. This might indicate, as previously shown (Vidal-Pineiro et al., 2020), that brain-age δ might not reflect accelerated brain aging but instead early life factors. However, the lack of this association might also be influenced by the short amount of time between time visits (average of 3 years) or the measurement used to measure longitudinal atrophy (aging signature). Therefore, further research is needed to determine the relative contribution of early life factors and accelerated aging to brain-age δ estimates.”</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>– ADNI dataset includes participants with a dementia diagnosis and many of those are in the AD continuum. What was the reason for not including those cases in this study?</p></disp-quote><p>We thank the reviewer for this relevant question. Estimates of brain-age have been described previously in AD dementia patients (Kaufman, 2019; Beheshti, 2918). The main novelty of our study is to assess the impact of abnormal AD biomarkers and risk factors on brain-age estimates. We believe that these are particularly informative in preclinical and prodromal AD stages in order to potentially inform therapeutic interventions.</p><p>We have now made this point explicit in:</p><p>Introduction, Page 4, lines 154-158: “Nonetheless, there remains a need to replicate some of these results and to study the associations between brain-age prediction and abnormal biomarkers of AD and neurodegeneration in preclinical and prodromal AD stages in different and independent cohorts and in a larger sample size. These results would be particularly informative to potentially inform therapeutic interventions.”</p><p>Materials and methods, Page 25, lines 676-679: “We did not include individuals with a dementia diagnosis in the AD continuum because we wanted to focus on assessing the impact of abnormal AD biomarkers and risk factors on brain-age estimates in preclinical and prodromal AD stages.”</p><disp-quote content-type="editor-comment"><p>– When correcting brain-age estimates for bias, the bias regression line was estimated for each cohort separately. I believe cohort refers to CU vs MCI cases in this context. Is there a rationale for expecting disease stage-dependent bias in brain-age estimates?</p></disp-quote><p>We thank the reviewer for this question. We would first like to clarify that the term 'cohort' in our study refers to the different datasets used in our analysis, rather than the diagnostic groups (CU vs MCI). Our study includes five distinct MRI datasets (UK BioBank, ALFA+, ADNI, EPAD and OASIS), and the term 'cohort' is used to distinguish between the five. We apologize for any confusion caused and appreciate your feedback. We have revised the text to make this distinction clearer, and hope that the revised explanation will clarify any confusion.</p><p>Materials and methods, Page 25, lines 670-675: “These cohorts included individuals with different diagnosis: CU and MCI. ADNI cohort included CU and MCI individuals from ADNI 1,2 and 3 (<italic>N =</italic> 751, CU = 253, MCI = 498), the EPAD cohort included CU and MCI individuals (<italic>N =</italic> 808, CU = 653, MCI = 155), the ALFA+ cohort included only CU individuals (<italic>N =</italic> 380) and the OASIS cohort included CU individuals (<italic>N</italic> = 407).”</p><p>Regarding the potential disease-stage bias in brain-age estimates, we agree with the reviewer that we did not expect a significant effect. We have actually assessed the regressions between brain-age and chronological age and have not found any differences in the slopes. Of course, we find different intercepts due to the fact that MCI patients show an ‘older-appearing’ brain due to the pathologic process with respect to healthy controls.</p><p>We hope this clarifies our rationale and appreciate the opportunity to address this issue.</p><disp-quote content-type="editor-comment"><p>– Please clarify the use of the term 'cohort'. does it refer to CU vs MCI diagnostic groups or does it refer to different datasets? if lateral, then I think certain analyses should have been performed by cohort and diagnostic groups since the brain age behavior might be different at different disease stages. for instance, since UKBioBank is all CU participants, it is highly likely that the model performance within ADNI CU and within ADNI MCI cases might be different in terms of R2 and MAE.</p></disp-quote><p>Thank you for your comment regarding the use of the term 'cohort' in our manuscript and your suggestions. The term 'cohort' in our study refers to the different datasets used in our analysis, rather than the diagnostic groups (CU vs MCI). Our study includes five distinct MRI datasets (UK BioBank, ALFA+, ADNI, EPAD and OASIS), and the term 'cohort' is used to distinguish between the five. Within two specific cohorts (ADNI and EPAD) we have two diagnostic groups (CU and MCI). We have revised the text to make this distinction clearer, and hope that the revised explanation will clarify any confusion.</p><p>To address the reviewer’s point, we have studied whether the brain age behavior is different at different disease stages in these cohorts. We have now included a Table in Supplementary Material (Supplemental Table S3) to show the model performance separately for CU and MCI individuals in the cohorts containing both diagnostic groups. The results show that there are no substantial differences in the behavior of brain age across cohorts and diagnostic groups. We believe that this result reinforces the robustness of the brain-age estimates across cohorts and diagnostic conditions. We hope that this will address the reviewer’s concerns.</p><disp-quote content-type="editor-comment"><p>– Once the brain-age estimates are corrected for bias based on regression against chronological age, including age as a covariate in linear regression models for each validation variable might lead to double correction for age bias.</p></disp-quote><p>We thank the reviewer for this insightful comment regarding the correction of brain-age estimates.</p><p>It has previously been shown in the literature that: if the estimated brain-age δ is not orthogonal to age, and if the other variables for which the association with brain-age δ are being studied have not been deconfounded with respect to age, then any associations between brain-age δ and these variables might be more driven by age and not brain-age δ (Smith 2019; de Lange and Cole, 2020). Therefore, to overcome this, the two-step procedure for correcting age bias that we have implemented has been previously proposed and used in previous studies in the field of brain-age δ (Smith 2019; de Lange and Cole, 2020; de Lange 2020). Therefore, we believe that, in order to account for all age-related bias, it is important to include age as a covariate in the subsequent regression models for each validation variable. We hope that this revised explanation will address the concerns you have raised.</p><disp-quote content-type="editor-comment"><p>– In reference to the paragraph: &quot;We also studied the differences in volumes and cortical thickness between females and males in the UKBioBank for the brain regions that contributed the most to the prediction according to the SHAP values. With this aim we performed regression models for each ROI with sex as a predictor variable, in which linear and quadratic expansions of age, site, and TIV (only included for volume ROIs), were included as covariates.&quot;, it is not clear why this regression modeling was necessary if SHAP was used to identify regions contributing the most to brain age prediction. Furthermore, ROI volumes were initially residualized for site and TIV and similarly, thickness values were residualized for site effects. If that's the case, why include site and TIV as a covariate in this analysis? Also, this is the only analysis that higher order age associations were considered. What was the rationale for pursuing non-linear age associations in this case but not in other models?</p></disp-quote><p>We thank the reviewer for raising this point. Please note that the aim of this analysis was not to identify regions contributing the most to brain age but to describe sex differences in brain regions contributing the most to brain-age models for males and females.</p><p>With respect to the inclusion of higher-order associations with age in this analysis, it was initially motivated by previous literature showing non-linear effects. However, we agree with the reviewer that it is inconsistent with the rest of the analysis in the manuscript to include non-linear associations in this analysis. Therefore, we have now only included linear ones.</p><p>We have modified the main text accordingly to introduce the revised changes and to clarify the aim of this secondary analysis further:</p><p>Materials and methods, Page 30, lines 956-960: “We also performed two different secondary and exploratory analyses. First, we assessed whether the brain regions (volumes and cortical thickness) that contributed the most to the prediction of females and males in the UKBioBank were different for each sex. With this aim we performed regression models to study the interaction effect of sex for each of the selected ROIs by including a sex-age interaction term.”</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>This is very nice work but I think that the findings could be really strengthened by addressing the limitations highlighted in the public review. I can definitely appreciate the impressive amount of work that has already gone into this study and I do not lightly ask for additional work. My concerns would be addressed by correcting your findings for multiple comparisons, re-interpreting your results after correction for multiple comparisons, and discussing the other limitations in-text that can address my concerns.</p></disp-quote><p>Thank you for your positive feedback on our work and for bringing to our attention the limitations that need to be addressed in order to strengthen our findings. We appreciate your constructive criticism and value your insights.</p><p>We have taken your comments into consideration and have performed corrections for multiple comparisons using FDR, re-interpreted our results after correction for multiple comparisons, and discussed the other limitations in the text. We believe that these changes will address your concerns and strengthen the validity of our findings.</p><disp-quote content-type="editor-comment"><p>I have two other main concerns that can be addressed by text edits. First, the novelty of this work is overstated and does not fairly represent the brain-age δ literature. The authors incorrectly state that &quot;there are no comprehensive studies validating this measurement in association with specific biological markers of AD pathology (i.e. Amyloid-B [Ab] and tau pathology), neurodegeneration and cerebrovascular disease. Various studies have reported associations between brain-age δ and biomarkers of amyloid-B, tau, neurodegeneration, and cerebrovascular disease (Cole et al., 2017 Neurobiology of Aging; Huang et al., 2021 Radiology Artificial Intelligence; Millar et al., 2022 bioRxiv; Popescu et al., 2020 Human Brain Mapping; Wagen et al., 2022 Lancet Healthy Longevity). Therefore, this particular emphasis on novelty is not correct and is not representative of the literature. Can the authors please de-emphasize this novelty and acknowledge the good work carried out by other researchers that have addressed some of these questions previously?</p></disp-quote><p>We have re-evaluated our claims regarding the novelty of our study and have revised our language to de-emphasize this aspect and acknowledge the good work carried out by other researchers that have addressed some of these questions previously. We also would like to emphasize that our research question focuses on studying the association of fluid and imaging biomarkers of AD pathology neurodegeneration and cerebrovascular disease in individuals that are in the preclinical stages of AD. Taking this into consideration, we have made the necessary additions in the main text:</p><p>The two above-mentioned works that are in line with our research question (Millar et al., 2022 bioRxiv; Wagen et al., 2022 Lancet Healthy Longevity), were not publicly available when we submitted our manuscript. Thanks to the reviewer, we have now included these references in the text (Introduction, Page 3, lines 135-142):</p><p>“Recent literature has studied the associations between brain-age δ and the above-mentioned biomarkers with different aims. Brain-age δ was recently associated with plasma biomarkers of neurodegeneration and with imaging biomarkers of cerebrovascular disease in the 1946 british Birth Cohort (Wagen et al., 2022), however it was not associated with CSF biomarkers of neurodegeneration (Millar et al., 2022). Moreover, although brain-age δ was significantly associated with AD biomarkers of amyloid and tau in MCI individuals, these associations were not found in CU individuals (Millar et al., 2022; Wagen et al., 2022).”</p><p>Regarding the two suggested references for Huang et al., 2021 Radiology Artificial Intelligence and Popescu et al., 2020 Human Brain Mapping, we know that these two works are very relevant to the field and well done. That is the reason why we had already mentioned Huang et al., 2021 Radiology Artificial Intelligence in the text: “A recent study used brain-age measurements to identify amnestic MCI (aMCI), the typical clinical presentation of prodromal AD, from other individuals with MCI, by studying the association with AD risk factors such as apolipoprotein E (APOE) and Aβ (Huang et al., 2021).”. Although these two works are very relevant, we wanted to emphasize that their research question was different from ours. They used brain-age δ in addition to other biomarkers to predict different disease stages or disease progression. Therefore, our mentioned original novelty was expressed considering that our work was different from theirs. However, now, thanks to the reviewer, we have also included Popescu et al., 2020 Human Brain Mapping in the text and we have de-emphasized the novelty: Introduction, page 3, lines 120-124:</p><p>“Even though these studies support the association of brain-age δ as a biomarker of biological aging with relevance to various brain diseases, it is of interest to further validate this measurement in association with specific biological markers of AD pathology (i.e. Amyloid-β [Aβ] and tau pathology), neurodegeneration and cerebrovascular disease in the earliest stages of AD. “</p><p>We didn’t originally include the work from Cole et al., 2017 Neurobiology of Aging, as it focuses on Down Syndrome individuals. However, now we have also mentioned their important and interesting work in the text: Introduction, page 4, lines 152-164:</p><p>“The association of brain-age with these biomarkers have also been shown in other diseases, by which brain-age was associated with A deposition in Down syndrome (Cole et al., 2017).”</p><disp-quote content-type="editor-comment"><p>Second, &quot;trend&quot; or &quot;trending&quot; is used in the manuscript to refer to findings that are nearly statistically significant. For example, see Lines 333-336, Lines 291-294, and Line 444. However, this is not a meaningful description of a statistical result as we do not know which way these results are 'trending'. It can give the impression that the results are likely significant but did not reach significance for some unstated reason. However, the distance between the sex*plasma interaction in CU (P=.092) than reaching statistical significance (.092 –.05 = .042) is further than the distance of the significant result for APOE-e4 carriers vs APOE-e33 carriers of P = .032 reaching 'non-significance' (.05 –.032 = .018). Likewise for the A+T+*sex interaction (P=.071). In that sense, if you are using language such as the trend to describe findings, you could equally use it to describe findings showing a trend towards non-significance. As such, please avoid using this language and state your results as they are.</p></disp-quote><p>We agree with the reviewer’s comment regarding the use of the term &quot;trend&quot; or &quot;trending&quot; to describe findings that are nearly statistically significant is imprecise and can lead to confusion. Therefore, we have now revised our language to state our results as they are, without relying on imprecise terminology. We believe that these revisions will ensure that our results are clearly and accurately represented in the manuscript.</p><disp-quote content-type="editor-comment"><p>Reviewer #3 (Recommendations for the authors):</p><p>– Consider the impact that the number of tests run has on the interpretation.</p></disp-quote><p>We appreciate your attention to the impact of multiple tests on the interpretation of the results. To address this concern, we have carefully considered the number of tests run and have used appropriate methods to correct for multiple comparisons: we have used the Benjamini-Hochberg procedure to control the false discovery rate and ensure that the results are robust. Additionally, we have reported the corrected p-values and effect sizes, along with their associated confidence intervals, to provide a more comprehensive picture of the results.</p><p>We hope this information provides a better understanding of our methods and findings, and we look forward to your continued feedback.</p><disp-quote content-type="editor-comment"><p>– It was not entirely clear from the Methods how MCI was defined in each cohort. If these definitions are not consistent between cohorts, this should be highlighted as a limitation.</p></disp-quote><p>We thank the reviewer for this important comment. We acknowledge that it is of high relevance to state the definition of MCI used in each cohort, as well as the limitations that using different definitions would bring up. In this case, for both ADNI and EPAD, we specified MCI by a Clinical Dementia Rating = 0.5. We have made sure to state this in the main text:</p><p>Materials and methods, Page 25, lines 675-676: “MCI individuals, which were only included from ADNI and EPAD cohorts, were specified by a Clinical Dementia Rating = 0.5.”.</p><disp-quote content-type="editor-comment"><p>– It is inappropriate to report accuracy performance metrics after correction for brain-age bias (e.g., Table 3). The point of the correction process is not to improve model performance post hoc, but instead to improve the interpretability of the metrics by removing residual correlation with age. All performance metrics 'after bias correction' should be removed from the manuscript</p></disp-quote><p>We appreciate your concern regarding the reporting of accuracy performance metrics after correction for brain-age bias. We understand the point you raised regarding the purpose of the correction process, which is to improve the interpretability of the metrics by removing residual correlation with age. Therefore, we have removed all the performance metrics “after bias correction” from the manuscript.</p><disp-quote content-type="editor-comment"><p>– Figure 4. It was not obvious what the interactions related to. Of the 9 interactions reported, one is by sex, the other by age. Also, why were the points grouped and coloured by positive versus negative brain-age δ? Generally, this figure could be improved for the sake of clarity.</p></disp-quote><p>Thank you for your feedback, we appreciate your attention on Figure 4. To clarify, the interactions are related to the relationship between the different biomarkers and brain-age δ across the range of chronological age. The interaction reported by sex was a typo that we had not realized before. Thank you again for your attention on these details.</p><p>Regarding the question about the grouping and coloring of the points, the grouping in two different groups is only for visual purposes. We believed that by grouping the individuals by positive versus negative brain-age δ we would highlight the difference between individuals who have a brain that is biologically younger than their chronological age (positive δ) and those who have a brain that is biologically older (negative δ) and, in this way, it would be more clearly shown the interaction effects with age. We recognize that the explanation for this was not clearly stated. Following your recommendation, we have worked to improve the clarity of the figure and its legend to better communicate our results.</p><p>Results, page 20: “Figure 5. The associations of brain-age δ and (a) CSF NfL and (b) plasma NfL for all CU and, when available, MCI individuals. For visualization purposes, individuals were categorized into 2 groups according to their brain-age δ: “brain-age δ &lt; 0” representing decelerated brain aging (blue); and “brain-age δ &gt; 0” representing accelerated brain aging (red). Scatter plots representing the associations of CSF NfL, plasma NfL and WMH with age in individuals with brain-age δ &gt; 0 and brain-age δ &lt; 0. Each point depicts the value of the validation biomarkers of an individual and the solid lines indicate the regression line for each of the groups. The regression coefficients (β) and the corrected P-values are shown and were computed using a linear model adjusting for age and sex. Additionally, we also computed the “brain-age δ x sex” interaction term.”</p><disp-quote content-type="editor-comment"><p>– Why was the 'aging signature' included? Please provide stronger motivation for why this was relevant.</p></disp-quote><p>We thank the reviewer for this relevant question. Dickerson’s aging signature reflect those brain regions that undergo cortical atrophy in normal aging. Therefore, we were motivated to compute this simple measurement as a ‘control’ method to (1) show the superiority of brain-aging methods to more simple estimates of brain aging and (2) to compute a simple metric of longitudinal brain changes associated with aging. However, we agree that showing cross-sectional aging signatures in association with brain-age δ is not necessary for our aims. Therefore, in order to simplify our manuscript, we have now removed these associations.</p><disp-quote content-type="editor-comment"><p>– The analysis on the top and bottom 10% of participants were not well motivated. Why include this when regression models have already by used that assess 100% of the data, instead of 20%? It was not clear where these results were reported either, so I would recommend omitting this analysis.</p></disp-quote><p>Our goal with this secondary analysis was to examine the impact of extreme individuals on the overall relationships observed in our sample in the expectation that the observed effect would be small. Of course, this has the drawback that some of the data is discarded, but, in spite of this, the resulting analyses may be more sensitive. We acknowledge that the results of the analyses with extreme groups add little to the main ones and, therefore, they are only presented as supplementary material for future reference.</p><p>We recognize that the analysis of the top and bottom 10% may not have been clearly motivated and we apologize for any confusion it may have caused. We have also reported the results of this analysis more clearly in the Supplementary Information section.</p><p>Materials and methods, Page 30, lines 962-972: “Secondly, we wanted to identify the individuals whose predicted brain-age deviate the most from chronological aging, i.e., individuals with the highest positive or lowest negative brain-age deltas, to study the above-mentioned associations. The aim of this secondary analysis was to examine the impact of these extreme individuals on the overall relationships observed in our sample, in the expectation that the observed effect would be small. Even though this procedure implies that some of the data is discarded, we expected that the resulting analyses may be more sensitive. With this aim, we selected the individuals whose brain-age δ was included within the 10th and 90th percentile of the distribution for each independent cohort and studied the differences between these groups. The methodology and the results of this analysis can be found in Supplementary Appendix A.”</p><disp-quote content-type="editor-comment"><p>– Avoid drawing interpretations that males and females are different in cases where there is no statistical test of this hypothesis. Being non-identical does not necessarily mean that sex differences are statistically significant (e.g., Figure 1d).</p></disp-quote><p>We agree with the reviewer on this point and have, therefore, revised the relevant sections of the manuscript to ensure that all interpretations are based on the results of the statistical tests performed. We have included a table in Suplemmentary Information (Supplementary Table S8) with an exploratory analysis in which we have performed linear regressions for each region that was selected as more important in the predication (according to SHAP values) for which we included the interaction term age*sex.</p><disp-quote content-type="editor-comment"><p>– I recommend reporting confidence intervals whenever you report an effect size. This facilitates the comparison of effect sizes between tests.</p></disp-quote><p>We thank the reviewer for this recommendation and following it, we have now made sure to include the confidence intervals in the cases where we had not done it before due to lack of space. (e.g., Table 4).</p></body></sub-article></article>